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General introduction: Congenital N DI 
1.1. CONGENITAL NEPHROGENIC DIABETES INSIPIDUS 
1.1.1. CLINICAL PRESENTATION AND DIAGNOSIS 
Diabetes insipidus, literally meaning flow of tasteless urine, is characterized by an 
inability to concentrate urine. The nephrogenic form results from failure of the 
kidney to respond to the neurohypophyseal hormone arginine vasopressin, where-
as the central or pituitary form is caused by a disorder in the production of this 
hormone. More than a century ago, still unaware of the exact pathogenetic mecha-
nisms, the clinical picture of congenital diabetes insipidus has been reported in 
detail by Mcllraith1: 
"The similarity of the three cases is interesting. In all of them the chief symptoms of 
excessive thirst and the passing of an unduly large amount of urine had been 
present from infancy." ' 
During infancy, however, these classical features are not always recognized. 
Instead, less specific signs like vomiting, anorexia, failure to thrive, fever and 
constipation usually dominate the clinical picture (chapter 6). 
"Three brothers died of wasting, aged five years, seven months, and eleven 
months. All had excessive thirst and passed a large amount of urine."1 
Especially in the past, the feeding problems manifested by these children often 
resulted in failure to thrive and further predisposed them to extreme, life-threate-
ning, dehydration. As a consequence, early infant deaths are reported in many 
family histories, the cause of death often being unclear (chapter 6). 
"Never in any case while under observation did the specific gravity of the urine rise 
higher than 1007."1 
Severe dehydration and hypernatremia, normally strong stimuli for release of 
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vasopressin and subsequent urinary concentration, do not elicit a substantial 
increase of urine specific gravity in either central or nephrogenic diabetes insipidus. 
Hence, fluid deprivation and the infusion of hypertonic saline have been used to 
diagnose diabetes insipidus and to distinguish the disease from psychogenic 
polydipsia. The administration of the hypophyseal hormone arginine vasopressin 
(AVP) was found to be a more convenient and less dangerous challenge of the 
urinary concentration mechanism which had the added advantage of discriminating 
between vasopressin-responsive and vasopressin-unresponsive diabetes insipidus. 
Nevertheless, the vasoconstrictory side-effects of arginine vasopressin (AVP) 
represented a considerable risk.2-3 Its synthetic analogue 1-desamino-8-D-arginine 
vasopressin (DDAVP, Minrin") was found to lack this pressor effect and is currently 
the most advocated diagnosticum. The standard DDAVP-test is performed by the 
administration of 0.3 дд DDAVP/kg intravenously in 10 minutes or 10-40 дд intrana-
sally followed by serial measurements of urine osmolality. In congenital nephroge­
nic diabetes insipidus (NDI), urine osmolality shows no significant increase, with 
maximal values of approximately 200 mosmol/kg4'5 (normally > 807 mosmol/kg"). 
Unfortunately, DDAVP seems not completely harmless either. Some case reports 
have been published in which cerebral or myocardial infarctions occurred after its 
administration, possibly as a result of the activation of blood coagulation.7'13 In 
contrast, evaluations of clinical trials showed no increased risk of thrombosis in 
patients treated with DDAVP.14,15 Furthermore, hyponatremia and seizures may 
occur when fluid intake is not in balance with urine production.1*"25 With some 
precautions, however, performance of a DDAVP-test is simple and safe. Hence, the 
diagnostic delay occurring in several patients with this congenital disease seems 
not due to a complex biochemical diagnosis, but rather to problems concerning the 
clinical diagnosis. When the aspecific symptoms of infanthood have not led the 
physician to a correct diagnosis, the drinking and urinating habits of an NDI patient 
can be considered some personal peculiarity or, in some cases, even be interpre­
ted as a problem that is primarily behavioral (chapter 6). 
12 
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1.1.2 LONG-TERM SEQUELAE 
Mental retardation 
Ήβ was always a backward boy, his intellect being slow."1 
In the past century, several NDI patients with moderate or severe mental disability 
have been described in literature.2*34 Since Hypernatremia of other etiology was 
also found to be associated with mental disability and cerebral abnormalities35,3*, 
periods of severe dehydration were thought to underly the mental retardation 
observed in patients with NDI. Moreover, the cerebral calcifications which have 
been reported in several NDI patients may be interpreted as physical evidence of 
brain pathology.30*4'37"39 These considerations have led to the assumption that NDI 
patients have an increased risk of mental retardation. Nevertheless, only two 
studies have been published which include psychometrical analyses of groups of 
patients26·27, indicating that this assumption lacks a firm basis (chapter 5). 
Dilation of the urinary system 
"The bladder in each case was found to be enlarged and that the capacity of it 
was considerable may be inferred from the fact that while in the out-patient room 
of the hospital Case I passed about two pints of urine."1 
The production of large amounts of urine, which can amount to 1 5 - 2 0 liters in 
adults, makes great demands on the urinary system. Dilation of the urinary tract, 
varying from slight enlargement of bladder and ureters to massive hydronephrosis 
and hydrourethers, has been reported in 67% of cases which included a descrip­
tion of the urinary tract.40 Bladder neck hypertrophy was observed in a few patients 
but in the majority no anatomical cause for obstruction could be found. In the latter 
patients, the dilation has been ascribed to functional obstruction due to excessive 
urine production. Three NDI patients have been described in which hydronephrosis 
was followed by the development of chronic renal failure.41-43 Another rare complica­
tion of hydronephrosis presented by one of these patients was traumatic rupture of 
the urinary tract.42 Unilateral obstructive uropathy has been described in one NDI 
13 
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patient with an ureterocele.44 Similar to the risk of mental retardation, the chance 
that hydronephrosis and its complications occur can not be deduced from these 
case reports since they are biased by selection (chapter 6). 
When and whether surgical intervention for hydronephrosis in NDI should be 
undertaken is controversial. Adequate therapy, regular bladder voiding and serial 
ultrasonography may prevent this outcome. Nevertheless, suprapubic cystostomy, 
bladder neck incision and bilateral nephrostomy or ureterostomy have been 
performed in a few patients.41,45"'7 
1.1.3. THERAPY 
The primary therapy of nephrogenic diabetes insipidus is spontaneously adopted 
by the patient as soon as he has gained the independency to fulfill his high fluid 
demand. In addition, several drug combinations can be applied to decrease the 
renal water loss. Thiazide diuretics are known to have an antidiuretic effect in NDI. 
This is thought to result from a reduction of extracellular sodium content and fall of 
glomerular filtration rate, which reduces delivery of fluid to the distal nephron and 
enhances proximal water reabsorption. An increase of medullary osmolality is 
another factor which might contribute to the antidiuretic effect of thiazides.4,4"·4" To 
ensure sodium depletion, a sodium-restricted diet should accompany this therapy. 
Moreover, when the thiazide treatment results in pronounced hypokalemia, potas-
sium suppletion is required. Prostaglandin-synthase-inhibitors have also been 
applied successfully, especially in combination with hydrochlorothiazide.4,50^2 The 
mechanism of action has not been clearly defined, but an increased osmolality of 
the renal papilla in response to these agents has been observed.53 In addition, an 
enhancement of vasopressin-stimulated cyclic AMP (cAMP) has been ascribed to 
inhibition of prostaglandin synthesis. In this regard, the pathogenesis of NDI has 
even been suggested to consist of prostaglandin-mediated suppresion of adenyla-
te cyclase.51 
14 
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Despite being effective in NDI, the risk of gastro-intestinal side-effects during long-
term use of prostaglandin-synthase inhibitors has resulted in the application of the 
hydrochlorothiazide-amiloride combination which has the same antidiuretic effect as 
the hydrochlorothiazide-indomethacin regimen, with the additional benefit of 
obviating the need for potassium suppletion.54"50 
1.1.4. HEREDITY 
"That diabetes insipidus is a condition which is inherited to a remarkable degree 
has been well shown.... The present cases are also marked examples of its 
inheritance and what seems to be a heredity occurring chiefly in males on the 
female side of the house.'* 
After the discovery that patients with diabetes insipidus could be classified accor-
ding to their sensitivity to exogenous arginine vasopressin, the foregoing descrip-
tion of X-linked recessive inheritance was found to apply to most families with the 
vasopressin-insensitive or nephrogenic form of the disease. In these families, 
unaffected females transmit the disease to sons who display the complete clinical 
phenotype. Linkage-analysis has shown that this form of NDI segregates with 
markers of the subterminal region of the X-chromosomal long arm (region Xq28). 
57-M
 In some families, however, inheritance of NDI is not in accordance with an X-
linked recessive trait. Families with clear autosomal recessive inheritance have been 
described.44·1*2 Kindreds in which the disease occurs in consecutive generations 
have been reported as well, but did not include well-documented examples of 
male-to male transmission.29·*4" Finally, isolated cases have been reported in which 
mutation analysis or future progeny should reveal to which category they be-
long.*·-·7*74 
15 
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1.1.5. ETIOLOGY 
The cellular basis of congenital nephrogenic diabetes insipidus 
Arginine vasopressin exerts its antidiuretic action by initiating a signaling sequence 
in principal cells of the renal collecting duct.75 The basolateral membranes of these 
cells harbor the vasopressin type 2 (V2) receptor, a G-protein coupled receptor 
with a seven-transmembrane structure. Binding of vasopressin to the V2 receptor 
activates a stimulatory G-protein, which induces adenylate cyclase activity with the 
formation of cyclic AMP (cAMP) as a result (Fig. 1.1). The pathway between cAMP 
and the luminal membrane is not completely known but protein kinase A and the 
cytoskeleton are thought to play a role. To explain the final events, which render 
the water-tight apical membrane water-permeable, Wade et al.76 proposed the 
membrane-shuttle hypothesis which, in the meantime, has been confirmed by 
basolateral 
ATP 
V2R 
AVP G » A C ( 
CAMP -» род » exocytosis 
vesicle with AQP2 proteins 
Fig. 1.1 The antidiuretic arginine vasopressin (AVP) signalling pathway in principal collecting duct 
cells. V2R, vasopressin type 2 receptor; G, stimulatory GTP-binding protein; AC, adenylate cyclase; 
PKA, protein kinase A; AQP2, aquaporin 2.20" 
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several lines of evidence (see page 30). According to the model of Wade, vaso-
pressin induces subapical vesicles containing water channel proteins to fuse with 
the apical membrane, whereas its withdrawal results in rapid endocytosis of the 
water channels. 
The cause of congenital nephrogenic diabetes insipidus could pertain to any stage 
of this cellular signaling pathway. 
Etiology of X-chromosomal recessive NDI 
An important clue to the elucidaton of the etiology of NDI was the observation that 
in patients with X-linked NDI not only the antidiuretic, but also the vasodilatory, 
coagulation and fibrinolytic responses to the antidiuretic vasopressin-analogue 
1-desamino-8-D-arginine vasopressin (DDAVP) were lacking. This resulted in the 
hypothesis that these patients have a generalized V2 receptor defect.77"82 Indepen-
dent support for the involvement of a V2 receptor defect in NDI was obtained when 
Fahrenholz et al.83 found that somatic cell hybrids containing the human Xq28 
region showed vasopressin-binding and an increase of cAMP which was abolished 
by a V2 receptor antagonist. Further refinement of both the gene region which 
conferred cells with V2 receptor activity and the location of the NDI gene strengthe-
ned the assumption that the V2 receptor gene and the NDI gene were identical.84 In 
1992, the V2 receptor gene was cloned and found to encode a 371 amino acid 
protein of which hydropathy analysis revealed the seven-transmembrane topolo-
gy.85 The final evidence for its role in the pathogenesis of NDI was provided by the 
detection of mutations in the V2 receptor gene in patients with X-linked NDI.8"8 
Since then, more than eighty mutations have been detected throughout this gene 
(Fig. 1.2, addendum I). Confirmation of the pathogenecity of several of these muta-
tions, particularly important for the amino acid substitutions, has been obtained by 
in vitro expression studies. These revealed a loss of hormone binding for the 
R202C, Y205C and V206D mutations in the third extra-cellular region, the Y128S 
and P286R mutations in the third and sixth transmembrane region, respectively, 
and for several frameshift and non-sense mutations.89""2 On the contrary, the recep-
17 
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tor with the R137H mutation, which is located at the junction of the third transmem-
brane and second intracellular domain, showed an unaltered binding affinity, but 
failed to stimulate the G-protein/adenylyl cyclase system.*3 Further heterogeneity of 
the cellular consequences of NDI mutations have recently been reported by 
Tsukaguchi et al.92,94 who found that the reduced binding capacity of the R143P 
and V278del mutant receptors results from impaired transport to the plasma 
membrane, whereas a frameshift mutation (804insG) did not result in production of 
a mutant protein despite adequate mRNA levels. Interestingly, the R113W mutation 
in the second extracellular region has been shown to cause a reduction of receptor 
affinity for AVP and DDAVP, a decrease of adenylate cyclase stimulation and lower 
expression at the plasma membrane compared to the wild-type receptor."5 
Reduced binding capacities have also been reported for the T204N and R181C 
mutation, located in the third extracellular region.80·1 In contrast to the foregoing 
mutations, no consequence for cellular signaling was found for the A61V mutation 
at the junction of the first extracellular and first transmembrane region, nor for a 
deletion of four amino acids in the third cytoplasmic loop, suggesting that these 
mutations are polymorphisms.91 Ttie possibility that certain mutations affect post-
translational processing of the receptor has been explored as well. Mutagenesis of 
the asparagine residue at position 22, which is thought to be involved in receptor 
glycosylation, revealed only slight impact on the degree of expression and not on 
functioning of the receptor, suggesting that glycosylation of the amino terminus is 
not crucial for receptor transport and function. Furthermore, elimination of the 
putative palmitoylation site (C341-342) at the carboxy terminus indicated that this 
modification is not essential for functioning of the V2 receptor either.""7 
Fig. 1.2 Model of the vasopressin type 2 receptor showing the seven-transmembrane structure. 
Filled symbols represent amino acids conserved within the vasopressin-oxytocin receptor family.1™ 
Mutations detected in patients with X-linked nephrogenic diabetes insipidus are indicated by text 
(missense/nonsense), boxes (deletions of one or more amino acid), bars (nucleotide-insertions or 
deletions resulting in a frameshift) or arrows (intron mutations). A detailed description of the 
mutations is given in addendum I. 
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Etiology of autosomal recessive NDI 
After it had been discovered that patients with X-linked NDI did not show extra-
renal responses to DDAVP, it was recognized that some patients displayed a 
normal response. Knoers and Monnens74 described such a patient, who was the 
single affected member of a family in which inheritance of the disease did not 
segregate with markers for the Xq28 region. Langley et al.62 reported similar obser-
vations in a family in which two sisters were affected. In these three patients the 
defect seemed to be confined to the kidney and it was postulated that a defect in 
the cellular pathway beyond the V2-receptor was involved. 
In 1993, a candidate gene became available when Fushimi et al.96 cloned a water 
channel of the rat renal collecting duct. Expression of this gene was found to 
increase in response to dehydration suggesting that it encoded the vasopressin-
regulated water channel. Subsequently, the human equivalent, the so-called 
aquaporin-2 (AQP2) gene, was cloned99,100, assigned to chromosome 12100,101 and 
found to harbor mutations in the patient described by Knoers and Monnens.74,99 
Etiology of dominant NDI 
Several families have been reported in which NDI occurred in consecutive genera-
tions.29,6**7·68 Convincing descriptions of male to male transmission of the disease, 
however, an event which excludes X-linked dominant inheritance, have not been 
published. Ohzeki et al.w reported a family with a mother and son suffering from 
NDI who showed an increase of urinary cAMP in response to DDAVP. Because the 
pedigree revealed an affected father and son as well, the authors stated that 
inheritance was autosomal dominant. Their hypothesis of a post-V2 receptor defect 
causing this dominant phenotype, however, is subject to debate since discrepan-
cies between urinary cAMP and intracellular or plasma cAMP have been demon-
strated.80,102 Dominant inheritance of NDI might indicate the existence of a third NDI 
gene. Another explanation could be that, in addition to autosomal and X-linked 
recessive inheritance, mutations in the known NDI-genes are also transmitted in a 
dominant fashion (chapter 4). 
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1.2 THE AQUAPORIN WATER CHANNELS 
Since the molecular cloning of the first water channel in 1991103, a spate of informa-
tion concerning the physiology of fluid balance has become available. The identifi-
cation of this aquaporin-1 water channel and the subsequent discovery of several 
related proteins has opened up a new research area in which physiology, molecu-
lar biology and clinical practice come together. Because aquaporin research has 
shed new light on the pathogenesis of NDI, the following section will give an 
update of current knowledge on the six mammalian members of the aquaporin 
family of water channels, with special emphasis on their role in renal physiology 
and disease. 
Renal water transport 
Water crosses most cellular plasma membranes by simple diffusion. Several 
biological membranes, however, show an exceptionally large water transport 
capacity, suggesting involvement of another mechanism. The vital importance of 
these highly water-permeable membranes is dearly demonstrated by the hydro-
osmotic events occurring in the kidney. Epithelia of proximal tubules and thin 
descending limbs of Henle constitutively reabsorb approximately 90% of the 
glomerular filtrate, a process which is driven by small osmotic gradients. Reabsorp-
tion of a variable amount of the remaining glomerular filtrate occurs in the collecting 
ducts, where water permeability of apical cell membranes is modulated by arginine 
vasopressin (AVP). These processes result in conservation of an enormous 
quantity of water, in an adult amounting to 180 l/day, thereby constituting our main 
defence against derangement of fluid homeostasis. 
Renal epithelia show characteristics of channel-mediated water transport 
The high osmotic water permeability exhibited by several epithelial membranes of 
the kidney is one of the features attributed to channel-mediated water transport.104 
21 
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It can be quantified by the osmotic water permeability coefficient (P,) which largely 
exceeds the coefficient of diffusional water transport (Pd), resulting in a PJPá ratio 
greater than unity. Other characteristics of channel-mediated water transport are a 
low activation energy and inhibition by mercurial sulfhydryl agents.104"10" These 
characteristics have not only been demonstrated in renal membranes, but also in 
red blood cells, a finding which has considerably facilitated research in this area. 
Water selectivity of the putative water channels in erythrocytes, proximal tubules, 
thin descending limbs of Henle, and vasopressin-sensitive tissues has been 
demonstrated by inhibition studies with mercurials.107'109 Moreover, the possibility 
that other transporters are responsible for the high water permeability of these 
membranes was contradicted by several studies.110"114 
cDNA 
I In vitro transcription 
Isotonic medium hypotonic medium 
Fig. 1.Э Schematic representation of the procedure used for the functional analysis of aquaporins 
in Xenopus laevis oocytes. 
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General features of aquaporins 
The recent molecular proof of the existence of aquaporins in tissues with a high 
water transport capacity confirmed the longstanding belief of physiologists that this 
water permeability could not be explained by diffusion only. Aquaporins turned out 
to be the missing piece of the puzzle. These proteins were found in high quantities 
in membranes which displayed the biophysical characteristics attributed to channel-
mediated water transport. Functional proof of the water transport function of aqua­
porins was obtained by studies in oocytes of the toad Xenopus laevis (Fig. 1.3). 
Because of the high translational capacity of Xenopus oocytes, injection of the 
specific RNA into the cytoplasm results in the synthesis of large amounts of water 
channel proteins. These are inserted into the plasma membrane, of which water 
permeability can be measured using an osmotic swelling assay. Reconstitution of 
the proteins in artificial bilayers confirmed these results.115,116 Recently, expression 
studies in renal cells have provided a means to obtain information on the behavior 
of aquaporins in more natural surroundings.117 
The way in which aquaporins create pores in membranes is not exactly known, but 
has been assessed by several approaches. Hydropathy analysis of their amino 
acid sequences predicted a six-transmembrane topology (Fig. 1.4). Sequence 
alignment revealed that several regions of the proteins are evolutionary conserved, 
indicating their functional importance.118 The NPA-boxes, for instance, amino acid 
sequences of asparagine-proline-alanine which are located in loop В and E (Fig. 
1.4), are shared by all members of the aquaporin family, suggesting that these 
residues are crucial to their function. Moreover, in most aquaporins, the cysteine 
residue which is thought to be involved in the inhibition of water transport by 
mercury compounds119, is located in close vicinity of these NPA-boxes. Studies 
using in vitro mutagenesis confirmed the hypothesis that the amino acid composi­
tion of loops В and E is critical to water transport and resulted in the proposal of 
the so-called hour-glass model.120 This model suggests that the relatively hydrop­
hobic loops В and E meet within the plasma membrane, with the two NPA-boxes 
forming the aqueous pore (Fig. 1.5). 
23 
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Flg. 1.4 Model of the AQP2 protein showing the six-transmembrane structure which is generally 
thought to apply to all currently known aquaporins. Filled symbols represent amino acids 
conserved within the family of membrane integral proteins.11' Mutations detected in patients with 
autosomal recessive nephrogenic diabetes insipidus are indicated by text (missense/nonsense) or 
a bar (deletion resulting in a frameshift)."210 A detailed description of the mutations is given in 
addendum II. 
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Fig. 1.5 The AQP1 hour-glass model as proposed by Jung et al." 
Aquaporins are known to assemble in a homotetrameric configuration in the 
plasma membrane.121 In contradiction with the hour-glass model, this might indicate 
that each pore is formed by a cluster of four aquaporins. This possibility, however, 
has been refuted by several studies.119,122"124 The tetrameric configuration seems to 
serve another goal, presumably the stability of the protein in the plasma membra-
ne. The water-selectivity of most aquaporins suggests that the aqueous pore is 
very tight, approximately 2 A in diameter.105 At least one of the aquaporins, 
however, allows passage of urea and glycerol as well.125·12* 
Aquaporins have now been found in a variety of tissues of mammals, plants, 
insects and bacteria. Not surprisingly, renal membranes, which are easily passed 
by huge amounts of water each day, were found to be crowded with these water 
channels. 
AQUAPORIN-0 (AQPO) 
The first identified member of the ancient family of membrane proteins to which the 
aquaporins belong127, the major intrinsic protein of lens (MIP), has only recently 
joined the aquaporin subfamily. The cloning of aquaporin-1 focussed attention on 
this MIP molecule, since the two proteins were found to be structurally related. A 
close evolutionary relationship between MIP and some other aquaporins is also 
25 
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reflected by the localization of the MIP gene within an aquaporin gene cluster in 
chromosome region 12q13.128 
Function and dysfunction of AQPO 
Although the MIP gene was already cloned in 1984127, the physiological function of 
MIP has remained questionable for more than a decade. Recently, however, 
studies in Xenopus oocytes have shown that it mediates water transport.129 
Although of lesser magnitude than manifested by other aquaporins, its water 
transport capacity was reason to rename the protein AQPO. Aberrant expression of 
the AQPO gene has been detected in mice with congenital cataract, suggesting that 
AQPO is involved in the induction or maintenance of lens transparency.130 This 
hypothesis has recently been confirmed by the detection of mutations in the AQPO 
gene of mice with congenital cataract.131 
AQUAPORIN-1 (AQP1) 
Aquaporin 1, the first cloned water channel (also referred to as channel-forming 
integral protein of 28 kd, CHIP28), disclosed its existence in red blood cells by 
showing up as a 28 kd by-product in the isolation of the Rhesus-antigen.132 Further 
studies revealed that it was not only present in erythrocytes but also in the proximal 
nephron.133 In 1991, its cDNA sequence was elucidated and, subsequently, its 
water transport function demonstrated by functional analysis in Xenopus laevis 
oocytes.103,115 AQP1 is the most widely distributed member of the aquaporin family. 
It is not only abundant in erythrocytes and the proximal nephron, but also exists in 
a variety of other tissues (Table 1.1).133"145 
Function and dysfunction of AQP1 
The abundance of AQP1 in both apical and basolateral membranes of the proximal 
tubule and descending limbs of Henle indicates that this water channel accounts 
for the high water transport capacity attributed to this part of the nephron and thus 
26 
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Table 1. Tissue distribution of the mammalian aquaporins 
Kidney 
proximal tubule 1 
thin descending limb of Henle 1 
vasa recta 1 
collecting duct principal cells (apical) 2 
collecting duct principal cells (basolateral) 2 3 4 
Blood/haematopoetlc tissue« 
erythrocytes 1 
bone marrow 1 
spleen 1 
Brain 
choroid plexus 1 
brain ependym 3 4 
glial cells 4 
hypothalamus (vasopressin secretory neurons) 4 
Purkinje cells of cerebellum 4 
astrocytes in spinal cord and brain 4 
Eye 
lens fibers 0 
lens epithelium 1 
corneal endothelium 1 
corneal epithelium 5 
conjunctival epithelium 3 4 
iris epithelium 1 4 
ciliary epithelium 1 4 
retina 4 
lacrimal glands 5 
lacrimal gland excreting tubules 4 
trabecular mesh-work 1 
Schlemm's canal endothelium 1 
Respiratory tract 
trachea 1 3 4 5 
bronchus 1 4 
lung 1 4 5 
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Table 1.1 (continued) 
Digestive system 
stomach 
liver 
pancreatic acinar cells 
gall bladder epithelium 
hepatic bile ducts 
intestinal lymphatic vessels 
colon 
Placental syncytial trophoblast cells 
Heart 
Non-fenestrated capillaries In diverse tissues 
Periosteum 
Peritoneum 
Skin epidermis 
Sweat glands 
Salivary glands 
excretory tubules 
secretory lobules 
Reabeorptlve eplthella of male reproductive tract 
Urinary bladder transitional epithelium 
Skeletal muscle 
3 4 
4S 
3 4 
4S 
Localizations are based on Northern blot analysis, in situ hybridization and/or immunostaining 
i25.i2e,i34.i«4,iK.i77.i7..iu-iee.îoe j ^
 a q u a p o n n ^ ^ nomenclature is used in which AQP1, 2. 3 and 4 
correspond to CHIP28, WCH-CD, GUP and MIWC, respectively. The alternatively spliced form of 
AQP4 mRNA is designated by 4s. 
is of paramount importance for antidiuresis.134,139-142 Indeed, quantification of AQP1 
in renal tubules revealed a number of water channels which was sufficient to 
explain the water permeability of these membranes.146 Thus, enough evidence 
exists to assume that in the proximal nephron transcellular water transport is 
accomplished predominantly through AQP1. In accordance, the initiation of AQP1 
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gene expression in the rat proximal nephron was found to coincide with the 
development of the urinary concentrating mechanism. The concurrent expression 
of AQP1 in erythrocytes was postulated to enable rapid rehydration of these cells 
after passage of the hypertonic renal medulla.135,147 Another location where AQP1 
seems to play a role in antidiuresis is the non-fenestrated endothelium of descen-
ding vasa recta. The observation that water transport in these structures is partially 
inhibited by mercury is consistent with this finding, but also suggests that AQP1 is 
not the only pathway. In fenestrated ascending vasa recta and peritubular capilla-
ries no expression of AQP1 has been found.142 
AQP1 seems not only involved in the absorption but also in the secretion of fluids. 
Its presence in choroid plexus in the pre- and post-natal period indicates that 
AQP1 mediates secretion of cerebrospinal fluid.1*5,138 Other locations of AQP1 (table 
1.1) suggest involvement in fluid transport occurring in the eye, lung, digestive 
system, placenta, peritoneum, sweat glands, male reproductive tract and several 
capillary beds. Moreover, a role in the development of several tissues is suggested 
by the detection of AQP1 in fetal periosteum, endocardium and cornea. At these 
sites, AQP1 might be involved in the deposition of extracellular matrix which is 
thought to be attended by changes in hydration.135 
Altogether, life without AQP1 seems impossible. The finding that the AQP1 gene 
shares its 7p chromosome localization with the Cotton blood group antigen, 
however, pointed out a rare category of people who turned out to be living proof to 
the contrary.148,149 Indeed, Colton-negative individuals were found to harbor 
mutations in the AQP1 gene. The finding that their erythrocytes showed decreased 
water permeability and that AQP1 was not found in their urine confirmed the 
functional consequences of the mutations. Surprisingly, however, these individuals 
appeared to be healthy, suggesting the existence of compensatory mechanisms 
and denying the supposed vital importance of AQP1. Recent studies have revealed 
a slightly reduced life span and deformability of their erythrocytes150, but, until now, 
a thorough assessment of renal function has not been accomplished. 
In addition to these Colton-negative individuals who suffer less than expected from 
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an AQP1 defect, it seems that some people benefit more from a functional AQP1 
than meant by physiology. AQP1 has been found in rat and human peritoneum, 
suggesting that it contributes to the permeability of this structure and thus plays a 
role in the mechanisms underlying peritoneal dialysis.143,144 
Although all findings mentioned above refer to the water transport function of 
AQP1, the selectivity of AQP1 for water has recently been doubted by Abrami et 
al.151, who suggested that AQP1 mediates glycerol transport as well. Urea, despite 
having a size similar to glycerol, was not transported, a finding which was explai-
ned by a lower flexibility of this molecule. At the moment, however, the assumption 
that the AQP1 channel is selective for water still prevails. 
AQUAPORIN-2 (AQP2) 
In contrast to the wide distribution of AQP1, the second aquaporin found in 
mammalians, showed unique expression in kidney medulla.98 Its expression was 
found to be upregulated by dehydration and arginine vasopressin, suggesting that 
this aquaporin is the vasopressin-regulated water channel.10*·152·153 In accordance, 
immunolocalization studies in renal cells have revealed that, in the absence of 
vasopressin, AQP2 was present in subapical vesicles of principal cells, while 
addition of vasopressin resulted in its insertion into the apical plasma membrane 
(Fig.1.1).15*"15* This finding was fully compatible with the membrane shuttling 
hypothesis, proposed by Wade et al.76 to explain the role of vasopressin in the 
rapid regulation of water transport across the apical membrane of the collecting 
duct cells. Studies assessing the effect of vasopressin type 2 (V2) receptor 
antagonists on the subcellular distribution of AQP2 underscored the involvement of 
the V2 receptor in this process.157 Furthermore, the involvement of cAMP as a 
second messenger has been confirmed by in vitro expression of AQP2.117-158 The 
presence of a protein kinase A (PKA) consensus site in the AQP2 amino acid 
sequence may be in accordance with the assumption that PKA constitutes another 
step in the antidiuretic signaling pathway, either regulating channel permeability or 
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modulating the distribution of AQP2 between plasmamembrane and intracellular 
compartments.158,158 Furthermore, evidence is accumulating that the cytoskeleton 
and vesicle-associated membrane proteins are involved in the targeting of AQP2 
proteins to the apical membrane.180"183 
Less information has been available concerning a putative long-term regulation of 
vasopressin-dependent antidiuresis. The cloning of AQP2 provided a direct means 
to study this subject. In Brattleboro rats, which lack endogenous AVP, a marked 
reduction of AQP2 expression was found compared to normal rats, whereas after 
chronic vasopressin infusion a nearly three-fold increase occurred.184 Likewise, 
Hayashi et al. observed decreased AQP2 expression in normal rats treated with 
vasopressin type 2 receptor antagonists.157 Thus, vasopressin seems to induce 
antidiuresis at two levels: by immediate insertion of AQP2 in the apical membrane 
and by an increase of AQP2 expression after long-term exposure. 
The pore through AQP2 is generally thought to have a structure similar to the one 
through AQP1, although it has been suggested that, instead of loops В and E, 
loops С and D are involved in its formation.185 
Function and dysfunction of AQP2 
Hereditary nephrogenic diabetes insipidus 
The exclusive localization of AQP2 in kidney medulla and its regulation by vaso­
pressin resulted in the hypothesis that this water channel accounts for the facultati­
ve reabsorption of the approximately twenty liters of pro-urine which reach the 
collecting duct. The detection of AQP2 gene mutations in patients with hereditary 
NDI and functional analysis of the mutant proteins has provided the final evidence 
for this assumption" (chapter 2). 
The detection of AQP1 in urine148,149 has been further elaborated for AQP2 by 
Kanno et al.18", who reported a study in which they quantified urinary AQP2 by a 
radioimmunoassay. In healthy volunteers and patients with central diabetes insipi­
dus, AQP2 was found to increase in response to vasopressin, but not in patients 
with X-linked and non-X-linked NDI. Hence, they suggested that this assay might 
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be used for detection of NDI patients and the differentiation from patients with 
central diabetes insipidus. Although interesting from the viewpoint of monitoring in 
vivo AQP2 expression in easily accessible material, this assay seems somewhat 
redundant and too complex for daily clinical use.187 Moreover, the fact that AQP2 
has been detected in urine of an NDI patient with a V2 receptor mutation168 shows 
that delineation of NDI from central diabetes insipidus will not be as simple as 
suggested and certainly inferior to the performance of a DDAVP-test. Moreover, the 
latter procedure has an important additional advantage (chapter 3). 
Acquired nephrogenic diabetes insipidus 
A well-known cause of acquired nephrogenic diabetes insipidus is chronic lithium 
therapy. Lithium is thought to exert this side-effect by interfering with the post-V2-
receptor pathway, although the exact mechanism of inhibition has remained 
unknown. Marples et al.168 found a down-regulation of AQP2 in renal medulla of 
rats on chronic lithium therapy. Cessation of therapy or DDAVP treatment for a 
week reversed this down-regulation only partially, consistent with the clinical 
observation of slow recovery from lithium-induced NDI. 
Other polyuric states which have been associated with reduced expression of 
AQP2 are those observed during hypokalemia, after release of bilateral ureteral 
obstruction and in experimental nephrotic syndrome induced by puromycin 
aminonucleoside treatment.170"172 In addition, Takahashi et al.173 found that AQP2 
expression is reduced in the polyuria accompanying chronic renal failure, a factor 
which might contribute to the urinary concentrating defect. In accordance with this 
observation and a long-term regulation of AQP2 expression by vasopressin, virtual 
absence of V2 receptor mRNA has recently been found in this clinical state.174 
Another condition in which, probably in addition to medullary wash-out, reduced 
expression of AQP2 could be involved is the initially reduced response to DDAVP 
which is often observed in patients with central diabetes insipidus. 
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Liver cirrhosis 
Abnormal expression of AQP2 has not only been associated with polyuria, but also 
with pathological water retention. An increase of AQP2 expression has been 
observed in kidneys of cirrhotic rats which correlated with the volume of ascites.175 
Polycystic kidney disease 
Epihelial cells lining cysts in autosomal dominant polycystic kidney disease have 
been found to express AQP1 and, to a much lesser extent, AQP2.178 Thus, al-
though not the primary cause of this pathology, aquaporins probably play a role in 
fluid movement into these cysts. 
AQUAPORIN-3 (AQP3) 
Although manifesting a water permeability similar to other aquaporins, this third 
member of the aquaporin family is strictly spoken not a true aquaporin. Several 
groups observed transport of urea and glycerol as well.125,128 The fact that its 
structure has closer identity to the bacterial glycerol facilitator than to the aquapo-
rins also suggests that AQP3 is not a conventionel water channel. Even its mercu-
ry-sensitivity raises questions, since AQP3 lacks a cysteine in the region thought to 
be responsible for this feature in AQP1, 2 and 5. 
AQP3 was first detected in rat kidney medulla, with exclusive presence at the 
basolateral membrane of collecting duct cells, and in colon.125,126 Subsequent 
studies in human tissues revealed a wider tissue distribution (Table 1.1).177'179 
Function and dysfunction of AQP3 
In kidney medulla, AQP3 is thought to serve as a pathway for water and urea exit 
in antidiuresis. Water flow across the basolateral membrane has even been found 
to exceed vasopressin-induced apical fluid transport.180 Recent data suggest that 
AQP3-mediated water transport is influenced by vasopressin as well. Expression of 
AQP3 has been shown to increase during dehydration.181-182 This regulation does 
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not seem to be mediated by cAMP, but by the Ca2+/protein kinase С system, 
indicating that the vasopressin type 1 receptor is involved.125,17* Considering the 
role of AQP3 in the exit of water that enters through AQP2 in the apical membrane 
and the potential regulation of its expression by vasopressin, it can be postulated 
that an AQP3 defect should result in nephrogenic diabetes insipidus. The observa­
tion, however, that the basolateral membranes of the inner medullary collecting 
duct harbor some AQP2 and AQP4 as well might suggest that these could 
compensate for an AQP3 defect, especially since basolateral permeability seems 
not rate-limiting for transcellular water transport.180 
AQUAPORIN-4 (AQP4) 
The high transcellular water permeability of lung alveoli urged Hasegawa et al.183 to 
assess whether, in addition to AQP1, other aquaporins are responsible for this 
feature. They detected a rat lung cDNA homologue encoding a novel, mercurial-
insensitive, water channel (MIWC) which was also found to be expressed strongly 
in brain, eye and colon (Table 1.1). The group of Agre isolated an aquaporin from 
brain, referred to as AQP4, which was found to be identical to MIWC, except for 
one amino acid.1" Presence of AQP4 mRNA was demonstrated in brain and. to a 
lesser extent, in eye, kidney, intestine and lung. Further study on the precise 
localization of this fourth aquaporin in rat brain revealed its presence in ependymal 
cells lining the aquaduct, glial cells forming the edge of cerebral cortex and 
brainstem, Purkinje cells of the cerebellum, in the hypothalamic area where 
vasopressin secretory neurons are located and in astrocytes of brain and spinal 
cord (Table 1 .i).1"·178·183·184 Recently, a human AQP4 equivalent has been detected 
in similar locations with strongest expression in brain and skeletal muscle.185 
Assessment of the localization of AQP4 in kidney revealed its exclusive presence in 
basolateral membranes of collecting duct principal cells and showed no influence 
of thirsting on its distribution within the cell.188 
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Function and dysfunction of AQP4 
The expression of AQP4 at certain sites of the brain raises the question what clini-
cal consequences a defect in this water channel might have. Based on its presence 
in the vasopressin secretory neurons of the hypothalamus, AQP4 has been sug-
gested to be an osmoreceptor. This hypothesis implicates that in case of a defect 
in the AQP4 gene, hyperosmolality will not result in release of vasopressin and thus 
might cause some form of hereditary central diabetes insipidus. Depending on the 
exact sites of AQP4 expression, however, the possibility of other clinical conse-
quences, e.g. a disturbance of liquor drainage, needs to be considered as well. 
Regarding a possible role in NDI, similar speculations can be made as for AQP3. 
AQUAPORIN-5 (AQP5) 
None of the aquaporins mentioned above are found in the secretory part of salivary 
and lacrimal glands.138,140 The high water-secreting capacity of these tissues, 
however, suggests the presence of aquaporins. Raina et al.187 isolated a cDNA 
from rat submandibular gland homologous to the known aquaporins. Its water 
transporting function was confirmed by expression in Xenopus oocytes. In addition 
to the submandibular gland, expression of the gene was shown to occur in parotid, 
sublingual and lacrimal glands and eye, trachea and lung. In situ hybridization 
revealed a strong signal over corneal epithelium and secretory lobules of salivary 
glands (Table 1.1). Recently, the same group cloned the human AQP5 gene as 
well.128 
Function and dysfunction of AQP5 
Based on its tissue distribution, AQP5 is thought to play an important role in 
generation of saliva, tears and pulmonary secretion and has been postulated to be 
involved in conditions such as the Sjögren syndrome. Together with AQPO, AQP5 
is currently the only mammalian aquaporin which has not been detected in the 
kidney. 
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1.3 EXTRA-RENAL EFFECTS OF ARGININE VASOPRESSIN AND 
1-DESAMINO-8-D-ARGININE VASOPRESSIN 
1.3.1 ARGININE VASOPRESSIN 
As can be inferred from its name, the action of the nonapeptide arginine vasopres-
sin is not restricted to the renal collecting duct, but also exerted in blood vessels. 
Its pressor effect occurs through the interaction with vasopressin type 1a (V1a)-
receptors located on vascular smooth muscle cells and is mediated by phosphati-
dyl inositol turnover and a rise in cytosolic calcium. A variety of other locations of 
V1 a receptors has been reported, including thrombocytes, hepatocytes and, in the 
kidney, glomerular, collecting duct, juxtaglomerular and mesangial cells.188"192 The 
V1b receptor, which shows a distinct pharmacological profile and molecular 
structure, is mainly expressed in adenohypophysis. In addition, reverse transcrip-
tase polymerase chain reaction (RT-PCR) in human tissues, showed some expres-
sion in brain, the digestive system, eye, thyroid, thymus and kidney.1*3,194 
In contradiction to its name, high local dosages of arginine vasopressin have been 
found to cause vasodilation in human forearm vasculature.195"199 Until now, it has 
remained speculative whether the receptor responsible for this action belongs to 
the V2-subtype (chapter 7). 
1.3.2 1-DESAMINO-8-D-ARGININE VASOPRESSIN (DDAVP) 
Based on its antidiuretic/pressor ratio of 4000200, DDAVP (Minrin", Ferring) is 
believed to be a V2 receptor specific agonist. Because of the lack of vasocon-
strictor side-effects resulting from V1 receptor stimulation, DDAVP has become an 
important antidiuretic agent which is not only used to differentiate between the 
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central and nephrogenic diabetes insipidus but also as treatment for central 
diabetes insipidus and enuresis nocturna.201 In addition to this well-known renal 
effect, DDAVP has several other actions, consisting of vasodilation, an increase of 
coagulation (factor VIII and von Willebrand factor) and fibrinolytic factors (tissue-
type and urokinase-type plasminogen-activator).202"204 The mechanisms underlying 
these extra-renal effects of DDAVP are largely unknown (chapter 7). 
1.3.3 THE LOCATION OF THE EXTRA-RENAL V2 RECEPTOR 
The search for the location of the extra-renal V2 receptor has been fraught with 
difficulty. Its presence on monocytes has been suggested by binding of radiolabe-
led arginine vasopressin with elevation of intracellular cAMP205, an observation 
which could not be confirmed by others (N.Knoers, personal communication). 
Hasegawa et al.206·207, however, did obtain functional evidence for its localization on 
monocytes when they found that the addition of supernatant of DDAVP-treated 
monocytes to cultured endothelium generated an increase of von Willebrand factor, 
whereas the addition of DDAVP did not. Moreover, their results indicated that 
platelet activating factor was the intermediating factor. In spite of these functional 
indications, convincing physical evidence for the presence of V2 receptors on 
monocytes or other extra-renal cells has not yet been gained. 
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1.4 AIM OF THE STUDY 
Despite being an extensively studied disease, several aspects of the heredity, 
pathogenesis and clinical phenotype of NDI remain to be elucidated. The conti-
nuous collecting of patients over the past ten years provided us with a relatively 
large group of patients with this rare disease and long-term follow-up of most of 
them. Thanks to this effort and the impulse of recent developments in aquaporin 
research, a large amount of molecular and clinical data could be obtained and 
applied to accomplish the following aims: 
1. Further delineation of the heredity patterns and molecular pathogenesis of 
NDI (Chapter 2 and 4) 
2. Assessment of the value of a DDAVP-test with measurement of extra-renal 
parameters to distinguish patients with an AQP2 defect from patients with a 
V2 receptor defect (Chapter 3 and 4) 
3. Assessment of the prevalence of mental retardation among patients with 
NDI and its relationship with clinical and genetic data (Chapter 5) 
4. Evaluation of clinical data of a large group of NDI patients with emphasis on 
the prevalence of urological complications and growth retardation 
(Chapter 6) 
5. Analysis of the effects and mechanisms of DDAVP- and AVP-induced 
vasodilation in forearm vasculature of healthy persons and patients with 
NDI (Chapter 7) 
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SUMMARY 
Mutations in the X-chromosomal V2 receptor gene are known to cause nephrogenic 
diabetes insipidus (NDI). Besides the X-linked form, an autosomal mode of inheritance 
has been described. Recently mutations in the autosomal gene coding for water 
channel aquaporin 2 of the renal collecting duct were reported in an NDI-patient. In 
the present study, missense mutations and a single nucleotide deletion in the 
aquaporin 2 (AQP2) gene of three NDI patients from consanguineous matings are 
described. Expression studies in Xenopus oocytes showed that the missense AQP2 
proteins are nonfunctional. These results prove that mutations in the AQP2 gene cause 
autosomal recessive NDI. 
INTRODUCTION 
Congenital nephrogenic diabetes insipidus (NDI) is a hereditary disorder characterized 
by inability of the kidney to concentrate urine in response to the hormone arginine 
vasopressin (AVP). Patients usually present in the first year of life with periods of 
severe dehydration, polyuria, fever, anorexia, vomiting and failure to thrive. In most 
families the disease shows an X-linked recessive mode of inheritance. It has recently 
been shown that in these families NDI is caused by mutations in the V2 receptor 
gene.1"7 However, other modes of inheritance have been described8"13 and it has been 
postulated that in these families a post-receptor defect is the cause of NDI. 
Normally, binding of AVP to V2 receptors triggers the cyclic AMP (cAMP) signaling 
pathway in principal and inner medullary collecting duct cells. Subsequent fusion of 
intracellular vesicles containing aquaporin 2 (AQP2) water channels with the apical 
membrane increases the water permeability of these cells.14,15 After disappearance of 
AVP, water channels are retrieved from the apical membrane by endocytosis, and, 
consequently, water reabsorption decreases. In this way, AVP regulates reabsorption 
of the 10 % of the glomerular filtrate that reaches the collecting duct. 
One of the post-receptor proteins that could be nonfunctional in autosomal NDI is the 
AQP2 water channel, also referred to as "WCH-CD".14 The human gene encoding this 
56 
AQP2mutationscausingautosomalNDI 
protein has been assigned to chromosome 12.1*-17 Its cloning and the application of 
a functional assay for water channel activity enabled us to study whether mutations 
in this gene are the cause of autosomal NDI. Strong support for this assumption was 
recently found in one of our patients who appeared to be a compound heterozygote 
for mutations in the AQP2 gene.18 Subsequent expression studies in Xenopus oocytes 
revealed that the mutated gene products were indeed nonfunctional. These results 
and the segregation of the mutations within the family made it very likely that aberrant 
AQP2 water channels caused the disease. 
In this study we present three additional NDI patients with mutations in both alleles of 
the AQP2 gene. Two of these patients are homozygous for missense mutations, 
whereas the third patient was homozygous for a single nucleotide deletion. Functional 
analysis revealed that the missense AQP2 water channels are inactive. These data 
provide conclusive evidence that nonfunctional AQP2 proteins cause autosomal 
recessive NDI. 
PATIENTS, MATERIALS AND METHODS 
Patients 
Blood samples for DNA analysis were obtained from individuals of three separate 
families. In all families, parents of the patients are consanguineous (Fig. 2.1). 
Family 1 is Dutch by descent. A sister, brother, and female cousin of the proband (P1) 
died about 30 years ago in their first year of life. Information about the proband's male 
cousin, who also died in early infancy, was not available. According to their medical 
records, the deaths of the other three children were preceded by clinical signs of 
dehydration, including severe hypernatremia. At the age of 2 weeks, the proband was 
admitted with the same clinical features (Na 157 mmol/l). A water-deprivation test did 
not result in a rise of urine osmolality, and neither did subsequent administration of 
AVP. As of the submission of this report he has had polyuria and polydipsia (8-10 
liters/day, no medication). 
Family 2 is of Italian origin. The brother of the proband died at the age of two weeks. 
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The cause of his death was unknown and preceding symptoms were not documented. 
The sister of the proband was admitted to the hospital because of fever and failure to 
thrive. These symptoms had started at the age of 4 weeks, when breastfeeding was 
changed for cow's milk. She developed pneumonia and died at the age of 5 months. 
According to the parents the clinical course of their youngest daughter (P2) was 
similar. At the age of 2.5 months, this girl also presented with unexplained fever and 
failure to thrive. At admission hypernatremia (155 mmol/l) was present, and, during her 
stay in the hospital, polydipsia and polyuria were noticed. Urine osmolality was low 
(56-160 mOsm/-kg) and did not increase in response to AVP. Twenty-five years later, 
she has a fluid-intake of about 10 liters per day, despite medication. After overnight 
fluid restriction, urine osmolality of both parents was normal: father 1,048 mOsm/kg; 
mother 915 mOsm/kg. 
Family 3 is Palestinian by descent. Except for the male proband (P3), family history is 
negative for NDI. Two siblings of the proband's mother died as adults, of causes not 
related to NDI. At the age of 6 weeks the proband presented with feeding difficulties, 
insufficient weight gain, and fever. Polyuria with low urine osmolality and a decrease 
of body temperature after administration of large fluid volumes were noticed. When he 
was seen at our hospital at the age of 7 months, he was severely dehydrated (Na 186 
mosmol/kg, serum osmolality 429 mosmol/kg), but urine osmolality was low (150 
mosmol/l). Intravenous administration of lysine vasopressin did not result in an 
increase of urine osmolality. Now, as an adult, he drinks 7-10 liters per day (no 
medication). 
Fig. 2.1 Pedigrees of the three NDI-families. Blackened symbols denote affected individuals; hatched 
symbols denote that NDI is suspected; and symbols with diagonal slashes through them denote 
deceased individuals. Presence of the mutant alleles is depicted by the relevant amino add 
substitution (R187C or G64R) or single nucleotide deletion (del); and normal alleles are denoted by 
a plus sign. 
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DNA sequence analysis of patients 
Genomic DNA was isolated by the salt-extraction technique. Primers used for 
amplification of the AQP2-coding regions and cycle sequencing were as described 
elsewhere.1' PCR conditions were 1 min at 92°C, 1.5 min at 60°C, and 1.5 min at 72°C, 
for 30 cycles. Cycle sequencing reactions were performed on both DNA strands, and 
sequences were analyzed on an automated fluorescence-based Applied Biosystems 
model 373A DNA sequencing system. 
Functional analysis 
To introduce the G190A transition in our human AQP2 expression construct (pT7Ts-
AQP2), genomic DNA of patient 1 was amplified using primers flanking the coding 
region of exon 1.1S A 61-bp Ncol-to-Apal fragment was isolated by gel electrophoresis 
and was cloned between the corresponding sites of pT7TsAQP2. Clone 
pT7TsAQP2GR, which has a nucleotide sequence identical to that of the wild-type 
AQP2 cDNA sequence, except for the G190A substitution, was selected by sequence 
analysis.19 Capped cRNAs were obtained by in vitro transcription of linearized DNA 
template (1 цд) according to Promega's (1991 ) Protocols and Principles guide, except 
that 1 mM final concentrations of NTPs and 7-methyl-diguanosine triphosphate were 
used. Each cRNA was purified and was dissolved in DEPC-treated H20, and its 
integrity determined by agarose gel electrophoresis. RNA concentration was deter­
mined spectrophotometrically. In vitro translation of cRNAs was done with wheat germ 
extracts as described elsewhere.80 Translation products were analyzed by SDS-PAGE, 
according to the procedure of Laemmli.21 Water permeability of Xenopus oocytes, 
injected with cRNA coding for wild-type and/or mutant aquaporins, was measured as 
described elsewhere22, except that all experiments were performed at 4°C. 
RESULTS 
Mutation analysis 
In three NDI patients, in whom a V2 receptor defect was either excluded or unlikely, 
direct sequencing of both DNA strands revealed that they were homozygous for 
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AGTGCGAGAG 
CGAGTGCCCGGAGCATCCTGGCCCTGAGACAGCTGGGCCAGCCCCGCAGGGCTCTGCAGC 
ATGTGGGAGCTCCGCTCCATAGCCTTCTCCAGGGCTGTGTTCGCAGAGTTCCTGGCCACA 60 
N H E I R S I A F S R A V F A E F L A T 20 
CTCCTCTTCGTCTTCTTTGGCCTCGGCTCIGCCCTCAACTGGCCACAGGCCCTGCCCTCT 120 
L I F V F F G L G S A L M U P O A L P S 40 
GTGCTACAGATTGCCATGGCGTTTGGCTTGGGTATTGGCACCCTGGTACAGGCTCTGGGC 180 
V L O I A H A F G L G I G T L V O A I G 60 
CACATAAGCGGGGCCCACATCAACCCTGCCGTGACTGTGGCCTGCCTGGTGGGC1GCCAC 240 
H I S G A M 1 N P A V T V A C L V G C H ВО 
GTCTCCGTTCTCCGAGCCGCCTTCTACGTGGCTGCCCAGCTGCTGGGGGCTGTGGCCGGA Ю 0 
V S V L R A A F T V A A O L L G A V A G 100 
GCCGCTCTGCTCCATGAGATCACGCCAGCAGACATCCGCGGGGACCTGGCTGTCAATGCT 3 6 0 
A A L L H E I T P A O I R G D L A V N A 120 
g t g a g t a g c c a c a a c t t t g c tcttctctgtccccsg 
Δ 
CTCAGCAACAGCACGACGGCTGGCCAGGCGGTGACTGTGGAGCTCTTCCTGACACTGCAG 420 
L S N S T T A G O A V T V E L F L T I Q Н О 
CTGGTGCTCTGCATCTTCGCCTCCACCGATGAGCGCCGCGGAGAGAACCCGGGCACCCCT 4 8 0 
L V L C I F A S T D E R R G E H P G T P 160 
GCTCTCTCUTAGGCTTCTCCGTGGCCCTGGGCCACCTCCTTGGGgtaggtcatggccit 525 
A L S 1 G F S V A L G H L L G 175 
g c c c t c c t c c c a c t g c a g 
ATCCATTACACCGGCTGCTCTATGAATCCTGCCCGCTCCCTGGCTCCAGCTGTCGTCACT 585 
I H T T G C S M N P A R S L A P A V V T 195 
GGCAAATTTGATGACCACTGGgtaatggctgaa t c c g c t c g c c c c c a g 6 0 6 
G K F O O H W 202 
GTCTTCTGGATCGGACCCCTGGTGGGCGCCATCCTGGGCTCCCTCCTCTACAACTACGTG 6 6 6 
V F W I G P L V G A I L G S L L T N T V 222 
CTGTTTCCGCCAGCCAAGAGCCTGTCGGAGCGCCTGGCAGTGCTGAAGGGCCTGGAGCCG 726 
L F P P A K S L S E R L A V L K G L E P 242 
GACACCGATTGGGAGGAGCGCGAGGTGCGACGGCGGCAGTCGGTGGAGCTGCACTCGCCG 786 
D T D W E E R E V R R R Q S V E I H S P 262 
CAGAGCCTGCCACGGGGTACCAAGGCCTGAGGGCCGCCAGCGG 813 
O S I P R G T K A * 271 
Flg. 2.2 Human AQP2 cDNA sequence and deduced amino acid sequence. Nucleotide numbering 
of AQP2 starts at the initiation site of translation. Exon and intron sequences are depicted by 
uppercase and lowercase characters, respectively. Flanking intron sequences are separated by dots. 
The nucleotides mutated in the AQP2 genes of the patients are indicated above the DNA sequence: 
» = C559 changed to Τ in patient 1 ; * = G190 changed to A in patient 2; and Δ = C369 deletion in 
patient 3. The genomic sequence is deposited in GenBank under accession number 229491. 
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Flg. 2.3 Proposed topology of the AQP2 protein. The positions of the single nucleotide deletion ала 
amino acid substitutions found in the patients are indicated by arrows. The amino acids residues that 
are conserved within the MIP family are indicated by blackenend symbols. 
mutations in the AQP2 gene (Fig. 2.2, 2.3). In patient 1, a C559T transition in exon 3 
was found, resulting in substitution of a cysteine for an arginine at codon 187 
(R187C).ln patient 2, a G190A transition in exon 1 was detected, leading to substitution 
of an arginine for a glycine (G64R). Sequencing of exon 2 in patient 3, in whom a 
mutation in the V2 receptor gene had been excluded, revealed a single С deletion at 
position 369 (369delC). This deletion shifts the reading frame, resulting in the 
generation of a sequence of eight missense amino acids followed by premature 
termination. Sequencing of exon 3 and 1 of the mothers of patient 1 and 2, 
respectively, revealed that they were heterozygous for the mutations present in their 
children. Unfortunately, DNA of the fathers was not available. The asymptomatic 
parents and brothers of patient 3 were found to be hetero-zygous for the C369 
deletion; his sister was homozygous for the normal allele (Fig. 1.1). 
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Flg. 2.4 Ρ, of Xenopus oocytes injected with cRNAs encoding wild-type AQP2 and/or AQP2 harboring 
the substitution of arginine 64 for glycine (G64R). Mean and SEM values of at least 10 oocytes are 
shown. 
Functional analysis 
In vitro translation, a reliable test for translation in Xenopus oocytes, was performed 
on cRNAs encoding the G64R mutant AQP2. Subsequent analysis by SDS-PAGE 
revealed that the level of expression and size of mutant AQP2 were comparable to 
those of wild-type AQP2 (data not shown). Next, cRNAs encoding wild-type and G64R 
AQP2 were injected into oocytes. Three days after injection, the cells were analyzed 
for their osmotic water permeability, P, (Fig. 2.4). The P, of oocytes injected with 
mutant cRNA did not differ from that of water-injected controls, whereas the Pf value 
of oocytes injected with wild-type AQP2 cRNAs was more than 10-fold higher. 
Furthermore, co-injection of mutant cRNAs with wild-type cRNAs resulted in a Pt similar 
to that of wild-type AQP2 alone. 
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DISCUSSION 
Many years before the genetic defect in X-linked NDI was discovered, it was noticed 
that NDI is genetically a heterogeneous disease. Several families have been reported 
in which the disease does not show the classical X-linked recessive mode of 
inheritance.8"13 Some of the patients in these families were differentiated from patients 
with X-linked NDI on the basis of their ability to increase coagulation and fibrinolytic 
parameters in response to the V2 receptor agonist 1-desamino-8-D-arginine 
vasopressin (DDAVP). Accordingly, it was postulated that in these patients a renal 
post-receptor defect must be the cause of NDI.1*12 Others stated that the disease can 
be divided into type I and II NDI on the basis of urinary cAMP responsiveness to 
DDAVP.88 However, evidence exists that urinary cAMP measurement is not a reliable 
parameter for differentiation.23 
Until recently, the V2 receptor was the only protein in the renal vasopressin signaling 
cascade for which the genetic code had been elucidated. Cloning of the human AQP2 
gene provided a second candidate-gene for NDI.17,18 The protein encoded by this 
gene is a member of a diverse family of transport proteins of which the major intrinsic 
protein (MIP) of the lens fiber cell is the prototype.24 In addition to the two conserved 
asparagine-proline-alanine sequences, which are characteristic for the MlP-family, its 
members have several other residues in common (fig. 3). Two of these are the 
arginine and glycine residues at positions 187 and 64, which are converted into 
cysteine and arginine in patient 1 and 2, respectively. Both are conserved in nearly all 
members of the MlP-family.25 The finding that substitution of these amino acids leads 
to nonfunctional water channels when expressed in Xenopus oocytes is in accordance 
with their conservation during evolution. 
MIP, AQP1 and AQP2 occur as tetramers in membranes, and one subunit is thought 
to form six transmembrane domains with both terminal ends located ¡ntracellularly.2*"28 
Although functioning of a multimene protein is often impaired when a particular subunit 
is mutated2830, the facilitated water transport of wild-type AQP2 was not affected when 
the latter was co-expressed with the G64R mutant. Similar results were obtained when 
wild-type AQP2 was co-expressed with R187C and S216P mutant AQP2 proteins.18 
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These findings are in accordance with the absence of clinical symptoms in parents 
and heterozygous siblings of the four patients described up to now. If transport of the 
mutant proteins to the plasma membrane is not impaired, these data support the 
prevailing idea that AQP2 is functional in its monomeric form.3132 
The identification of three additional NDI patients with mutations in the AQP2 gene 
provides conclusive evidence that NDI has at least two distinct genetic causes. This 
has important implications for genetic counseling in NDI, especially in isolated cases. 
However, knowledge of the inheritance of NDI might still be incomplete; analysis of 
more patients with NDI could result in definition of a third category of patients, in which 
the defect is located between the receptor and the water channel. Furthermore, finding 
new AQP2-mutations in patients with NDI will increase knowledge of the relationship 
between structure and function of the AQP2 water channel. 
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SUMMARY 
Three patients with autosomal recessive nephrogenic diabetes insipidus (NDI), 
homozygous for mutations in the aquaporin 2 gene (AQP2), were tested for their 
fibrinolytic and hemodynamic responses to intravenous administration of 1-des-
amino-8-D-arginine vasopressin (DDAVP). They all showed an increase of tissue-
type plasminogen activator antigen, facial flushing, an increase of heart rate and a 
decrease of diastolic blood pressure. These results confirm the hypothesis that NDI 
patients with an AQP2 defect can be discriminated from NDI patients with a 
vasopressin type 2 receptor defect by their normal extrarenal responses to DDAVP. 
INTRODUCTION 
The main functions of the neurohypophyseal hormone arginine vasopressin (AVP) 
are reflected by its two names; "vasopressin" refers to the vasoconstriction resulting 
from binding to vasopressin type 1 receptors on vascular smooth muscle cells, 
while "antidiuretic hormone" designates the urinary concentration occurring in 
response to binding to vasopressin type 2 (V2) receptors in renal collecting ducts. 
Strong activation of the V2 receptor can be accomplished by administration of 
1-desamino-8-D-arginine vasopressin (DDAVP), a V2 receptor agonist with an 
antidiuretic/pressor ratio of 4000.' In addition to its renal antidiuretic action, DDAVP 
elicits vasodilation and an increase of coagulation and fibrinolysis factors.2,3 The 
exact location of the V2 receptors which mediate these effects is unknown. Studies 
in anephric subjects have contested the possibility that they are situated in the 
kidney.2·4 Moreover, evidence supporting the presence of V2 receptors on 
monocytes has been gained.58 Hereditary nephrogenic diabetes insipidus (NDI) is 
a rare disease in which the antidiuretic response to AVP and DDAVP is lacking, 
resulting in polyuria, polydipsia and an increased risk of dehydration. Furthermore, 
most NDI patients lack the extra-renal responses to DDAVP, indicating a generalized 
V2 receptor defect.3·7"8 Evidence for the hypothesis that a V2 receptor defect causes 
NDI was gained when mutations in the V2 receptor gene were found in patients with 
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the X-linked recessive form of the disease.10 Some patients have been reported, 
however, who showed normal fibrinolytic, coagulation and hemodynamic responses 
to DDAVP, indicating that their extra-renal V2 receptor functions normally.11'13 The 
observation that, in these patients, only the renal response to DDAVP is impaired, 
can be explained by presence of a defect in the antidiuretic AVP pathway beyond 
the V2 receptor. Recently, the gene was cloned which encodes the aquaporin 2 
(AQP2) water channel, a protein that is inserted into the apical membrane of 
collecting duct cells in response to activation of the V2 receptor.14 The first patient 
in which we observed a normal extra-renal response to DDAVP was demonstrated 
to be a compound heterozygote for mutations in this autosomal AQP2 gene, a 
finding which confirmed the postulated presence of a renal post-V2-receptor 
defect.15 Since this is the only patient with a proven AQP2 defect whose extra-renal 
responses to DDAVP have been studied, we performed DDAVP-tests in three 
additional patients with distinct AQP2 mutations, with the objective to confirm the 
assumption that in these NDI patients extra-renal responses to DDAVP are normal. 
PATIENTS, MATERIALS AND METHODS 
Patients 
DDAVP-tests were performed in three NDI patients in whom homozygosity for an 
AQP2 mutation had been detected by sequencing analysis (Table 3.1). All patients 
gave informed consent prior to the test. A detailed description of the case histories, 
Table 1. Data on NDI patients with an AQP2 defect 
Patient 
1 
2 
3 
Age 
29 
25 
1B 
Sex 
M 
F 
M 
Mutation 
Arg187Cys 
Gly64Arg 
C369del 
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DNA analysis and in vitro expression of the mutations has been given in a previous 
report.1" Patient 1 and 3 did not take any medication. Patient 2, who used amiloride-
hydrochlorothiazide two times a day, discontinued medication 12 h prior to the test. 
DDAVP-tests 
Food and water were not restricted before or during the test. After cannulation of 
a cubital vein, patients rested for 50 min in the recumbent position. From t = 0 to 
t = 10, a dose of 0.3 ßg DDAVP (Minrin", Ferring, Malmö, Sweden) per kg body 
weight, diluted in 100 ml 0.9% sodium chloride, was infused. Systolic and diastolic 
blood pressure and heart rate were monitored at 3 min-intervals during the first 25 
min and at 10 min intervals thereafter. Blood samples were taken from the 
indwelling venipuncture 10 min before (t = -10), immediately before (t = 0) and 10, 
20, 30 and 60 min after the start of the DDAVP infusion. Each time the first 4 ml of 
blood were discarded. The next 4.5 ml were collected in a new syringe and 
transferred into tubes containing 0.5 ml 3.8% sodium citrate. The tubes were 
immediately cooled on melting ice. Platelet-poor plasma obtained by centrifugaron 
at 4°C for 10 minutes at 3000 g, was quickly frozen in aliquots of 0.5 ml and stored 
at -70°C until assays were performed. Tissue-type plasminogen activator antigen 
(tPA:Ag) was measured by an enzyme-linked ¡mmuno assay (Innotest, 
Chromogenix, Zwijndrecht, Belgium). Data were compared with those obtained from 
six NDI patients3 in whom a V2 receptor gene mutation had been found. 
RESULTS 
In the three patients with an AQP2 defect, a significant rise of tPA:Ag values occur-
red in response to the DDAVP administration. The intensity and time course of the 
responses varied, but the pattern was clearly distinct from those obtained in 
patients with a V2 receptor defect (Fig. 3.1). Furthermore, a few minutes after the 
start of the DDAVP infusion, an increase of heart rate, varying from 29 to 48% 
compared to the baseline heart rate (t = 0), and a facial flush were observed. 
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Flg. 3.1 Tissue-type plasminogen activator antigen response (tPA:Ag) to DDAVP in the 3 patients 
studied (patient 1 -•-, patient 2 -»-, patient 3 -»-)· Mean and SEM values of 6 NDI patients " with 
a V2-receptor mutation (-x-) are shown as well. tPA:Ag values at t = 0 are expressed as 100%. 
During the DDAVP infusion, all patients showed a decrease of diastolic blood 
pressure (15-22%) compared to the baseline value. No significant decrease of 
systolic blood pressure was observed (3-9%) (data not shown). 
DISCUSSION 
Two genetically distinct forms of hereditary NDI are currently known to exist; X-
linked NDI is caused by mutations in the V2 receptor gene, autosomal recessive 
NDI results from mutations in the AQP2 gene. The clinical phenotypes in these two 
categories of patients seem identical16, rendering discrimination between the two 
forms on this basis impossible. Observations made in the first-described AQP2-NDI 
patient, however, suggested that these patients may be distinguished from patients 
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with a V2 receptor defect by means of their extra-renal responses to DDAVP.12, 
The present study confirms this hypothesis by demonstrating an increase of tPA:Ag 
and heart rate, a decrease of diastolic blood pressure and the occurrence of a facial 
flush in three additional NDI patients with an AQP2 defect. Discrimination of the two 
subgroups of NDI patients on the basis of a DDAVP test is useful in families in 
which only one patient or several siblings are affected, since in these families the 
nature of the genetic defect can not be inferred from the pattern of inheritance. In 
these families, results of the test permit a more efficient approach for DNA analysis. 
Moreover, in circumstances where facilities for DNA analysis are lacking, they may 
provide the sole basis for genetic counseling. 
When performed in female patients, interpretation of the test is more complicated. 
Although in female patients an AQP2 defect seems obvious, we observed a 
phenotype similar to the phenotype of male NDI patients, including absence of the 
extra-renal response to DDAVP, in female carriers of a V2 receptor mutation 
(chapter 4). A plausible explanation for this phenomenon is predominant inactivation 
of the X-chromosome carrying the normal V2 receptor allele in both renal collecting 
duct cells and cells mediating the extra-renal response to DDAVP. Since patterns 
of X-inactivation have been described to vary between different tissues18, it is 
possible that the extra-renal response to DDAVP is normal in some of the 
symptomatic female carriers of a V2 receptor mutation. This could be the case, for 
instance, in the female patients described by Brenner11 and Moses19. Therefore, ft 
seems hazardous to discriminate female NDI patients homozygous for an AQP2 
mutation from female patients hemizygous for a V2 receptor gene mutation on the 
basis of a normal extra-renal DDAVP-test. Absence of this response, however, 
appears to be a distinguishing feature. 
In conclusion, normal extra-renal responses to DDAVP have now been demon-
strated in four NDI patients with a proven AQP2 defect, thereby confirming that this 
test can discriminate between male AQP2 patients and male V2 receptor patients. 
In female patients with a normal response, however, the possibility that hemizygosity 
for a V2 receptor mutation causes the disease needs to be considered. 
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Addendum 
Recently, the female patient described by Moses et al.18 has indeed been found to 
be heterozygous for a V2 receptor mutation: Moses AM, Sangani G, Miller JL: 
Proposed causes of marked vasopressin resistance in a female with an X-linked 
recessive V2 recepto abnormality. J Clin Endocrinol Metab 1995; 80: 1184-1186. 
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SUMMARY 
Nephrogenic diabetes insipidus (NDI) usually shows an X-linked recessive mode of 
inheritance caused by mutations in the vasopressin type 2 (V2) receptor gene. 
In the present study, three NDI-families are described in which females show 
clinical features resembling the phenotype in males. Maximal urine osmolality in 
three female patients did not exceed 200 mosmol/kg and the absence of extra-
renal responses to 1-desamino-8-D-arginine vasopressin was demonstrated in two 
of them. All affected females and two asymptomatic female family members were 
shown to be heterozygous for a V2 receptor gene mutation. Skewed X-inactivation 
is the most likely explanation for the clinical manifestation of NDI in female carriers 
of an V2 receptor mutation. It is concluded that, in female NDI-patients, the 
possibility of heterozygosity for a V2 receptor gene mutation has to be considered 
in addition to homozygosity for mutations in the aquaporin 2 gene, 
INTRODUCTION 
Congenital nephrogenic diabetes insipidus (NDI) is a hereditary renal disorder 
occurring predominantly in males. The disease is characterized by failure of the 
kidney to concentrate urine in response to the neurohypophyseal hormone arginine 
vasopressin. As a consequence, large volumes of urine are produced (polyuria), 
resulting in a water loss that has to be compensated by ingestion of a similar 
quantity of fluid (polydipsia). Most patients present in their first year of life with a-
specific symptoms such as vomiting, anorexia, growth retardation and fever. After 
infanthood, the clinical picture is dominated by the less alarming symptoms of 
polyuria and polydipsia. In most families, NDI shows an X-linked recessive mode of 
inheritance; female carriers have no or only mild symptoms of the disease. In 1992, 
this form of NDI was found to be caused by mutations in the vasopressin type 2 
(V2) receptor gene.1"3 Several families have been reported, however, in which 
females are affected by the disease from childhood (Table 4.1). One explanation for 
the complete manifestation of the disease in females was recently found when 
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Table 4.1 Female NDI-patlents" reported in literature 
Author 
Dancis et al.17 
Carter and Simpkiss" 
Brodehl and Braun1' 
Feigin et al.20 
Wiggelinkhuizen et al." 
Zimmerman and Green" 
Schreiner et al.21 
Niaudet et al.10 
Aggarwal et al.'5 
Brenner et al.22 
Moses et al." 
Schofer et al.23 
Langley et al.24 
Pallacks et al.25 
Age at 
presentation 
6.5 m 
in childhood 
in childhood 
2 m 
3 y 
3 m 
2.8 y 
1.3 y 
? 
3 m 
7-11 y 
3 m 
in childhood 
6 m 
1 m 
2 m 
3 m 
Maximal urine 
osmolality or s.g.b 
1016" pHT) 
1006" (AVP) 
1018" (ONFD 
1011" (ONFD) 
80e 
82(DHT) 
80 (AVP) 
55 (AVP) 
75 (AVP) 
no response 
(DDAVP) 
148 (AVP) 
82 (AVP) 
70 (AVP) 
101 (DDAVP) 
160 (AVP) 
1000* (AVP) 
100θ"(ΑνΡ) 
? 
Affected relatives 
no 
son 
son of sister 
father (mildly affected) 
2 brothers, 1 halfbrother 
brother 
no 
no 
several females 
no 
2 brothers 
1 brother 
no 
no 
sister 
sister 
father 
* Only patients reported to be affected from childhood are mentioned." s.g. specific gravity, 
с during dehydration, m months, y years, DHT dehydration test, AVP after AVP, DDAVP after 
DDAVP, ONFD overnight fluid deprivation 
mutations in the aquaporin 2 (AQP2) water channel gene were shown to cause 
autosomal recessive NDI.4,5 Furthermore, affected females have been described in 
families in which inheritance of NDI seemed dominant.6"10 This heredity pattern 
could, theoretically, reflect the presence of another defect that interferes with signal 
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transduction somewhere between the receptor and water channel. Finally, it has 
been suggested that the expression of X-linked NDI can be nearly complete in 
female carriers, but, to our knowledge, this hypothesis has never been substantia­
ted by DNA-analysis.11"1· 
Here, we report three NDI families in which female carriers of a V2 receptor gene 
mutation show a clinical phenotype similar to male NDI-patients. 
PATIENTS, MATERIALS AND METHODS 
The human studies performed by the NDI research group have been reviewed by 
the Ethics Committee of the University of Nijmegen. 
Patients 
Family 1 
The female patient (IV.I) in this Austrian family (Fig. 4.1 A) was born at term after an 
uncomplicated pregnancy. Family history was negative for NDI and her parents 
were not known to be consanguineous. On the seventh day of life, the girl was 
hospitalized because of diarrhoea with hypertonic dehydration. At admission, 
serum sodium was 156 mmol/l; urine osmolality was not measured. Escherichia 
coli was isolated from her blood. She was treated successfully with intravenous 
fluid and antibiotics and discharged two weeks after admission. 
The following year her brother (IV.2) was born. He was admitted on the tenth day 
of life in dehydrated condition (serum sodium 166 mmol/l, serum osmolality 357 
mosmol/kg). Diarrhoea and fever had been present for one week. Despite dehydra­
tion, urine osmolality was low (118 mosmol/kg). After intravenous fluid therapy, the 
child was noticed to be excessively thirsty and polyuric (intake 360 ml/kg per day). 
Fig. 4.1 Α-C Pedigrees of the NDI families. Black symbols denote affected individuals; hatched 
symbols indicate that NDI Is suspected; symbols with diagonal slashes denote deceased 
individuals; SB depicts stillborn infants. Presence of the mutant alleles is depicted by the relevant 
amino acid substitution (L219R) or deletion (del); normal alleles are denoted by a plus sign. 
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A dehydration test with subsequent administration of 1-desamino-8-D-arginine 
vasopressin (DDAVP) was performed, resulting in a maximum urine osmolality of 
152 mosmol/kg with a concurrent serum osmolality of 313 mosmol/l (Table 4.2). He 
was treated with hydrochlorothiazide and an ample supply of fluid, a regimen on 
which daily urine production amounted to 250 ml/kg and serum osmolality remai-
ned in the normal range. Now, at the age of 19 months his fluid intake is 250 - 290 
ml/kg per day (medication hydrochlorothiazide and amiloride). Growth and mental 
development are normal. 
Because of the diagnosis of NDI in this boy, attention was again focussed on his 
sister. A renewed medical history revealed that she had been excessively thirsty 
and polyuric since birth. At the age of two years, the girl was hospitalized for 
further evaluation. She was in good general condition (weight and stature P^. 
Serum osmolality, sodium and potassium were normal; random urine osmolality 
was low (82 mosmol/kg). Oral fluid intake ranged from 260 to 350 ml/kg/day. A 
dehydration test did not result in a normal increase of urine osmolality, neither did 
intravenous administration of DDAVP (Table 4.2). Now, at the age of 3 years, she 
has a fluid intake of 300 ml/kg per day (medication hydrochlorothiazide and 
amiloride). Growth and mental development are normal. The mother of these 
children has no symptoms of NDI (daily urine production 1 liter). 
Family 2 
The female proband (IV. 15) in this Dutch family (Fig. 4.1 B) was born at term. The 
pregnancy was complicated by fluxus and hyperemesis after 3 months, mild hyper-
tension and maternal varicosis for which aspirin was used. The girl had feeding 
problems from birth; she vomited frequently and showed aversion to solid foods. 
Growth retardation became manifest at the age of 14 weeks. When she was 8 
months old, she was referred to a pediatrician because of persistent feeding 
problems and growth retardation (length P,0, weight < P3). At laboratory examina-
tion, a high serum sodium concentration (157 mmol/]) and serum osmolality (319 
mosmol/kg) were found. A DDAVP-test showed a minimal increase of urine specific 
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Tabi· 4.2 Data on dehydration and (DD)AVP tests performed in patients in the three families 
Patient Age Max. urine osmolality 
before - after test 
Remarks 
IV.1 family 1 
Г .2 family 1 
IV.15 family 2 
III.7 family 2 
111.10 family 3 
111.11 family 3 
IV.3 family 3 
2 y 
1 m 
β m 
11 y 
ЗЗу 
43 y 
11 y 
16y 
1 m 
8 m 
82 
64 
1000 
76 
240 
225 
1005 
200 
1000" 
150 
-105 
-152 
-1006" 
- 97 
-270 
-309 
- 1014" 
- no increase 
- no increase 
- no increase 
5.5 hrs fluid-deprivation 
(serum osm. 311) 
+ 0.1 цд/кд00А Р i.v. 
4.0 hrs fluid deprivation 
(serum osm 303) 
+ 0.3 цд/кд DDAVP i.v. 
20 цд DDAVP i.n. 
20 цд DDAVP i.n. 
dosis DDAVP i.n. unknown 
40 pg DDAVP i.n. 
both tests performed with a 
standard testdose of pitressin 
after fluid deprivation of 
unknown duration 
standard test-dose of pitressin 
standard test-dose of DDAVP 
The age when the test was performed is expressed in years (y) or months (m), i.v. intravenously, 
i.n. Intranasally, о specific gravity 
gravity (Table 4.2). An intravenous pyelogram (IVP) revealed no abnormalities. Fluid 
intake ad libitum and administration of hydrochlorothiazide in combination with a 
salt-restricted diet resulted in normalization of serum sodium and osmolality and 
she was discharged nine weeks after admission. At present (age 13), daily urine 
production amounts to 150 ml/kg (medication hydrochlorothiazide). She shows a 
normal mental development but is small for age (< P10). 
Family history revealed that the mother (III.7) had a large fluid-intake since child­
hood. When she was in primary school, she was hospitalized because of severe 
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vomiting. In the same period, diabetes mellitus was excluded as a possible cause 
of her polydipsia. At the age of 33, as a consequence of the diagnosis made in her 
daughter, a DDAVP-test was performed, which showed impairment of her anti-
diuretic response (Table 2). An I VP showed slight dilatation of the right pyelum and 
ureter. Treatment with chlorthalidon and a salt-restricted diet resulted in a decrease 
of polydipsia and polyuria. Except for bile stones, for which cholecystectomy was 
performed, she has had no major medical problems. Symptoms of NDI were 
absent from the other family members. Urine osmolality after overnight fluid 
deprivation of the father of patient IV. 15 was normal (905 mosmol/kg). Her sister 
showed a borderline value (735 mosmol/kg). 
Family 3 
The female patient (patient 111.10) in this Dutch family (Fig. 4.1 C) presented at the 
age of 5 months with severe vomiting. Symptoms had started after discontinuation 
of breastfeeding and resulted in a 3 kg decrease of weight in the following two 
weeks. Soon thereafter, she was admitted to a hospital, where the diagnosis of 
hypertrophic pyloric stenosis was made (no additional medical data available). 
Despite surgical intervention, vomiting and anorexia continued for some time, but 
eventually decreased. During childhood, her craving for water was remarkable: 
when she was playing outside for a long time, she used to eat snow or drink from 
puddles on the road. For this reason, she was hospitalized at the age of 5 years 
and a diagnosis of psychogenic diabetes insipidus was made. Six years later, she 
was again examined for excessive thirst and polyuria. A dehydration test with 
subsequent administration of pitressin showed an abnormal response (Table 4.2). 
No diagnosis was made, however, until she was 16 years old. At that time, her half-
brother (patient 111.11) was found to suffer from NDI: after a neonatal meningitis, he 
showed persistent Hypernatremia and polyuria and no response to pitressin (Table 
4.2). The diagnosis in this boy made it reasonable to evaluate his half-sister for a 
third time: a dehydration test revealed a maximal urine osmolality of 200 mos-
mol/kg, despite serum hyperosmolality, and pitressin induced no additional rise 
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(Table 4.2). Antidiuretic hormone concentrations during dehydration were six times 
the normal value, with concurrent hypotonic urine. Now, at adult age, daily urine 
volume amounts to 8-10 l/day (no medication). 
When patient 111.10 was 29 years old, her son (patient IV.3) was born. At the age of 
8 months, he was referred to the hospital because of growth retardation, anorexia, 
polyuria and a positive family history for NDI. Serum sodium concentration was 174 
mmol/l. Urine osmolality varied between 100 and 150 mosmol/kg and did not rise in 
response to DDAVP (Table 4.2); the same diagnosis was therefore made as for his 
mother and uncle. 
Family history revealed that two maternal uncles of patient 111.10 had died in their 
first year of life with symptoms of dehydration. Her aunt died from a cause not 
related to NDI. Interpretation of symptoms of her mother (II.7) was hampered by 
her history of a borderline diabetes mellitus type II and unilateral nephrectomy at 
adult age, performed for an unknown reason. However, she mentioned stress 
incontinence during childhood, excessive thirst during pregnancy and inability to 
maintain fluid deprivation prior to surgery. The sister of patient 111.10 had no 
symptoms at all. 
DDAVP-test with measurement of extra-renal parameters 
Parents of the patients gave informed consent prior to the tests. Tests were 
performed independently in two different centres, resulting in a few procedural 
differences: 
Procedure 1 (family 1) 
A dose of 0.3 мд/kg DDAVP (Minrin", Ferring, Malmö, Sweden) was administered 
intravenously over 30 min. Blood pressure and pulse rate were recorded every 10 
min. A 2.7 ml blood sample was collected at time points: -60, 0, 30, 60, 90 and 120 
min. Blood samples were transferred to tubes containing 0.3 ml citrate solution and 
briefly kept in iced water until centrifugaron at 2000 rpm. The time between blood 
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sampling and performance of the factor VIII coagulant (FVIIIc) activity assay did not 
exceed 4 h. FVIIIc activity was quantified by a one-stage clotting assay using 
factor-VIII-deficient human plasma according to Lechner26. Remaining plasma was 
stored at -70°C. In these samples, tissue type plasminogen activator antigen 
(tPA:Ag) was measured by an enzyme-linked immunosorbent assay (Coaliza t-PA, 
Chromogenix). 
Procedure 2 (family 2) 
Protocol 2 is identical to the protocol described by Knoers and Monnens.27 Briefly, 
DDAVP (0.3 дд/kg) was administered intravenously over 10 min. Blood pressure 
and heart rate were recorded at 3-min intervals during the first 25 min and at 10-
min intervals thereafter. Blood samples were collected and handled as described 
previously.27 t-PA:Ag levels were measured by an enzyme-linked-immunosorbent 
assay (Innotest, Innogenetics). 
DNA analysis 
Genomic DNA was isolated from blood cells by the salt-extraction technique.28 
Linkage analysis was performed by standard procedures using markers defining 
the loci DXS134, DXS52 and F8 (family 2) or DXS52, DXS707 and DXS605 (family 
3).2" Amplification and direct sequencing of AVPR2 exons and introns and AQP2 
exons were performed as described elsewhere.1,4 
In family 1, Smal restriction fragment analysis was used to assess inheritance of the 
mutation. A 526-bp fragment was generated by polymerase chain reaction (PCR) 
using primers 297 and 300 (Table 4.3, Fig. 4.2). After digestion with Smal, frag­
ments were resolved on a 3% agarose gel and visualized by UV-irradiation. 
In family 2, a PCR fragment with the expected length of 319 bp in wild-type DNA 
was generated with primers 295 and 296. In the last cycle, o^PdCTP was added to 
the reaction mixture. PCR products were digested with Bgl\ and resulting fragments 
were separated by electrophoresis on a 15 % non-denaturing Polyacrylamide gel 
and subjected to autoradiography. In family 3, PCR was performed using com 
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Tab!· 3. 
Nr. 
366 
295 
297 
296 
269 
300 
301 
291 
304 
Primers 
Position 
14-34 
intron 1, 97-101 
334-353 
42CM01 
560-579 
859-840 
761-780 
1067-1047 
1252-1233 
Sequence 
S'-CAGAGGCTGAGTCCGCACATC-З' 
5'-ccgactcctgcccagCTGTG-3' 
5'-TGGCTCTGTTCCAAGTGCTG-3' 
5'-ACTTCACGGCCCGACACAGG-3' 
5'-TTGGGCCTTCTCGCTCCTTC-3· 
5'-GACACGTGGGCTCCCTCACG-3' 
5'-GGAGATTCATGCCAGTCTGG-3' 
S'-CACGCTGCTGCTGAAAGATGC-S' 
5'-ACGGAAGGACCCCGACCAGG-3' 
binations of primers 366 and 291, primers 289 and 291 and primers 301 and 291. 
Carrier detection in this family was performed as follows: total DNA was digested 
with ßamH1, fragments were separated by electrophoresis on a 0.6% agarose gel 
and the standard procedure for Southern blotting was applied. A PCR fragment 
generated with primer 301 and 304 and normal genomic DNA as a template, radio-
actively labeled as described above, was used as the probe. 
/ / 
'A 
ЭМ 2Ш as 37 2И 31 
Fig. 4.2 Schematic representation of the V2 receptor gene with the location of the primers 
indicated by arrows. Open boxes denote the sequences encoding the predicted domains of the 
V2 receptor (E extracellular; TM transmembrane; С cellular). Hatched boxes represent intron 
sequences. 
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RESULTS 
DDAVP-tests 
A DDAVP-test with measurement of extra-renal parameters was performed in the 
patients of family 1 and their parents and in patient IV. 15 of family 2. In none of 
these individuals a significant change of blood pressure was found during the test 
(data not shown). Both parents showed a slight increase of pulse rate during the 
DDAVP-infusion which was absent in the three patients (data not shown). Facial 
flushing was observed only in the father. The increase of t-PA:Ag and FVIIIc activity 
found in the parents, did not occur in the patients (Fig. 4.3, 4.4). In patient IV.15 of 
family 2, no significant rise of t-PA:Ag was detected either (FVIIIc not measured) 
(Fig. 4.3). 
t-PA:Ag (ng/ml) 
-60 -10 0 30 60 90 120 
time (min) 
Flg. 4.3. Tissue type plasminogen activator antigen response to DDAVP in patient (V.1 (--) and 
IV.2 (-•-) from family 1, their mother (-»-) and father (-»-) and patient IV.15 (-x-) from family 2. 
DDAVP was administered during 10 minutes (0 to 10 min) in patient IV.15 from family 2 and during 
30 minutes (0 to 30 min) in members of family 1. 
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FVIIIc (%) 
400 ι 
-60 0 30 60 90 120 
time (min) 
Flg. 4.4 Factor Ville activity response to DDAVP in patient IV.1 (-·-) and IV.2 (-•-) from family 1, 
their mother (-»-) and father (-»-). DDAVP was administered during 30 minutes (0 to 30 min). 
DNA analysis 
Family 1 
Direct sequencing of all exons and introns of the V2 receptor gene demonstrated 
the presence of a T727 to G transversion in exon 2 in both affected children, 
resulting in substitution of an arginine for a leucine (L219R) in the fifth transmem­
brane region of the predicted V2 receptor model. The Smal restriction site introdu­
ced by this mutation was present in both affected children and their asymptomatic 
mother, but was absent in their father, maternal grandparents and aunt. In the 
affected girl and her mother, the 526 bp fragment was also present. In the affected 
girl, sequencing of the complete coding region of the AQP2 gene revealed no 
mutations. 
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Family 2 
Linkage-analysis with polymorphic markers for the Xq28 region showed that the 
Xq28 allele shared by the clinically affected women originated from the maternal 
grandfather of the proband (data not shown). The V2 receptor gene sequence of 
the proband revealed a deletion of one of two adjacent CT-nucleotide doublets 
(337-340) in exon 2, resulting in a frameshift 3' to codon 90 in the second trans-
membrane region with a premature stopcodon 101 codons downstream. Segrega-
tion of the deletion in the family was analyzed by detection of a 2-nucleotide size 
reduction of the wild-type 42-bp fragment generated by Bgl\ digestion of the PCR-
fragment (primers 295 and 296). This procedure confirmed the presence of the 
deletion in the proband and revealed that this deletion was also present in her 
mother, but absent in her sister and maternal aunts and uncles. The 42 bp 
fragment was also detected in both affected females. Sequencing of the complete 
AQP2 coding region in the affected girl revealed no mutations. 
Family 3 
Linkage analysis with markers DXS52 and DXS605 (DXS707 was not informative) 
showed that all patients inherited the same Xq28 allele from their mother. The 
unaffected brother (III.9) of patients 111.10 and 111.11 received the other allele. The 
asymptomatic female and the clinically affected female in generation III shared the 
same Xq28 haplotype (data not shown). In the two affected males, no PCR product 
could be generated using primers 366 and 291 and primers 289 and 291. The 
combination of primer 301 and 291, however, resulted in the generation of a 
fragment of approximately 400 bp (including intron 2), indicating a deletion in the 
5'-region of the gene prior to nucleotide 761. In the affected female (111.10), no 
absence or abnormalities of any PCR products were found and sequencing of the 
V2 receptor gene revealed no mutations. In order to assess the carrier status of the 
females in this family, the Southern blot procedure was employed. In the two male 
patients, a SamH1 fragment with a length approximately 1 kb larger than that of the 
fragment found in control individuals was detected (data not shown). In individuals 
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11.7, III.8 and 111.10 both the normal SamH1 fragment and the larger fragment were 
detected, indicating that these females are all heterozygous for the deletion in the 
V2 receptor gene. 
DISCUSSION 
In most families, NDI shows an X-linked recessive inheritance. Variable expression 
of the disease occurs in some of the mothers of these patients, but polyuria and 
polydipsia are generally of such a minimal degree, that these symptoms are either 
not noticed or accepted as a personal characteristic. In addition to these subclinical 
carriers, severely affected females, both isolated and familial cases, have been 
described in literature (Table 4.1). Except for the autosomal recessive form, caused 
by mutations in the recently discovered AQP2 gene4,5, the genetic cause of the 
disease in female patients has not been elucidated. The present study shows that 
female carriers of a V2 receptor gene mutation can present in early childhood with 
symptoms resembling the clinical phenotype of male NDI patients, with three of the 
four females demonstrating a maximal urine osmolality not exceeding 200 mos-
mol/kg (normally > 807 mosmol/kg). In family 1, the apparent autosomal recessive 
inheritance of NDI suggests the presence of an AQP2 defect. Because of the 
severity of the disease in the girl and recent origin of the V2 receptor mutation, the 
classical X-linked recessive pattern of heredity is lacking. Although conclusive 
evidence that the L219R substitution causes NDI can only be obtained by in vitro 
expression studies, the change of a hydrophilic for a hydrophobic residue in a 
region in which hydrophobicrty has been conserved during evolution30 indicates 
that the L219R substitution abolishes the normal function of the receptor. Moreover, 
the absence of extra-renal responses in both patients is in accordance with a V2 
receptor defect.27,31 The deletions found in the other two families undoubtedly 
impair the function of the receptor. 
Several explanations for the complete manifestation of NDI in females deserve 
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consideration. One explanation could be homozygosity or compound heterozygosi-
ty for a V2 receptor mutation or carriership of a V2 receptor mutation in combina-
tion with an abnormal karyotype (45.X0; 45.X0/46.XX; 46.XY); a second V2 receptor 
mutation was excluded in our patients, and both haplotype analysis and Smal, BgH 
and SamH1 digestion patterns confirmed the presence of two V2 receptor alleles. 
The latter findings make the possibility of sex chromosome aneuploidy less likely, 
although mosaicism can not be excluded. Another possibility is the presence of 
other causes of NDI; involvement of the AQP2 gene was ruled out in two of the 
female patients, and indications of secondary NDI were present in none of the 
patients. Clustered occurrence of female symptomatic carriers in certain families 
could reflect the presence of a V2 receptor mutation with more severe functional 
consequences. Mutations, however, that can be regarded as deleterious to the 
AVP2R protein as the deletions described here have been reported in asymptoma-
tic female carriers.32 Moreover, the intra-familial variability of expression observed in 
families 1 and 3 is not in accordance with this explanation. 
Skewed X-inactivation, resulting in predominant expression of the mutant V2 
receptor allele, is by far the most plausible mechanism underlying the occurrence 
of different phenotypes, varying from no symptoms to full manifestation of the 
disease, in female carriers of a V2 receptor gene mutation. This phenomenon has 
been described in female carriers of mutations causing other X-linked recessive 
diseases, including haemophilia A and B, Hunter disease and Duchenne muscular 
dystrophy.*"7 In our female patients, the absence of extra-renal responses to 
DDAVP suggests that predominant inactivation of the X-chromosome carrying the 
wild-type allele occurs in both renal collecting duct cells and the extra-renal cells 
that mediate vasodilation and release of coagulation and fibrinolysis factors. A 
similarity of X-inactivation patterns in different tissues has also been described for 
Duchenne muscular dystrophy.36 On the other hand, variation in the pattern of X-
inactivation between different tissues has been reported38 and could result in a 
discrepancy between renal and extra-renal response to DDAVP in female carriers of 
an V2 receptor mutation. The observation that female carriers of a mutation in the 
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V2 receptor gene can show the clinical phenotype of NDI has important implicati-
ons for genetic counseling and DNA-research into NDI. We observed this pheno-
menon in a relatively high percentage, viz. 8.8% (3 out of 34) of the NDI-families in 
which we found a V2 receptor gene mutation. Therefore, if consanguinity of parents 
is lacking, heterozygosity for an V2 receptor mutation is a likely cause for NDI in 
sporadic female patients. Furthermore, the present study suggests that, in some of 
the families in which NDI shows a dominant mode of inheritance, an V2 receptor 
gene defect could be the cause of the disease. Consequently, in addition to the 
discovery of the AQP2 gene, this study sets the stage for further confinement of the 
number of families with unexplained inheritance of NDI. Finally, for clinical practice, 
it is important to realize that, in female carriers of an V2 receptor mutation, clinical 
and laboratory data can be found which resemble those obtained in male NDI pa-
tients. 
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SUMMARY 
Mental retardation (MR) is generally considered one of the main complications of 
congenital nephrogenic diabetes insipidus (NDI). However, psychometric studies of 
NDI patients are scarce and outdated. In the present study, seventeen male NDI 
patients underwent psychological evaluation. Total intelligence quotient of fourteen 
patients was within (n = 13) or above (n = 1) the normal range, one patient had 
an intelligence score between - 1 and - 2 standard deviations (sd) and two young 
patients had a general cognitive index more than 2 sd below the norm. Attention 
deficit hyperactivity disorder criteria were met by eight out of seventeen patients 
and scores on short term memory were low in seven out of ten. No relation 
between test performances and age at diagnosis or hypernatremia could be found, 
with the exception of a negative correlation between age at start of therapy and 
verbal IQ in one age group. Although several explanations for an association 
between MR and NDI can be postulated, it seems that the current prevalence of 
MR among patients with this disease is considerably lower than suggested in 
literature. 
INTRODUCTION 
Patients with congenital nephrogenic diabetes insipidus (NDI) lack the ability to 
concentrate urine in response to the neurohypophyseal hormone arginine vaso-
pressin (AVP). Consequently, as soon as fluid intake is insufficient to compensate 
for their large renal loss of fluid, disturbance of fluid homeostasis will occur. 
Especially in the first year of life, patients are at risk of severe, sometimes life-
threatening, dehydration. At this age, polyuria and polydipsia are often not mani-
fest. Instead, the clinical picture is dominated by nonspecific symptoms such as 
vomiting, anorexia, failure to thrive, fever, constipation and developmental delay.1 
Accordingly, in most infants diagnosis of NDI is not made until severe hyper-
natremia occurs. 
Mental retardation (MR), varying from mild to severe intellectual impairment has 
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been reported in patients with NDI and is generally considered to be a sequel of 
severe brain dehydration.2'5 However, the abundance of reports which mention MR 
as a clinical hallmark of NDI is in striking contrast with the paucity of psychometric 
data obtained in these patients. Furthermore, the question arises whether the 
current prevalence of MR among NDI patients has decreased due to improved 
therapeutic management of the disease. 
In the present study, general intelligence, cognitive profiles and psychosocial 
functioning of seventeen male NDI patients were evaluated and related to factors 
which could predispose these patients to cognitive deficits. In addition, neuropsy-
chological evaluation of visual-motor integration, attention and memory was made 
to investigate basic functions required for normal learning abilities. 
PATIENTS, MATERIALS AND METHODS 
Patients 
Twenty-seven male Dutch NDI patients were known at the University Hospital of 
Nijmegen, which is the centre where nearly all Dutch NDI patients are referred to 
for DNA analysis. Twenty-two patients of this group were asked by letter to 
participate in the study, with a positive response from seventeen patients. The five 
patients who did not respond were estimated to be of average intelligence, since 
they all attended normal education. Five patients were not approached for different 
reasons. Two of them were too young to be examined by the tests used in this 
study and one had, in addition to NDI, diabetes mellitus since childhood. The two 
other patients were severely mentally retarded and therefore not amenable to the 
tests used in this study. The latter two were evaluated retrospectively. 
In the study group (n = 17), DNA analysis had shown mutations in the vasopressin 
type 2 (V2) receptor gene in fourteen patients, consisting of eight missense 
mutations and six nonsense mutations, and compound heterozygosity for two 
aquaporin 2 (AQP2) missense mutations in one patient (Tables 5.1 and 5.2). In two 
brothers, DNA-analysis was not yet completed, but there was no doubt about the 
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clinical diagnosis and linkage analysis was compatible with X-linked recessive 
inheritance. Except for patient 2 and 5 (brothers), 6 and 9 (brothers) and 3 and 14 
(nephew/uncle), patients were unrelated. In two of the fourteen families, additional 
patients (n = 5) had been identified, of whom only one had been treated for a 
short time. Four of these patients (aged 23-52), all relatives of patient 8, were 
working at a protected employment setting, where simple work is carried out under 
close supervision. They were not willing to participate in our study. The fifth patient 
(aged 53), the uncle of patient 12, was known to be mentally retarded and to be 
living in a protected environment, but additional information was not available. 
Family history did not show other mentally retarded individuals. None of the 
patients in the study group had a history of prematurity or perinatal asphyxia. All 
socio-economic segments appeared to be represented. Except for patients 6 and 
8, all patients were right-handed. 
The two oldest patients of our NDI population, two brothers (aged 39 and 37, 
respectively) in whom a missense V2 receptor gene mutation (S167L) had been 
detected, are both severely retarded and were therefore not able to participate in 
our study protocol. Fragile X syndrome had been excluded in both. They were 
macrocephalic (skull circumference > Ρ 90) but had no specific dysmorphic 
features. Parents and the nonaffected brother and sister are of normal intelligence. 
In the eldest brother, respiration directly postpartum was reported to be insufficient. 
Diagnosis of NDI was not made until the age of 2 4/12 years. Therapy initially 
consisted of salt-restriction and ample fluid supply, followed by start of chlorothiazi­
de and potassium one year later. Routine measurements of serum sodium were 
repeatedly reported to be around 160 meq/l. At the age of 4.5, severe electrolyte 
imbalance occurred with a maximum sodium level of 225 meq/l. Motor develop­
ment was delayed: he did not stand until 2.5 years of age and started walking at 
the age of 5. At the age of 4.5, he was institutionalized. Psychological testing has 
demonstrated severe MR (IQ < 30). Skull X-rays made at the age of 33 revealed 
no calcifications. In the younger brother, no signs of perinatal asphyxia had been 
noticed. At the age of 8 months, he was recognized to have NDI. Medication was 
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initiated soon thereafter, but, similar to his brother, adequate therapeutic manage­
ment of the disease appeared to be difficult and he was admitted for hyperelectro-
lytemia several times (sodium values unknown). He showed a less retarded motor 
development than his brother, with standing at the age of 2 and walking at the age 
of 2.5 years. When he was 10 years old, he was institutionalized. He functions at 
high imbecile level (IQ 46) and shows autistic behavior. 
Materials and Methods 
Cognitive assessment 
Cognitive functioning of the youngest children, aged 3 to 6 (n = 5), was assessed 
by the Dutch adaptation of the McCarthy Developmental Scales of Children's 
Abilities.6 The eighteen subtests are ordered into four cognitive subscales, consis­
ting of a verbal, a perceptual performance, a quantitative, a memory scale and one 
motoric subscale which was not included in this study. The verbal, performance 
and quantitive subscales indicate the general cognitive index (GCI, mean = 100, sd 
= 16). All subscale scores are Τ scores (mean = 50, sd = 10). 
Intellectual abilities of the patients aged 7 - 16 (n = 8) and patients aged 17-30 
(n = 4) were measured by the Dutch adaptation of the Wechsler Intelligence Scale 
for Children-Revised (WISC-R)7 and the Wechsler Adult Intelligence Scale (WAIS)8. 
respectively. The total intelligence quotients (IQ) of the WISC-R and WAIS are 
based on a series of subtests. These subtests are ordered in two groups which 
measure verbal IQ and performance IQ, respectively. Mean value of the total, verbal 
and performance IQ is 100 (sd = 15). In order to facilitate comparison among 
WISC-R and WAIS subtests, the standard scores of the WISC-R were converted to 
Τ scores. Verbal and spatial abilities, concentration and distractibility were evalua­
ted by reorganization of the WISC subtests.'·10 
Neuropsychological screening 
All patients were given the Developmental Test of Visual-Motor Integration (VMI)11 to 
evaluate the age-related development and integration of perceptual and motor 
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skills. To examine aspects of attention and memory, an additional series of neuro­
psychological tests was given, which only applies to persons above the age of 9 (n 
= 10). The Dutch translation of the Stroop Color-Word Test was used to investigate 
the capacity to sustain attention independent of intruding or interfering stimuli.12 The 
adult form of Reitan's Trailmaking Test (TMT)13, which has been standardized for 
the whole age range, was applied to measure attention and sequential visual 
processing (Part A) and ability to shift attention (Part B).14 Verbal memory was 
screened by the Dutch translation of the Auditory-Verbal Learning Test (AVLT).1S 
Retention was measured after 15 minutes. The Benton Visual Retention Test 
(BVRT)1* was used to assess visual short-time memory by drawing geometric figu­
res immediately after an exposure of 10 seconds. The WISC-R subscale Mazes was 
added because of its sensitivity to complex mental functioning involving deter­
mination and organization of steps in goal-directed behaviour. The WAIS does not 
include this test, but it is allowed to use the Mazes and its highest WISC-R norm 
(16.0 -16.5) to estimate the adequacy of the adult performance.14 
Psychosocial functioning and school achievement 
Patients aged 7 to 30 (n = 12) were administered the Dutch Personal Inventory 
adapted to patients with somatic diseases17, a self-report which gives insight into 
personality traits like emotional stability, social competence and self-esteem. Daily 
activities, social competence and school achievement were evaluated by the three 
competence scales of the Child Behaviour Checklist (CBCL, mean = 50, sd = 10)1β 
adapted for the Dutch population. Parents of children aged 5 to 16 answered this 
questionale and were subsequently asked to exemplify some of the answers. 
During the test sessions, standard observations according to Sattler19 were made 
in order to evaluate emotional status and behavioral patterns suggestive for brain 
damage. In addition, the criteria of the Diagnostic and Statistical Manual of Mental 
Disorders (3rd revised edition, American Psychiatric Association, 1987) for Attention 
Deficit Hyperactivity Disorder (ADHD) were applied. 
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Clinical data 
The following clinical data were obtained from medical records of the patients: age 
at diagnosis, age at start of therapy, highest registered serum sodium level and 
months spent in hospital during the first two years of life for reasons related to 
dehydration. 
Statistical analyses 
Means and standard deviations were computed for all measures of the McCarthy 
scales, WISC-R and WAIS. Two-tailed T-tests were used to compare the means of 
the different subtests and subscales and one-tailed paired T-test to assess 
directional differences. To investigate linear relationships between medical and 
psychological data, Pearson-R coefficients of correlation were computed for those 
variables which were measured on interval scale. Statistical evidence was found at 
a P-level of <.05. To reduce the probability of type I errors in the paired T-tests, α 
was divided by the number of T-tests according to the Bonferroni procedure, 
resulting in an α of 0.004 (0.05/12) for data of the group aged 7-30 and an α of 
0.01 (0.05/5) for data of the youngest age group. All data were analyzed by an 
SPSS/PC* program. 
Test administrations, parental interviews and observations were carried out by the 
same examiner in all patients. 
RESULTS 
Cognitive assessment 
Clinical data, GCI, ADHD diagnoses and McCarthy subscales of the five children 
aged 3 to 6 are shown in Table 5.1. According to the GCI scores, patient 3 and 5 
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were mentally retarded. Patient 3 had the highest recorded serum sodium concen­
tration of this age group and was the only patient who developed seizures during 
rehydration. In patient 5, the finding that his younger brother (patient 2), who was 
diagnosed nearly three years earlier, had a GCI within the normal range, suggests 
a negative influence of the large diagnostic delay. The remaining two patients (1 
and 4) showed an average cognitive development. Mean GCI score of this group 
of five children was 84.6 ± 20.2. Means of the quantitative and memory subscales 
were more than 1 sd below the means of the normal population. Table 5.2 presents 
the clinical data and results of psychological evaluation of the patients aged 7 to 16 
(WISC-R group, η = 8) and 17 to 30 (WAIS group, η = 4). Mean total IQ of the 
total group (n = 12) was 96.6 ± 10.3. The one patient (patient 7) with a total IQ 
more than 1 sd below the mean of the normal population, had been diagnosed 
relatively late. All other patients, including the patient with the largest diagnostic 
delay of the whole group, scored within (n = 10) or above (n = 1) the normal 
range. Mean total IQ of the WISC-R group was 93.25 ± 7.42 and of the WAIS-
group 103 ± 11.3. In the WISC-group, a significant negative correlation was found 
between age at start of therapy and verbal IQ (r = - .90, Ρ < .01). Except for the 
latter relationship, neither in the total group, nor in the three subgroups, could a 
significant correlation be found between age at diagnosis or start of therapy, 
highest recorded sodium level or time spent in the hospital related to dehydration 
during the first two years of life on the one hand and the results of psychological 
assessment on the other. Patients with low to moderate intelligence scores did not 
share a specific site or type of mutation. In fact, the highest and lowest scores were 
obtained in two patients (3 and 14) from one family. 
The WISC-R and the WAIS group showed a mutually similar cognitive profile (Fig. 
5.1), but the WAIS group scored higher at nearly all subtests. In both groups, 
scores on Comprehension were significantly higher than scores on Arithmetic (P < 
.004). 
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mean Τ score 
IN SI A V С DS PC PA BD OA CO MA 
Fig. 1 Mean Τ scores on subscale measures of the Wechsler Intelligence Scales (mean 50, sd 10) 
of the WISC-R group (n = 8) and the WAIS group (n = 4). IN, Information; SI, Similarities'; A, 
Arithmetic3; V, Vocabulary1; C, Comprehension1; DS, Digit Span3; PC, Picture Completion2; PA, 
Picture Arrangement; BD, Block Design2; OA, Object Assembly2; CO, Coding3; MA, Mazes (verbal1 
abilities and spatial2 abilities according to Bannatyne (1974), distractibility factor3 according to 
Kaufman (1975)). 
Neuropsychological screening 
Mean Τ scores on visual-motor integration (VMI) for the three age groups were 44 
± 7.4 (n = 5), 46.63 ± 7.35 (n = 8) and 41.75 ± 6.44 (n = 4), respectively. Five 
patients scored 1 sd or more below the mean of the normal population (patient 7, 
8, 13, 15 and 16). Most errors were made in the three-dimensional figures. Additio­
nal neuropsychological testing of the ten oldest patients showed that three patients 
had scores of 1 sd below the mean of the normal population on the Stroop Color-
Word test (patient 8, 12, and 15). On the TMT, three patients (9, 13, and 17) 
showed low performances on Part A, but scored in the normal range on Part B, 
indicating that they had problems with visual tracking but not with the ability to 
shift. Two patients (15 and 16) scored more than 3 sd below the mean of the 
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normal population on both Part A and Part B. In seven of the ten patients, verbal 
short-term memory, as measured by the learning trial of the AVLT, was equal to or 
more than 1 sd below the mean. In all patients, performance on the retention trial 
was in the normal range and equal to or better than on the learning trial. At the 
BVRT, deviation scores of seven patients were 1 to 6 errors below the norms for 
age and IQ. Errors were mostly made in the small peripheral figures of the three-
figure design and consisted of perseverations, misplacements and distortions. Du­
ring the exposure time, most patients verbalized the parts to facilitate remembering. 
The seven patients who scored low on the AVLT had low scores on the BVRT as 
well. In the WISC group, mean Τ score of the WISC subtest Mazes was average 
(50.5 ± 6.82) whereas in the WAIS group, it was nearly 1 sd below the mean 
(41.75 ± 6.5). 
Psychosocial functioning 
Play observation in the youngest children (n = 7) demonstrated that only three 
children played in an age-related way (patient 1, 4 and 6). The other children were 
not interested in the play material or built something in a distorted way and left the 
table within a few minutes. ADHD criteria were met by eight children. Five out of ten 
patients tested with the Dutch Personal Inventory showed a pronounced lack of 
self-esteem, especially in social situations. Mean Τ score (n = 14) on the compe­
tence scale of the CBCL was 45.36 ± 10.42. Eight of the fourteen children scored 
low or very low on the activity scale, with only one patient being member of a 
sporting club. Parents associated this general lack of activity with the tiredness of 
which the children complained frequently. Four children scored below -1 sd on the 
social scale. Three children were members of a youth association and two had 
other outdoor hobbies. Nearly all parents, except those of the two youngest, repor­
ted that their children had good contact with a few friends but preferred to play 
alone. They all mentioned that polyuria and polydipsia seemed to hamper social 
interactions. In this regard, the clinical presentation of patient 16 is illustrative. 
Although polyuria and polydipsia had been present since childhood, these signs 
108 
Cognitive functioning of NDI patients 
had been overshadowed by severe behavioral problems, resulting in the psychiat­
ric diagnosis of borderline personality disorder. It was not until, at the age of 10, his 
behavior necessitated institutionalization, that his polyuria and polydipsia received 
appropiate medical attention, shortly thereafter resulting in diagnosis of NDI. After 
withdrawal of the fluid restrictions imposed on him in the past and start of medicat­
ion, his behavior improved. 
School achievement 
Of the nine children who visited elementary or secondary schools, the CBCL 
showed subnormal scores on general school performance in six (four patients 
between - 1 and - 2 sd, two patients below - 2 sd) and insufficient results on 
arithmetic in seven patients. After examination, two children changed to specialized 
schools (Tables 5.1 and 5.2). Five parents reported restlessness in school and 
difficulty in concentrating on homework. 
Clinical data (see table 5.1 and 5.2) 
None of the patients of the study group had demonstrated signs of asphyxia at 
birth. In the majority of patients (82%), diagnosis of NDI had been made within the 
first eightteen months of life. In all patients except one, medication (hydrochlorothia-
zide/indomethacin) had been initiated directly after or within three months after 
diagnosis. Only in patient 8 had medication been started sixteen months later. 
During the past six years, in most patients, indomethacin has been changed for 
amiloride, which is equally effective but has fewer side-effects. Nearly all admissions 
related to dehydration took place in the first two years of life. 
DISCUSSION 
Ever since the first description of NDI in 1892го, MR has been associated with this 
disease and generally been attributed to its main characteristic i.e. dehydration. 
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Table 5.3 Patients with N01 and cerebral calcifications reported in literature 
Reference 
Kanzaki et a l ." 
Freycon et a l .* 
Schofer et al.41 
Schofer et al.49 
Di Rocco et al.43 
Nozue et al.44 
Mendonca et al.3" 
Tohyama et al.37 
Age at 
diagnosis 
2yl1m 
11y 
9y 
6m 
4weeks 
7m 
10y 
14y 
n.m. 
6y 
3.5y 
2y10m 
βτπ 
Age at 
evaluation 
2y11m 
18y,25y 
16y, 23y 
4y 
6y 
7m, 14m 
17y, 19y 
14y, 25y 
15y 
6У 
1By 
19y 
17y 
location calcifications 
BG 
-
+ 
+ 
+' 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
frontal other 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
temporal 
occipital 
parietal 
occipital 
disseminated 
disseminated 
parietal 
temporal 
parietal 
occipital 
occipital 
parietal 
occipital 
cognitive 
development 
17m delayed 
IQ60 
ICI 60 
IQ 40-45 
2 y delayed, 
improving 
n.m. 
severe MR 
severe MR 
n.m. 
normal 
severe MR 
I Q < 40 
IQ79 
y years; m months; MR mental retardation; + present; - absent; n.m. not mentioned; * at autopsy. 
All patients except one41 are male. 
Dehydration can cause permanent brain dysfunction, manifested by an increased 
prevalence of MR and convulsive disorders, and autopsy reports have demonstra­
ted several cerebral abnormalities including extensive intracranial hemorrhage, 
thrombosis and diffuse encephalopathy with focal necrosis and small hemorrha-
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ges.21,22 Events of this nature might occur in patients with NDI. Additional evidence 
underscoring the assumption that NDI has adverse effects on the cerebrum is 
provided by several reports describing intracranial calcifications in NDI patients, 
lesions which are generally considered a sequel of hemorrhage or necrosis 
(references in Table 5.3). Besides constituting a possible cause for these macro-
scopic abnormalities, brain dehydration is also known to have profound effects at 
the cellular level. Plasma hypertonicity has been found to disrupt the blood-brain 
barrier by opening tight junctions between endothelial cells. Moreover, in an 
attempt to regain and maintain cellular volume, several processes occur, including 
the accumulation of organic solutes like inositol, taurine and glutamina. Although 
meant to be protective, the presence of these osmolytes is thought to have 
adverse consequences as well, especially during rapid rehydration.23 
In addition to osmotic imbalance, the genetic defect of patients with NDI has been 
suggested to be a factor involved in the pathogenesis of MR.24 In most patients, 
NDI is caused by mutations in the X-chromosomal V2 receptor gene.125,2® These 
patients not only lack the antidiuretic V2 receptor-mediated effect but also the 
hemodynamic, coagulation and fibrinolytic responses to the V2 receptor agonist 1-
desamino-8-D-arginine vasopressin (DDAVP), indicating a generalized V2 receptor 
defect.26 Studies in rats have shown that, at least at a certain stage of development, 
expression of the V2 receptor gene occurs in the brain27,28 Therefore, it can be 
argued that inability to accomplish V2 receptor-mediated cerebral processes has 
repercussions on mental functioning of patients with X-linked NDI. 
Despite this variety of factors that could contribute to an increased prevalence of 
MR or cerebral lesions among patients with NDI, caution for bias is warranted. 
Mentally retarded NDI patients are more likely to be examined for cerebral abnor-
malities and to be reported in literature. Moreover, the lack of recent psychometric 
studies might result in an outdated, unduly negative, prognosis of mental develop-
ment. In the present study, the prevalence of MR among patients with NDI was 
assessed by studying cognitive functioning of a major part of our NDI population. 
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The results suggest that prevalence of MR in patients with N01 is lower than 
suggested in literature.2'4 In our study group of seventeen patients, two young 
patients were mentally retarded, one patient had a total IQ between -1 and - 2 sd, 
thirteen patients scored within the normal range and one had a high intelligence 
level. In order to avoid distortion of facts, we also described the two severely 
retarded patients of our NDI population. Only in the elder brother could several 
explanations for his degree of mental disability be found, namely extreme hyperna-
tremia, a relatively late diagnosis and perinatal problems. In the younger brother, 
we were not able to demonstrate a predisposing factor. However, four decades 
ago, management of NDI could have been less optimal, providing an explanation 
for the high incidence of mental retardation in the older literature as well. The 
favorable outcome in most of our patients might also be explained by the generally 
young age at diagnosis in our study group, even in the oldest age group. In fact, 
results of the youngest age group, which included the two most severely retarded 
children, were the lowest. Although this age group is too small to allow firm 
conclusions, it is possible that development is maximally delayed in the first years 
of life, with a catch-up occurring later in childhood. This tendency can also be 
discerned in the study of Reuss and Rosenthal3 and has been alluded to by 
Niaudet et al.5 as well, but needs to be confirmed by longitudinal studies. Notwith-
standing the generally accepted benefit of an early diagnosis, no significant relation 
could be detected between age at diagnosis and intelligence. Age at start of 
therapy correlated with verbal IQ in a subgroup of patients only. It can be postula-
ted that when a patient has obtained enough independency to fulfill his high fluid 
demands, the influence of such factors decreases, leaving a short period during 
which these can induce variability in outcome, especially when assessing a 
relatively small group of patients. Moreover, other factors like intercurrent illnesses 
and environmental factors might confound the relationship between hypernatremia 
and outcome. With respect to the relation between hypernatremia and intelligence, 
similar remarks can be made. In addition, the highest recorded sodium level might 
be a less reliable parameter due to its dependency on frequency of monitoring. In 
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other studies, it was also found to be of little prognostic value. A measure like 
time spent in the hospital for reasons related to dehydration, did not correlate with 
intelligence either. 
Although, in general, intelligence of our patients was not severely impaired, 
remarkable findings were the generally low scores on subtests measuring concen-
tration and distractibility and a high prevalence of ADHD. These deficits have been 
attributed to dysfunction of the frontal lobe1429, a region which, in NDI patients, is 
frequently affected with calcifications (Table 5.3). Attention deficits could also be 
involved in the low short term memory scores.30 Moreover, although the exact 
mechanism has not been unravelled yet, AVP as well as its V2 receptor specific 
agonist DDAVP, have been found to influence learning and memory processes.27-31 
In this respect, the hypothesis that a cerebral V2 receptor is normally involved in 
these functions is intriguing. Nevertheless, it cannot be excluded that another 
receptor is involved27 or that the effects of DDAVP on mental processes occur 
indirectly, for instance by influencing water homeostasis or suppressing intracere-
bral AVP production32. An interesting approach to investigate this hypothesis would 
be to study the prevalence of mental deficits in NDI patients with an AQP2 gene 
defect. Since these patients have normal V2 receptors, the hypothesis of involve-
ment of a V2 receptor in cerebral processes would be confirmed by a lower 
prevalence of MR or specific cognitive deficits among these patients. Unfortunately, 
the number of identified AQP2 patients is still small. The test results of the one 
patient included in this study did not clearly differ from those of the other patients. 
Likewise, comparison of the occurrence of cerebral calcifications in V2R-NDI, 
AQP2-NDI and central diabetes insipidus could provide new insights in the cause 
and consequences of these lesions. In a large study of patients with central 
diabetes insipidus in which CT scans were performed, no cerebral calcifications 
were mentioned33, suggesting that they are specific for the nephrogenic form. 
However, they do occur in a large variety of other diseases34 and have been 
reported in a child with a normal renal response to AVP, who developed hyperna-
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tremía as a result of hypodipsia35. Presence of calcifications in the basal ganglia, a 
frequently affected region in N01 (table 5.3), is especially regarded as a non-
specific finding.34,38 It seems that these highly vascularized, neuron-rich structures 
are very vulnerable to a variety of factors, including hypernatremia. Whether the 
presence of intracranial calcifications relates to MR is not completely clear. Notwith-
standing the possibility of selection bias, a high association can be inferred from 
Table 5.1. Of the thirteen NDI patients with cerebral calcifications reported in the 
literature, at least eight were mentally retarded, whereas in only one case a normal 
intelligence was mentioned. Furthermore, Tohyama et al.37 and Mendonca et al.38 
both described an early diagnosed patient who was not retarded and had no cal-
cifications in contrast to their elder brothers. In our patient group, only a CT scan of 
the patient with the highest total IQ was available, which showed slight calcification 
of the basal ganglia. 
In conclusion, the majority (82 %) of a group of NDI patients aged 3 to 30 years, 
had an intelligence within the normal range. This finding indicates that, possibly as 
a result of improved management of the disease, MR can no longer be regarded a 
clinical hallmark of NDI. 
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SUMMARY 
Congenital nephrogenic diabetes insipidus (NDI) is characterized by insensitivity of 
the distal nephron to arginine vasopressin. Clinical knowledge of this disease is 
largely based on case reports. In this study, we report data on clinical presentation 
and longterm follow-up of thirty male NDI patients. 
The majority of patients (87%) was diagnosed within the first 2.5 years of life. Main 
symptoms at clinical presentation were vomiting and anorexia, failure to thrive, fever 
and constipation. Four older patients were diagnosed as a result of events not 
directly related to NDI. Most patients were on hydrochlorothiazide-amiloride 
treatment without significant side-effects. 
Two patients suffered from severe hydronephrosis with a small rupture of the 
urinary tract after a minor trauma and two patients experienced episodes of acute 
urinary retention. Height standard deviation (SD) scores for age remained below 
the 50th percentile in the majority of patients, whereas weight for height SD scores 
showed a catch-up after several years of underweight. 
INTRODUCTION 
Congenital nephrogenic diabetes insipidus (NDI) is caused by a hereditary defect 
of arginine vasopressin signal transduction in the distal nephron which results in 
inability to accomplish a normal antidiuretic response to this hormone. In most 
cases, a mutation in the vasopressin type 2 (V2) receptor gene is the genetic 
cause of the disease, resulting in X-linked recessive inheritance.1 The autosomal 
recessive and dominant forms of NDI, which are caused by mutations in the 
aquaporin-2 (AQP2) water channel gene, have a much lower prevalence.2"4 The 
primary clinical consequence of these genetic defects is polyuria, causing dehydra-
tion and compensatory polydipsia. In infancy, however, children present with a 
variety of other signs. Several longterm clinical sequelae are also mentioned in the 
literature. Growth retardation, for instance, is thought to result from inadequate food 
intake due to uncontrolled polydipsia and from general poor health because of 
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dehydration and Hypernatremia.5 In addition, urological complications, running the 
gamut from slight dilation of the urinary tract to severe hydronephrosis, have been 
reported."'11 Finally, patients with NDI are generally thought to be at risk for mental 
retardation and the occurrence of intracranial calcifications, complications which 
have been discussed in a previous study.12 
Due to the sporadic occurrence of NDI, a correct impression of the prevalence of 
the various features and complications of this disease, is difficult to obtain. More-
over, selection of severe cases in literature may cause an overestimation of the 
complications of NDI. Finally, since accurate genetic identification of these patients 
has only recently become possible, patient populations of previous studies were 
not defined by mutation analysis. In the present study, we describe a group of 
thirty male NDI patients with special emphasis on clinical presentation, growth and 
the occurrence of urological complications. 
PATIENTS AND METHODS 
A retrospective analysis of clinical data of thirty male NDI patients (aged 1 month to 
40 years) from eightteen Dutch families, collected between 1956 and 1995, was 
performed. All patients had been referred to the University Hospital of Nijmegen for 
clinical evaluation and/or DNA analysis. Follow-up varied from 1 month to 40 years. 
No detailed clinical information was available on two index patients and on seven 
affected relatives. These patients were therefore not included in the study group. 
Two female patients of our population, both manifesting carriers of a V2 receptor 
defect, have been described previously.13 
Except for two brothers in whom linkage analysis and extra-renal responses 
suggested a V2 receptor defect, a mutation had been identified in all patients. In 
twenty-eight patients, DNA analysis had revealed sixteen different mutations in the 
vasopressin type 2 receptor gene. In two patients, two different mutations in the 
aquaporin 2 water channel gene had been found.2,3 
Growth data were collected from medical records and infant welfare centres. In 
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twenty patients, growth had been recorded at regular intervals during follow-up. In 
ten patients, only incidental values were available. Height standard deviation (SD) 
scores were calculated according to the formula SDS = (χ, - xJ/SD,, where x, is the 
individual value and x. and SD, are the sex-specific mean and SD of the standard 
population for the calendar age of the individual. Weight for height SD scores were 
calculated similarly. P50 values and corresponding standard deviation values of the 
Dutch population were derived from the national survey of Roede and Van Wierin-
gen." Since this study provides weight for height data in the form of percentiles 
only, these were transferred in SD scores assuming a normal distribution. The 
intervals between the 10th and 50th and 50th to 90th percentile each divided by 
1.28 were used as SD for calculation of SD scores for individuals with a weight 
below or above the sex- and height specific mean value, respectively.15 
RESULTS 
Clinical presentation 
Age at diagnosis was distributed as shown in figure 6.1. Median age was 9 
months, mean age 25 ± 44 months. The majority of children (63%) were diagno-
number of patients 
5 
3 
2 
1 
0 - , 
0 2 4 6 В 10 1 2 4 6 β 10 12 14 16 18 
age at diagnosis (months/years) 
Fig. 6.1 Histogram of the age at diagnosis of 30 patients with congenital nephrogenic diabetes 
insipidus. 
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sed during the first year of life and another 24% in the next 1.5 year. In nearly all 
cases, drug therapy was initiated shortly thereafter. The reasons for referral had 
been recorded in twenty-nine patients (Fig. 2). Feeding problems, consisting of 
vomiting and anorexia, were presented by twenty-one patients. In one of them, sur-
gical intervention for a supposed pyloric stenosis had been performed but did not 
result in cessation of vomiting. Only one young patient did not have a history of 
clear feeding difficulties. In fifteen patients, failure to thrive was mentioned as a 
major problem. Recurrent fever was recorded in twelve patients and constipation in 
ten patients. At first evaluation, polydipsia was mentioned by the parents of four 
young patients. In one patient, diagnosed at 4 years of age, rumination and 
psychomotoric retardation had been the reason for referral. Two affected siblings of 
known patients had been detected at the age of 2 weeks before significant 
problems occurred. Three older patients (aged 9, 10 and 17 years, respectively) 
were referred for reasons which were not or indirectly related to NDI. Hematomas 
ascribed to a fall of the stairs were the reason for referral of the first patient. In the 
second case, the classical diabetes insipidus signs had been overshadowed by 
severe behavioral problems, diagnosed as borderline personality. It was not until 
appendicitis , 
hematomas , 
behavioral problems
 ( 
ps mot retardation , 
polydipsia
 ( 
constipation , 
fever( 
failure to thrive . 
vomltfng/anorexl. '¡/Ш//////////1>Ί//ΜϊϊΤΤΤλ 
7Ш 
'/////////////A 
'///////////////M 
'////////////////////A 
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number of patients 
25 
Fig. 6.2 Histogram of the reasons for refería! in twenty-nine patients with congenital nephrogenic 
diabetes insipidus 
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behavior problems required institutionalization that the polyuria, polydipsia and 
enuresis nocturna manifested by this patient received appropiate medical attention. 
The final case was diagnosed when medical history taken during pre-operative 
evaluation for an appendectomy revealed polyuria and polydipsia. Retrospectively, 
an admission at the age of 3 years because of drinking a bottle of paraffin is 
illustrative for his life-long thirst. Since he seemed to show some response to 
DDAVP (max. osmolality 330 mosmol/kg), he was initially diagnosed as a case of 
central diabetes insipidus. DNA analysis performed after the birth of a nephew with 
NDI, however, revealed a V2 receptor gene mutation. In addition to this patient, 
three other affected individuals (not included in this patient population) were also 
identified by DNA analysis performed because of the family history of a younger 
proband. 
Initial serum sodium values ranged from 142 to 176 mmol/l (mean 158.5 ± 9.0 
mmol/l, η = 24). Hypernatremia (> 144 mmol/l) was present in all patients except 
one. Convulsions occurred in one patient during intravenous rehydration therapy 
and in one patient who was thought to have meningitis. 
Infant deaths were reported in several families. An uncle of two affected brothers 
died at the age of one year with a medical history highly suspective of NDI but was 
thought to have a brain tumor. Dehydration was mentioned as the cause of death 
in five young children from two different families. In one large family in which a V2 
receptor mutation was found, five paternal uncles of the mother of a patient had 
died between the ages of 3 weeks and 9 months, all with symptoms of vomiting, 
failure to thrive, fever and convulsions. Interestingly, the maternal grandfather had 
never been diagnosed but was said to be Polydipsie.1" Another maternal grandfa­
ther, of which family history only revealed that sometimes he drank ditch-water, was 
also identified retrospectively. One daughter of a carrier of a V2 receptor mutation 
drowned in a water tub. A sister of the two patients in whom the genetic defect has 
not yet been found died from Potter syndrome. 
Diagnosis was usually made by the observation of a lack of increase of urine 
osmolality or specific gravity (s.g.) after administration of arginine vasopressin or its 
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analogue 1-desamino-8-D-arginine vasopressin (DDAVP), although exact values 
were not always recorded. The available values reached from 64 to 225 mosmol/kg 
or 1000 to 1004 (s.g.) (n = 9). In two patients, among whom the patient who had 
been taken for a case of central diabetes insipidus, DDAVP was given immediately 
after a dehydration test resulting in final values of 315 and 330 mosmol/kg. These 
patients shared a glycine 185 to cysteine (G185C) amino acid substitution of the V2 
receptor. Both had been diagnosed long after infancy and had undiagnosed 
affected family members in previous generations. Some other patients with the 
same mutation, however, showed a clinical phenotype similar to the majority of 
patients. Finally, in one patient (with a valine 88 to methionine substitution), a 
maximal urine osmolality of 545 mosmol/kg was registered during a water deprivati-
on test, whereas, after rehydration, no response to DDAVP was found. 
Drug treatment 
Most patients had initially been treated with hydrochlorothiazide with or without 
¡ndomethacin and potassium suppletion. One patient suffered from gastric he-
morrhage during ¡ndomethacin treatment. In another patient the ¡ndomethacin 
dosage was reduced because he was thought to have a peptic ulcer. 
Sixteen patients were treated with hydrochlorothiazide-amiloride therapy for a 
period ranging from three to nine years. Four patients had also been treated with 
this combination in the past, but discontinued because of persistent nausea (n = 
2), lesser effect on diuresis compared to treatment with hydrochlorothiazide/in-
domethacin (n = 1) and preference of the medical attendant for conventional 
treatment (n = 1). Two adult patients did not use any medication. The first patient 
had a urine output of about 12 to 14 liters, to which he feels adjusted. The second 
patient has a similar output but refrained from medical treatment and follow-up. 
Urologlcal problems 
Nine patients, aged 1 to 34 years, have not shown dilation of the urinary tract on 
ultrasonographic follow-up. In eleven patients, the medical records did not mention 
125 
Chapter 6 
renal imaging or problems of urological origin other than enuresis nocturna (see 
below). Four patients were reported to have slight non-progressive or transient 
pyelum dilation (n = 3) or transient ureteral dilation (n = 1). 
In two out of thirty patients severe dilation of the urinary tract occurred. Routine 
physical examination of the first patient at the age of 4 years revealed a distended 
abdomen. Since one year, he had been nearly toilet-trained with occasional 
bedwetting. Ultrasonography and intravenous pyelography revealed bilateral 
dilation of the pyeium and ureters and miction cystography showed minimal reflux 
at the left side. Cystography showed no obstruction. A prostaglandinsynthethase 
inhibitor was added to his hydrochlorothiazide-treatment, after which his 4 to 5 liter 
urine output reduced by 50%. Bladder voidance at 2-hour periods was advised. 
Follow-up ultrasonography revealed persistent hydro-uretero-nephrosis. At the age 
of thirteen he was admitted to the hospital for extreme pain and vomiting after he 
had been hit with a volley-ball in his left flank. Ultrasonography revealed a thin renal 
cortex at the left and nearly absent cortex at the right side. A fluid collection was 
surrounding the left kidney. Intravenous pyelography showed severe hydronephro­
sis and leakage of contrast with nearly no function of the left kidney. Bladder 
voidance problems were reason for transient catheterization. His drug dosage was 
adjusted resulting in a reduction from 10 liters to 6.4 liters of urine per day. 
Creatinine levels decreased from 88 μπηοΙ/Ι at admission to 66 μπιοΙ/Ι at discharge. 
Now, at the age of sixteen, his condition is stable with use of an alpha,-receptor-
blocker to facilitate bladder voidance, a daily urine output of 7 to 8 liters and a 
serum creatinine of around 80 μπιοΙ/Ι. 
The second patient was diagnosed with NDI at the age of 16 months and received 
drug treatment ever since. At routine evaluation at the age of 7 years, severe 
hydronephrosis and hydroureters were found (see Fig. 6.3). These abnormalities 
persisted during follow-up, with stable serum creatinine levels around 100 дтоІ/І. 
Evaluation because of pain in his left flank after he fell during ice-skating did not 
show additional abnormalities. At the age of 20, a Magill scan showed bilateral low 
kidney function. Shortly thereafter he was admitted with fever, dehydration and a 
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years old and severely mentally retarded. Urological problems began at the age of 
33, after thirty years of treatment with chlorothiazides. He experienced two episo-
des of colicky pain, accompagnied by hematuria. Ultrasonography showed slight 
ureterodilation and a large bladder but no hydronephrosis. Chronic urinary infection 
occurred during the following years. Urological evaluation at the age of 37 showed 
a trabeculated bladder wall and a miction residu of 1.4 liter. Incision of the bladder 
neck was performed. During the past three years he suffered several times of acute 
urine retention. Ultrasonographic follow-up shows no dilation but still a considerable 
residu after miction. His younger brother, who is also mentally retarded, has no 
urological problems, neither clinical nor on ultrasonography. 
One other patient had also been treated with a parasympathomimetic agent for a 
few weeks because he had difficulty emptying his bladder but he does not show 
dilation or an increased bladder capacity. Enuresis nocturna above the age of 7 
years was known to exist in eight patients at ages varying from 8 to 14.5 years. 
Ten patients were toilet-trained at the age of 7. In the other patients enuresis was 
either not mentioned or data on this subject after the age of 7 were not available. In 
addition to the two patients described above, urinary infection occurred in one 
other patient at two occasions. 
Growth of patients with NDI 
The distribution of SD scores in figure 6.4 shows that the majority of children grows 
under the 50th percentile, most of them having SD scores lower than - 1 . There is 
no clear catch-up effect after the first years of life. Bone ages have not been 
measured systematically, but were available in eleven patients and were generally 
in accordance with calendar age. Weight for height SD scores showed initial under-
weight followed by global normalization at school age (Fig. 6.5). 
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Additional medical findings 
Significant medical problems not directly related to NDI consisted of, presumably 
congenital, unilateral perceptive deafness (n = 1), perceptive hearing-loss of 30-40 
dB in a mentally retarded adult, osteochondritis of the humerus (n = 1) and 
hypertension (n = 1). In one patient of normal intelligence, computerized tomo-
graphy performed because of headaches, showed small bilateral calcifications of 
the basal ganglia. 
DISCUSSION 
The aspeclfic, but largely uniform clinical presentation of infants with NDI is clearly 
illustrated by the data of this large patient population. Vomiting and anorexia, failure 
to thrive, fever and constipation were, in order of frequency, the most reported 
clinical symptoms. Four older patients had been referred for reasons other than the 
classical diabetes insipidus signs, indicating that the latter are easily overlooked. 
Some affected relatives even remained undiagnosed until adulthood and were only 
traced as a result of family history. On the other hand, infant deaths highly suspec-
tive for cases of NDI occurred as well. 
Maximal urine osmolality after vasopressin or DDAVP showed some variation, which 
may be explained by interindividual variation, age-dependency and use of different 
protocols. After the first year of life, performance of the standard DDAVP-test 
should result in an osmolality > 807 mosmol/kg.17 In patients with congenital NDI, 
values are usually below 200 mosmol/kg.16 Previous thirsting, rather than a less 
severe mutation, may explain the values > 300 mosmol/kg found in some patients. 
It can not be excluded, however, that certain mutations do not completely abolish 
signal transduction, a hypothesis which can be studied by in vitro expression.1" 
Apart from this observation, the clinical picture of the thirty patients was largely 
uniform. Rather than from genetic heterogeneity, differences in age at diagnosis 
seem to result from factors like variability in acquaintance with the disease, the 
presence or absence of affected family members and the occurrence of medical 
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problems which may accelerate diagnosis. In females, variability of the clinical 
phenotype is a more common phenomenon, with severe symptoms in females 
homozygous for an AQP2 mutation and either similar, mild or no signs at all in 
female earners of a V2 receptor mutation.13 
Treatment with combinations of indomethacin, hydrochlorothiazide and amiloride 
and a low sodium diet is known to reduce urine-output in patients with NDI.1820 We 
prefer the hydrochlorothiazide-amiloride regimen because of the possible side-
effects of chronic treatment with prostaglandin-synthetase-inhibitors. In our expe-
rience, initial nausea occurs in some patients who start on amiloride but is general-
ly transient and rarely reason for discontinuation of therapy. 
Among the putative longterm sequelae of NDI, mental retardation is most frequently 
cited in literature. A recent study in seventeen patients of our population, however, 
revealed that the current prevalence of this complication is generally overestimated. 
The majority of patients were found to have a normal intelligence.12 Our population 
has not been screened for intracranial calcifications. These lesions have been 
reported in several NDI patients but their exact cause and clinical significance 
remain unknown.12 Urological complications of NDI have also been published in 
several case reports. In their review of literature, Uribarri et al.11 found that abnor-
malities, varying from slight dilation to severe hydronephrosis, were reported in 
67% of cases which included a description of the urinary tract. In a few patients, 
the latter condition has been treated by surgical drainage.8·9 Three patients have 
been described in whom severe hydronephrosis was followed by chronic renal 
failure.8'10 Because of selection bias, however, such data can not be used to inform 
the individual patient about the chance that these complications will occur. The 
present evaluation revealed significant urological problems in four out of thirty 
patients, consisting of severe hydronephrosis or acute urine retention. In patients 
with severe hydronephrosis, the possibility of renal contusion or rupture of the 
urinary tract after a minor trauma should be considered. This complication has 
been described in literature only once, but occurred in both of our patients with 
severe hydronephrosis.' Considering the potentially severe consequences of 
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hydronephrosis, ultrasonographic follow-up is indicated in every patient with NDI. 
Moreover, prevention or reduction of serious renal, uretheral or bladder dilation 
may be achieved by drug therapy and voidance at 2-hour intervals. 
Growth retardation is a frequently cited feature of NDI, but has not been assessed 
systematically. Moreover, it is generally not clear whether the initial failure to thrive 
is meant or a more chronic growth retardation. Niaudet et al.21 reported growth 
retardation in two-thirds of a group of thirty-nine patients but did not mention 
anthropometric data or the age of the patients. Williams et al.22 mentioned a slight 
impairment of growth in five out of seven patients. Until now, only Caletti et al.23 
reported a systematic assessment of growth in patients with NDI. They evaluated 
ten patients and found a mean SD score of - 2.61 at diagnosis which improved to 
- 1.59. Our evaluation also shows that the majority of patients is small for age, 
though the deviation is not extreme and in general not experienced as a major 
problem by the patients themselves. Apart from the initial feeding problems, several 
factors could predispose patients with NDI to a reduction of final height. The 
ingestion of large amounts of fluid decreases appetite, but this is more likely to 
cause chronic underweight. Such a tendency was not found in our population in 
which several patients are even on a low calory diet. In older patients, the low 
protein diet advocated in the past to reduce urine output may have contributed to 
growth retardation. With adequate therapy and fluid intake, chronic dehydration is 
not likely to be a major factor, especially not after the the first years of life. It can 
not be excluded, however, that the constant tendency for dehydration in patients 
with NDI has some unknown consequences, for example on the secretion of 
growth hormone. 
We conclude that NDI has a rather uniform clinical phenotype. On the long term, 
one needs to be aware of the possibility of a decreased statural growth and the 
occurrence of hydronephrosis and abnormal bladder function in these patients. 
132 
Clinical presentation and follow-up of 30 patients 
Acknowledgements 
We thank the following colleagues for referring patients to us and/or for supplying 
us with clinical data: N. Ceelie, H. Doorn, J.H.M. Berden, R. van Eijk, T. van Essen, 
M. den Hartog, LH.A. Hinkofer, I.J.P. van de Kamp, G.H. van Leeuwen, J. Nauta, 
B.C. van Pelt, R.R. Pereira, W.C.C. Reitsma-Bierens, J.M. Werre, J.A.M. Widdersho-
ven, J.C.H.M. Wijffels, S.P.M, van der Zee, H.L van Zijll Langhout. 
REFERENCES 
1. Knoers NVAM, van den Ouweland AMW, Verdijk M, Monnens LAH, van Oost BA. Inheritance 
of mutations in the V2 receptor gene in thirteen families with nephrogenic diabetes insipidus. 
Kidney Int 1994; 46: 170-176. 
2. Deen PMT, Verdijk MAJ, Knoers NVAM, Wieringa B, Monnens LAH, van Os CH, van Oost BA. 
Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concen-
tration Of urine. Science 1994; 264: 92-95. 
3. van Lieburg AF, Verdijk MAJ, Knoers WAM, van Essen AJ, Proesmans W, Mallmann R, 
Monnens LAH, van Oost BA, van Os CH, Deen PMT. Patients with autosomal nephrogenic 
diabetes insipidus homozygous for mutations In the aquaporin 2 water channel gene. Am J 
Hum Genet 1994; 55: 646-652. 
4. Bichet DG, Arthus M, Lonergan M, Balfe W, Skoreckl K, Nivet H, Robertson G, Oksche A, 
Rosenthal W, Fujiwara M, Morgan K, Sasaki S. Autosomal dominant and autosomal recessive 
nephrogenic diabetes insipidus: novel mutations in the AQP2 gene. J Am See Nephrol 1995; 
6: 717. 
5. Behrman RE, Vaughan VC. Nelson Textbook of Pediatrics. W.B. Saunders Company, 
Philadelphia. 1979, p. 1347-1349. 
6. ten Bensel RW, Peters ER. Progressive hydronephrosis, hydroureter and dilation of the 
bladder in siblings with congenital nephrogenic diabetes insipidus. J Pediatr 1970; 77: 
439-443. 
7. Wiggelinkhuizen J, Wolff B, Cremin BJ. Nephrogenic diabetes insipidus and obstructive 
uropathy. Am J Dis Child 1973; 126: 398-401. 
8. Nakada T, Miyauchi T, Sumiya H, Shimazaki J. Nonobstructive urinary tract dilation In 
nephrogenic diabetes insipidus. Int Urol Nephrol 1990; 22: 419-427. 
9. Zender HO, Ruedin P, Moser F, Bolle JF, Leski M. Traumatic rupture of the urinary tract In a 
133 
Chapter 6 
patient presenting nephrogenic diabetes insipidus associated with hydronephrosis and 
chronic renal failure: case report and review of the literature. Clin Nephrol 1992; 38: 196-202. 
10. Hoftzman EJ, Harris HW, Kolakowski LF, Quay-Woodford L, Botelho B, Ausiello DA. Brief 
report: a molecular defect in the vasopressin V2-receptor gene causing nephrogenic 
diabetes insipidus. N Engl J Med 1993; 328:1534-1537. 
11. Uribarri J, Kaskas M. Hereditary nephrogenic diabetes insipidus and bilateral nonobstructive 
hydronephrosis. Nephron 1993; 65: 346-349. 
12. Hoekstra JA, van Lieburg AF, Monnens LAH, Hulstijn-Oirkmaat GM, Knoers WAM. Cognitive 
and psychosocial functioning of patients with congenital nephrogenic diabetes insipidus. Am 
J Med Genet 1996; 61: 81-88. 
13. van Lieburg AF, Verdijk MAJ, Schoute F, Ligtenberg MJL, van Oost BA, Waldhauser F, 
Dobner M, Monnens LAH, Knoers NVAM. Clinical phenotype of nephrogenic diabetes 
insipidus in females heterozygous for a vasopressin type 2 receptor mutation. Hum Genet 
1995; 96: 70-78. 
14. Roede M J, van Wieringen JC. Growth diagrams 1980. Netherlands third nationwide survey. 
Tijdsch Soc Gezondh 1985; 63: 1-34. 
15. Schaefer F, Burgard P, Batzler U, Rupp A, Schmidt H, Gilii G, Bickel H, Bremer HJ. Growth 
and skeletal maturation in children with phenylketonuria Acta Pediatr 1994; 83: 534-541. 
16. Wijffels JCHM. Nephrogene diabetes insipidus. Stenfert-Kroese N.V., Leiden, 1959. 
17. Monnens L, Smulders Y, van Lier H, De Boo T. DDAVP test for assessment of renal concen­
trating capacity in infants and children. Nephron 1981; 29: 151-154. 
18. Monnens L, Jonkman A, Thomas C. Response to indomethacin and hydrochlorothiazide in 
nephrogenic diabetes insipidus. Clin Science 1984; 66: 709-715. 
19. van Lieburg AF, Verdijk M, Knoers Ν, Afer E, Pastina R, Fahrenholz F, van Oost BA. In vitro 
expression of mutations in the V2-receptor gene - confirmation of their role in the pathogene­
sis of X-linked nephrogenic diabetes insipidus. Pediatr Nephrol 1994; 8: C75. 
20. Knoers N, Monnens LAH. Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothia-
zkte in the treatment of nephrogenic diabetes insipidus. Clin Lab Observ 1990; 117: 499-502. 
21. Niaudet P, Dechaux M, Leroy D, Broyer M. Nephrogenic diabetes insipidus in children. Front 
Horm Res 1985; 13: 224-231. 
22. Williams RH. Nephrogenic diabetes insipidus occurring in males and transmitted by females. 
J Clin Invest 1946; 25: 937-938. 
23. Caletti MG, Giménez A, Lejarraga H. A longitudinal growth in height of 10 children with 
familiar nephrogenic diabetes insipidus (NDI). Congress of the International Pediatric 
Nephrology Association, Santiago, Chili 1995; P132. 
134 
Chapter 7 
EFFECTS OF ARGININE VASOPRESSIN AND 
1-DESAMINO-8-D-ARGININE VASOPRESSIN 
ON FOREARM VASCULATURE OF HEALTHY SUBJECTS 
AND PATIENTS WITH A V2 RECEPTOR DEFECT 
A.F. van Lieburg1, N.V.A.M. Knoers2, LA.H. Monnens1, P. Smits3 
Departments of Pediatrics1, Human Genetics2 and Internal Medicine3, 
University Hospital Nijmegen, The Netherlands 
Journal of Hypertension 1995; 13: 1695-1700 
Chapter 7 
SUMMARY 
The objectives of this study were to assess which vasopressin receptor subtype 
mediates the vasodilation occurring in response to arginine vasopressin (AVP) and 
1-desamino-8-D-arginine vasopressin (DDAVP) and whether nitric oxide (NO) is 
involved in these effects. Vasoactive effects of AVP and DDAVP on forearm vas-
culature were studied in healthy subjects and in patients with congenital nephroge-
nic diabetes insipidus (NDI) with a vasopressin type 2 (V2) receptor gene defect. 
Venous occlusion plethysmography was used to assess the forearm blood flow 
(FBF) responses to infusion of AVP and DDAVP into the brachial artery, in the 
presence and the absence of the NO-synthase inhibitor L-NQ-monomethyl-arginine 
(L-NMMA). In healthy subjects (n = 10), DDAVP (0.1, 1 and 10 or 5, 10 and 20 
ng/min per dl) induced a dose-related increase in FBF, but did not affect FBF in the 
patients with NDI (n = 3). In two healthy subjects, seven increasing dosages of 
AVP (0.25 to 12 ng/min per dl) induced an initial decrease in FBF and then a 
gradual increase. In one of the patients, the same AVP doses produced a persis-
tent decrease in FBF. In the healthy subjects, infusion of L-NMMA reduced FBF 
significantly (n = 10). Subsequent administration of DDAVP during L-NMMA 
infusion produced a slight reduction in the FBF increase compared with DDAVP 
alone, but this was significant only for the absolute FBF increase induced by 10 
ng/min per dl in all subjects. Infusion of AVP in the presence of L-NMMA did not 
increase FBF significantly. We conclude that in human forearm vasculature, extra-
renal V2 receptors mediate the vasodilation induced by DDAVP or high doses of 
AVP, whereas these receptors are not necessary for AVP-induced vasoconstriction. 
The DDAVP-induced vasodilation seems to be mediated predominantly by a 
mechanism other than endothelial NO release, whereas AVP-induced vasodilation 
seems to involve NO release only. 
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INTRODUCTION 
The neurohypophyseal hormone arginine vasopressin (AVP), which is also referred 
to as the antidiuretic hormone, owes its two names to its main functions: va-
soconstriction and antidiuresis. Vasopressin type 1 (V1) receptors on vascular 
smooth muscle cells mediate the vasoconstrictive action, whereas vasopressin type 
2 (V2) receptors are involved in the antidiuretic effect exerted in renal collecting 
duct cells. A less well-known effect of AVP is vasodilation, which has been found to 
occur in response to high local concentrations of the hormone.1"5 Attempts to 
assess the type of receptor mediating this vasodilatory action have yielded con-
tradictory results, with discrepancies between in vivo and in vitro studies, among 
different species and among vascular beds.64 In vivo studies using V1 receptor an-
tagonists have indicated that the vasodilation occurring in response to high doses 
of AVP is mediated by V2 receptors1·3,9"13, an observation which is in accord with 
the vasodilatory effect of the V2 receptor agonist 1-desamino-8-D-arginine vaso-
pressin (DDAVP).1 Furthermore, recent investigations have suggested a role for 
endothelium-derived nitric oxide (NO) in the vasodilator response to AVP.4,14"17 
In the present study, we assessed in human forearm vasculature which vasopres-
sin receptor subtype mediates AVP- and DDAVP-induced vasodilation by compa-
ring the responses of healthy subjects with those of patients with a proven V2 
receptor defect and whether NO is involved in these vasodilatory effects. 
MATERIALS AND METHODS 
Subjects 
The study protocol was approved by the local ethical committee of the University 
Hospital Nijmegen. All subjects gave written informed consent. 
Fifteen healthy male volunteers (age 1 9 - 3 1 years) and three male patients with 
congenital nephrogenic diabetes insipidus (NDI) (age 21-30 years) participated in 
the study. All of the NDI patients had had polyuria and polydipsia since early 
childhood and showed no antidiuretic response to DDAVP. In the three patients, 
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DNA sequencing analysis of the V2 receptor gene had been performed as descri-
bed previously.1" In all of the patients, point mutations had been detected in this 
gene, resulting in amino acid substitutions in two of them (phenylalanine 44 to 
leucine and arginine 202 to cysteine, respectively) and introduction of a premature 
stopcodon in the third patient (arginine 337 to stopcodon). A physical examination 
and electrocardiography revealed no abnormalities in any of the participants. The 
experiments were performed after overnight fasting by the subjects. During the 24 
h preceding the experiment, they did not smoke or drink beverages containing 
caffeine or alcohol. In the two weeks preceeding the study, none of the healthy 
volunteers had taken any medication. One of the NDI patients complied with a 
request to stop taking hydrochlorothiazide, amiloride and indomethacin 36 hours 
before the start of the experiment, and one patient, who was taking hydrochloro-
thiazide and amiloride, continued using the medication. The third patient was not 
taking any medication. 
Study design 
The brachial artery of the left arm was cannulated. The experiments started after an 
equilibration period of 30 min. Forearm blood flow (FBF) of both arms was 
measured by venous occlusion mercury-in-silastic strain gauge plethysmography. 
Simultaneously, circulation of the hand was arrested by inflating a cuff around the 
wrist. The FBF values obtained during the last two minutes of each infusion were 
used for further analysis. Blood pressure and heart rate were recorded intra-arte-
rially (Hewlett-Packard GmbH, Böblingen, Germany). 
Protocols were designed to assess the vascular response to DDAVP and AVP in 
healthy subjects; the vascular response to DDAVP and AVP in NDI patients with a 
V2 receptor defect; and the effect of L-NQ-monomethyl-arginine (L-NMMA) on 
DDAVP- and AVP-induced vasodilation. One healthy subject and one NDI patient 
participated in both the DDAVP- and the AVP-experiment. 
138 
Vascular effects of AVP and DDAVP 
Drugs 
Desmopressine-acetaathydraat (1-desamino-8-D-arginine vasopressin, Minrin"; 
Ferring, Malmö, Sweden; 0.4 дд/І) was diluted with 0.9% sodium chloride. Doses of 
either 0.1, 1 and 10 or 5, 10 and 20 ng/min per dl forearm volume were infused 
during subsequent 5-min periods. Arginine vasopressin (Pitressin; Parke- Davis, 
Berlin, Germany; 0.05 g/l) was diluted with 0.9% sodium chloride. Doses of 0.25, 
0.5, 1, 2, 4, 8 and 12 ng/min per dl were administered during subsequent 5-min 
periods. L-Nemonomethyl-arginine (L-NMMA) was dissolved in 0.9% sodium 
chloride and administered at a dose of 0.1 mg/min per dl. An L-NMMA infusion was 
started 5 min before and maintained during the second infusion of DDAVP or AVP. 
All drugs were infused intra-arterially by an automatic syringe infusion pump at a 
constant total infusion rate of 50 μΙ/min per dl. 
Statistical analysis 
Paired student's t-tests were used to evaluate the effect of L-NMMA on baseline 
FBF and, by comparison of changes in FBF from baseline, the effect of L-NMMA 
on DDAVP-induced vasodilation. 
RESULTS 
Effects of DDAVP and AVP in healthy subjects 
Infusion of DDAVP in a dosage scheme of 0.1, 1 and 10 ng/min per dl had no 
significant effect at the lowest dose but an increase in FBF occurred at the two 
higher doses (from 1.6 ± 0.5 during saline infusion to 7.9 ± 2.5 ml/min per dl at 
the highest dose (n = 3). Doses of DDAVP at 5, 10 and 20 ng DDAVP/min per dl 
administered to seven healthy subjects produced a dose-related increase in FBF 
(Table 7.1; Fig. 7.1). The administration of increasing doses of AVP (0.25 - 12.0 
ng/min per dl) resulted in a slight initial decrease of FBF, from 1.4 ± 0.4 to 1.1 ± 
0.4 ml/min per dl, and then a gradual increase to 3.1 ± 0.5 at the highest dose (n 
= 2, Fig. 7.2). 
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Table 7.1 Forearm blood flow (FBF) response of healthy subjects to intra-arterial infusion of 
1-desamlno-e-D-arginine vasopressin (n = 7) 
Baseline 
Dose (ng/min per dl) 
5 10 20 
FBF (ml/min per dl) 
Before L-NMMA 2.3 ± 0.7 
During L-NMMA 1.7 ± 0.3 
% FBF (ml/min per dl) 
Before L-NMMA 100 
During L-NMMA 100 
Values are expressed as mean ± SEM 
Effects of DDAVP and AVP In patients with NDI 
The administration of DDAVP at 5, 10 and 20 ng/min per dl in the three patients 
with NDI did not affect FBF (Fig. 7.1). Infusion of the AVP dose scheme into one of 
the patients resulted in a decrease in FBF from 1.2 ml/min per dl during saline 
infusion to 0.4 ml/min per dl at the highest AVP dose (Fig. 7.2). 
Effects of L-NMMA on DDAVP and AVP-induced vasodilation in healthy 
subjects 
During the 5-min period of L-NMMA infusion preceding the second DDAVP infusion, 
FBF decreased significantly from 2.3 ± 0.5 to 1.6 ± 0.2 ml/min per dl (n = 10, ρ = 
0.05). Subsequent administration of DDAVP at 0.1, 1 and 10 ng/min per dl (n = 3) 
and 5, 10 and 20 ng/min per dl ( η = 7) during L-NMMA infusion revealed a partial 
reduction in the FBF increase induced by DDAVP, which reached statistical signifi­
cance for the 10 ng dose administered to all 10 subjects (5.7 ± 1.0 versus 4.2 ± 
0.8 ml/min per dl, η = 10, ρ < 0.01, Fig. 7.3). The FBF increase at the 5 and 20 ng 
doses was not significantly reduced during L-NMMA. The FBF increase as a per-
6.6 ± 1.3 
5.0 ± 0.9 
223 ± 3 3 
228 ± 62 
7.7 ± 1.7 
5.9 ± 1.1 
270 ± 54 
272 ± 56 
10.3 ± 2.5 
8.1 ± 1.6 
394 ± 94 
423 ± 95 
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Forearm blood flow (ml/min/dl) 
15-
Base 
DDAVP dose (ng/min/dl) 
Fig. 7.1 Forearm blood flow response to 1 -desamino-8-D-arginine vasopressin (DDAVP) in seven 
healthy subjects ( • - • ) and three patients with nephrogenic diabetes insipidus with a V2 receptor 
defect ( · - · ) . Values are expressed as means ± SEM. 
Forearm blood flow (ml/min/dl) 
4 
Base 0 25 0 50 10 20 4 0 80 12 0 
AVP dose (ng/min/dl) 
Fig. 7.2 Forearm blood flow response to arginine vasopressin (AVP) in two healthy subjects ( • - • ) 
and a patient with nephrogenic diabetes insipidus with a V2 receptor defect ( · - · ) . Values are 
expressed as means or means ± SEM. 
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DDAVP-induced increase in FBF (ml/min/dl) 
Fig. 7.3 Forearm blood flow (FBF) increase from baseline as a result of 1-desamino-8-D-arginine 
vasopressin (DDAVP) Infusion (10 ng/min/dl) with and without concomitant infusion of L-№-
monomethyl arginine (L-NMMA) in ten healthy individuals. 
rentage of the baseline value was not significant for any of the doses. The increase 
in FBF induced by a second infusion of DDAVP at 5, 10 and 20 ng/min per dl 
without concomitant L-NMMA (n = 4) did not differ significantly from the increase 
during the first infusion. 
Administration of AVP at 0.5, 4 and 12 ng/min per dl during an infusion of L-NMMA 
revealed no significant increase in FBF (0.8 ± 0.1 at baseline versus 0.7 ± 0.1, 1.0 
± 0.0 and 1.2 ± 0.2 ml/min per dl, respectively). 
None of the studies showed significant changes in blood pressure, heart rate or 
FBF in the contralateral arm. 
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DISCUSSION 
Studies assessing the vase-dilatory mechanism of AVP and its analogue DDAVP 
have yielded conflicting data. In vitro experiments in canine cerebral vessels and rat 
pulmonary artery and aorta have suggested involvement of V1 receptors.15,16·19 
Similarly, in human in vitro studies, AVP-induced vasodilation of cerebral and 
mesenterial arteries was found to be independent of V2 receptor stimulation.20,21 
However, most in vivo studies provide evidence that V2 receptors are involved in 
AVP- and DDAVP-induced vasodilation.1,5,9'13. Furthermore, it has been postulated 
that the vasodilation and associated release of coagulation and fibrinolysis factors 
occurring in response to AVP and DDAVP administration is neither mediated by V1 
nor by V2 receptors because studies in rat aorta and in conscious dogs have 
revealed an absence of inhibition both by V1 and by V2 antagonists.22-23 The most 
plausible reason for this confusion seems to be the variability in the pharmacolo-
gical profile of agonists and/or antagonists that has been suggested to exist 
among species, between in vitro and in vivo studies and among different vascular 
beds.". 
Human in vivo studies assessing the effect of high systemic doses of AVP in 
humans are scarce because of the risk of severe vasoconstriction. However, it is 
clear that no substantial increase in blood pressure occurs despite maintenance of 
high plasma AVP levels.24 The vascular effects of V2 receptor antagonists have only 
recently been examined in a human in vivo studie, which appeared to confirm that 
in the human forearm V2 receptors are involved in the vasodilatory effect of AVP.5 
However, these conclusions need to be considered with caution because most V2 
receptor antagonists show partial V1 receptor antagonism and their putative 
specificity has been based mainly on their aquaretic potencies in animals." 
However, studies in patients with X-linked NDI have provided convincing evidence 
for involvement of the V2 receptor in the vasodilatory action of DDAVP.25 As a result 
of mutations in the V2 receptor gene, patients with NDI lack the renal antidiuretic 
response to DDAVP.2* In addition, these patients show no vasodilatory, coagulation 
or fibrinolytic responses to DDAVP, indicating that these extra-renal effects are 
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normally mediated either by an extra-renal V2 receptor encoded by the same gene 
or by the renal V2 receptor. 
In the present study we circumvented the restrictions imposed by the side-effects 
of high systemic doses of AVP and DDAVP and the problems caused by lack of 
specificity of V2 receptor antagonists, by studying the vascular effects of AVP and 
DDAVP in the human forearm of both healthy subjects and of patients with a 
proven V2 receptor gene defect. The absence of vasodilation during DDAVP and 
high doses of AVP in NDI patients proves that both effects are mediated by the 
receptor encoded by the V2 receptor gene, excluding the occurrence of non-
specific vasodilatory effects or actions mediated by other receptors, for instance 
the V1 or oxytocin receptor. In addition, it shows that the high selectivity of DDAVP 
for the renal V2 receptor also applies to the extra-renal V2 receptor. Moreover, the 
present study unequivocally proves that the absence of extra-renal responses to 
DDAVP in patients with X-linked NDI is a direct consequence of an extra-renal V2 
receptor defect and is neither caused nor influenced by their renal V2 receptor 
defect. 
As in studies seeking the receptor involved in AVP- and DDAVP-induced vasodila-
tion, attempts to determine which vasodilatory substance mediates this action have 
produced varying results. In vitro studies in canine cerebral vessels and rat aorta 
have suggested that NO causes these effects.1*"1' However, Russ and colleagues 
14,27
, observed only partial inhibition of DDAVP-induced vasodilation by high-doses 
of NO synthase inhibitors in rat lungs and provided evidence against involvement 
of prostaglandins and hyperpolarization of vascular smooth muscle. Moreover, in 
their in vitro study of human cerebral and mesenterial arteries, Martinez et al.20,21 
found that release of NO in these vessels accounts neither for AVP- nor for DDAVP-
induced vasodilation. 
It has been shown that the counterregulation observed In healthy humans after 
systemic administration of high doses of AVP is abolished by indomethacin, 
suggesting that prostaglandins are involved in its vasodilatory effect.28 In contrast, 
studies of AVP-induced vasodilation in the human forearm by Suzuki et al.2 
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suggested that prostaglandins are not involved while experiments by Tagawa et al.4 
strongly implied the involvement of NO. Hasunuma et al.29 found that vasodilation 
after systemic DDAVP infusion was not influenced by indomethacin or propanolol 
administration; however, they did observe an increase in urinary 6-keto prosta-
glandin F,^ . We observed that the L-NMMA induced reduction in DDAVP-response, 
if any, was rather small, whereas the current data show, in accord with the findings 
of Tagawa et al.4, that L-NMMA inhibited AVP-induced vasodilation almost comple-
tely. 
How can these observations be reconciled with the conclusion that AVP and 
DDAVP both cause vasodilation by stimulating the V2 receptor ? Since DDAVP 
elicited a threefold stronger increase in FBF than AVP did, the present L-NMMA 
dose of 0.1 mg/min per dl might not have been sufficient to compete with the 
quantity of NO released by DDAVP, whereas it is adequate in the case of AVP. 
However, even with DDAVP at 5 ng/min per dl, the inhibition was not complete and 
did not clearly decrease with higher doses of DDAVP. 
A more plausible explanation is based on the fact that AVP interacts with both V1 
and V2 receptors. The V1 receptor pathway could, for instance, attenuate an L-
NMMA-insensitive vasodilatory component of the V2 receptor-pathway. Another 
possibility is that AVP, because of a possible lower availability or affinity for the V2 
receptor, initiates only the NO-dependent mechanisms, whereas DDAVP is capable 
of inducing an additional L-NMMA-insensitive pathway.30 
Insight into these mechanisms might be increased by the discovery of the exact 
location of the extra-renal V2 receptor. Although physiological evidence has now 
been obtained that these receptors exist in the human forearm, radioligand binding 
studies have not been able to affirm their presence in endothelial or vascular 
smooth muscle cells.31 However, blood cells, especially monocytes, are a likely 
location.32,33 Furthermore, although the present study shows that extra-renal V2 
receptors are the product of the same gene as renal V2 receptors, the possibility 
cannot be excluded that, as a result of alternative splicing, there is some heteroge-
neity among receptors encoded by the V2 receptor gene, as recently shown to be 
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the case in the kidney.34 Further research awaits the detection of extra-renal gene 
expression of this gene at the messenger RNA or protein level. 
The present study proves that extra-renal V2 receptors in the human forearm 
mediate the vasodilation induced by DDAVP and high doses of AVP, whereas 
these receptors are not necessary for AVP-induced vasoconstriction. Secondly, 
DDAVP-induced vasodilation seems to be mediated predominantly by a mechanism 
other than endothelial NO release, whereas AVP-induced vasodilation seems to 
involve NO release only. Thus, despite the fact that the same receptor is involved, it 
appears that the mechanisms underlying AVP- and DDAVP-induced vasodilation 
are not completely identical. 
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8. SUMMARY AND GENERAL DISCUSSION 
The molecular pathogenesis of congenital nephrogenic diabetes insipidus 
In the past four years, the molecular pathogenesis of NDI has revealed most of its 
secrets. As a result, accurate genetic counseling has become feasible for nearly all 
NDI families. In chapters 2, 3 and 4 of this thesis the genetic identification of two 
categories of patients which do not fit in the classical X-linked recessive pattern of 
inheritance is described. 
Chapter 2 presents a study on three families with clear autosomal recessive 
inheritance of NDI in which patients were found to be homozygous for mutations in 
the AQP2 water channel gene. Previously, only one patient with an AQP2 defect 
had been described in the literature.1 The identification of more patients confirmed 
the hypothesis that AQP2 mutations cause autosomal recessive NDI and hence, 
that AQP2 is the vasopressin-sensitive water channel. In vitro expression of the 
mutant cRNA in Xenopus laevis oocytes was in accordance with the in vivo 
consequences of the mutations. Compared to control oocytes, no increase of water 
permeability was observed in oocytes expressing mutant AQP2, whereas, in 
accordance with the autosomal recessive inheritance of the mutations, co-injection 
of mutant and wild-type cRNA resulted in the same water permeability as injection 
of wild-type cRNA only. A recent study on the fate of mutant aquaporins in 
Xenopus oocytes has shown impairment of their transport to the plasma membra-
ne.2 Therefore, the absence of water transport in oocytes expressing the mutant 
proteins does not provide information on the structure-function relationship of the 
aqueous pore. The co-injection studies and the autosomal recessive inheritance of 
the mutations suggest that the presence of the mutant proteins in the Xenopus 
oocyte or collecting duct cell does not interfere with functioning of the wild-type 
proteins. Recently, however, Bichet et al.3 reported two families with autosomal 
dominant inheritance of NDI in which patients were heterozygous for mutations in 
the AQP2 gene. Both mutations were located in the carboxy terminal part of the 
protein, a region considered important in targeting of proteins. Apparently, unlike 
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the mutations that cause autosomal recessive NDI, these mutants interfere with 
functioning of the wild-type AQP2, e.g. by interfering with their transport to the 
plasma membrane or by affecting the function of neighboring wild-type water 
channels in the homotetramer. 
Consistent with the lower prevalence of the non-X-linked forms of NDI, progress in 
the search for AQP2 mutations has not been as fast as for V2 receptor mutations. 
Our group of Dutch NDI families, which is thought to contain nearly all NDI families 
in the Netherlands, includes only two families with an AQP2 defect versus twenty-
one families with a V2 receptor defect and one family in which the defect has not 
yet been found. At present, the total number of mutations identified by our group 
consists of thirty-five V2 receptor mutations and eight AQP2 mutations (addendum I 
and II). 
Patients with an AQP2 defect can not be distinguished from patients with a V2 
receptor defect on the basis of their clinical symptomatology. In chapter 3, the 
reliability of another approach is demonstrated. Intravenous administration of 
DDAVP was found to result in an increase of tissue-type plasminogen activator 
antigen and pulse rate in three patients with an AQP2 defect, a response which is 
absent in patients with a V2 receptor defect. In male patients, especially when they 
are sporadic or belong to the sole affected sibship in a family, this test makes 
DNA-analysis more efficient and allows genetic counseling in circumstances where 
facilities for DNA-analysis are lacking. Furthermore, in rare cases where no mutation 
in the exons and introns of the known NDI causing genes can be found, this test 
may be the mainstay for more extensive research. 
In some families in which inheritance did not show the clasical X-linked recessive 
mode of inheritance, sequencing of the AQP2 gene revealed no mutations. In 
chapter 4, several female NDI patients are described who turned out to be hetero-
zygous for mutations in the V2 receptor gene. They all required hospitalization 
during infancy for reasons which can be traced back to manifestations of NDI. 
Since then, we found the same phenomenon in two patients from other families. In 
addition, the female patient described by Moses et al.4 was recently shown to be 
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carrier of a V2 receptor mutation as well.5 Another report which seems to confirm 
our findings concerns a large kindred with an X-linked dominant pattern of inheri-
tance.' Maximal urine osmolality after DDAVP varied from 125 to 550 mosmol/kg 
and linkage with markers for the Xq28 region was demonstrated. Nevertheless, no 
mutations were found in the coding sequence of the V2 receptor gene. Although 
the authors emphasized the possible involvement of another NDI gene, in the light 
of our observations, a mutation in the non-coding V2 receptor sequence or failure 
to detect a mutation present in the coding regions seems more probable. 
As shown for some other diseases7"13, skewed inactivation of the X-chromosome is 
the most likely explanation for the manifestation of NDI in some of the female 
carriers of a V2 receptor mutation. Moreover, lesser degrees of skewness can 
explain the subclinical symptoms manifested by some others. Not all carriers of a 
particular mutation are clinically affected, indicating that the type of mutation is not 
a critical factor. Since the foregoing observations do no longer justify maintenance 
of the simple rule that female carriers are not affected with NDI, accurate genetic 
counseling requires the identification of factors which might predispose to the 
occurrence of skewed X-chromosome inactivation. In the meantime, however, this 
phenomenon has to be considered as a rare, unpredictable variant of the normal 
distribution. 
In two female patients of our study, the absence of the extra-renal response to 
DDAVP already indicated the presence of a V2 receptor defect. In contrast, a 
normal response can not be interpreted as indicative of a defect beyond the V2 
receptor. The female patient reported by Moses et al. showed a two-fold increase 
of FVIII activity.45 This discrepancy between the extra-renal and renal response to 
DDAVP may be due to variability of the pattern of X-chromosome inactivation 
between different tissues.14 It is also possible that the extra-renal response requires 
a lower number of cells with a functional V2 receptor than the renal response. The 
latter explanation, however, is contradicted by the fact that several asymptomatic 
carriers show a decreased or delayed extra-renal response to DDAVP.15 In this 
regard, it can also be postulated that the lack of reliability of this DDAVP-test for 
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carrier detection15"1* is based on interindividual differences in the pattern of X-
chromosome ¡nactrvation. 
Mental retardation In patients with NDI 
In most literature on NDI, mental retardation is mentioned in the list of clinical 
feastures. The general assumption that mental retardation has a high prevalence 
among patients with NDI, however, is contested by the study described in chapter 
5. Cognitive and psychosocial functioning of seventeen male NDI patients, aged 3 
to 30 years, have been examined. Of this group, thirteen patients showed a total 
intelligence quotient or a general cognitive index within (n = 12) or above (n = 1) 
the normal range. Two young children showed a general cognitive index more than 
2 standard deviations (sd) below the mean and one boy had an intelligence score 
between - 1 and - 2 sd. Notwithstanding the small absolute number of patients, this 
study represents the largest psychometrical study in patients with NDI in the 
literature. Moreover, the other two studies can not be considered representative for 
the current situation since in the meantime diagnostic and therapeutic possibilities 
have improved considerably. Although no clear relationship between test results 
and clinical data could be found, these improved circumstances are likely to 
explain the favorable outcome in our study group. This explanation is underscored 
by the fact that the two patients who could not be included in the psychometrical 
tests due to severe mental retardation are the oldest of our population. In addition, 
two other patients had uncles of similar age who worked or lived in a protected 
environment. Indirectly, this apparent secular trend corresponds with dehydration 
as a major etiological factor for impaired mental development. A large amount of 
data is available which demonstrates the importance of osmotic homeostasis within 
the brain at the cellular level.1' In addition, clinical illustration of the adverse effects 
of Hypernatremia on the cerebrum has been provided by case reports of subdural 
effusions, intracranial hemorrhages, necrotic lesions and sinus thrombosis.20,21, 
Moreover, cerebral pathology is suggested by the reports of NDI patients with 
calcifications, especially in basal ganglia and frontal lobes. The susceptibility of the 
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basal ganglia to Hypernatremia has been illustrated in vivo by the observation of 
transient hypodensity of these structures in a boy suffering from salt poisoning.22 
Furthermore, the observation of an increase of glutamate receptor density in 
hypothalamus and basal ganglia in response to water deprivation has supplied 
other evidence for a specific effect of dehydration on these brain regions.23 
The genetic defect in NDI has been proposed to signify a risk for mental retar-
dation as well, a hypothesis which assumes the existence of a cerebral V2 recep-
tor.24 Until now, our attempts to detect this receptor by immunohistochemistry of 
adult human brain tissue have not been successful (unpublished observations). 
Likewise, radioligand binding, in situ hybridization and reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis all failed to detect the protein or its 
RNA in adult rat brain.25"28 The latter method, however, did indicate transient 
neonatal expression.27 Recently, in situ hybridization analysis of newborn rat brain 
revealed the presence of V2 receptor mRNA in epithelial and vascular endothelial 
cells of choroid plexus and in neurons of the hippocampus and granular layer of 
the cerebellum. Expression of the V2 receptor in cerebellum persisted into adult-
hood.28 The normal mental functioning of most of our patients, however, pleads 
against an important function of V2 receptors in the cerebrum. In addition, none of 
our patients shows signs of cerebellar dysfunction. Considering the possibility that 
a V2 receptor defect predisposes to more subtle mental deficits, comparison of 
psychological test results of patients with a V2 receptor defect with those of 
patients with an AQP2 defect would be interesting. Unfortunately the number of 
patients with an AQP2 defect is still too small to allow conclusions on this issue. It 
can also be argued, that the putative cerebral V2 receptor is not encoded by the 
classical V2 receptor gene. Several studies have suggested the existence of 
cerebral V2-like receptors30*2, but their molecular structure has not been assessed. 
Clinical presentation and follow-up of NDI patients 
Chapter 6 describes the clinical presentation and follow-up of a relatively large 
group of male Dutch patients. The majority of patients was detected within the first 
154 
Summary and general discussion 
2.5 years of life, with the exception of four older patients who came under medical 
attention for reasons not directly related to NDI. Family history and/or subsequent 
DNA analysis revealed several adult patients who had never been diagnosed as 
well as infant deaths suspective for NDI. Most patients had been treated with 
hydrochlorothiazide-amiloride without significant side-effects. 
In addition to the mental retardation discussed in chapter 5, several other long-term 
effects of NDI are mentioned in literature. In our study group, Urological complica-
tions occurred in four patients. Two patients had severe hydronephrosis despite 
being diagnosed within the first 1.5 years of life and receiving drug treatment ever 
since. Both suffered from a small traumatic rupture of the dilated system after a 
minor trauma. Two other patients experienced several periods of acute urine 
retention. Urinary infections were recorded in three patients. 
Similar to mental retardation, the putative growth retardation of patients with NDI 
has been abundantly cited but scarcely studied. In our population, the majority of 
patients was small for age and remained so despite the fact that they were all 
diagnosed rather early and received drug treatment ever since. Weight for height 
was generally low during the first years of life, but showed a catch-up thereafter. 
Thus, the putative clinical pitfalls of NDI consist of an aspecific presentation during 
infancy and a considerably less dramatic symptomatology thereafter. In extreme 
cases, diagnostic delay can be life-long. Notwithstanding the latter observation, 
the risk of urological complications warrants a careful medical follow-up. 
Extra-renal effects of arginine vasopressin (AVP) and 1-desamino-8-D-arginine 
vasopressin (DDAVP) 
As illustrated earlier in this thesis, the extra-renal effects of DDAVP provide informa-
tion on the pathogenesis of NDI. Conversely, studies in patients with NDI can help 
elucidate the mechanisms underlying the extra-renal-effects of AVP and DDAVP. 
This approach was used in chapter 7 with the purpose to assess whether extra-
renal V2 receptors and the endogenous endothelium-derived vasodilator nitric 
oxide (NO) are involved in AVP- and DDAVP-induced vasodilation. The comparison 
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of responses of healthy volunteers and patients with a V2 receptor gene defect, an 
approach which obviates the use of receptor antagonists, provided direct evidence 
for the involvement of an extra-renal V2 receptor in both responses. In addition, it 
showed that the high degree of specificity of DDAVP for the renal V2 receptor also 
applies to the extra-renal V2 receptor. Considering the conclusion that the V2 
receptor mediates the vasodilation induced by both DDAVP and AVP, it appears 
that the post-receptor signaling pathways of DDAVP and AVP are identical. 
Surprisingly, however, DDAVP-induced vasodilation showed a large L-NMMA-
insensitive component, whereas AVP-induced vasodilation did not. Since the high 
affinity of AVP for the V1 receptor is the most prominent difference between the two 
agents, it seems most likely that the explanation lies in this direction. V1-receptor 
stimulation by AVP may inhibit the L-NMMA-insensitive component of the V2 
receptor pathway. In the nephron, for instance, V1-receptor-mediated inhibition of 
the post-V2 receptor pathway has been reported.3334 It is also possible that, due to 
lower availibility or different binding properties, AVP activates only one signaling 
route, whereas DDAVP may initiate more pathways. Such ligand-dependency of the 
events occurring after stimulation of a single receptor has been described for other 
G-protein coupled receptors and is thought to result from subtle differences in the 
conformation of the receptor when bound to different ligands.35"40 
Our study proves that the V2 receptors involved in AVP and DDAVP-induced 
vasodilation are encoded by the same gene. This is important information in the 
light of the putative existence of V2-like receptors, a possibility which, in the kidney, 
has recently been illustrated by the cloning of a novel receptor that binds both 
vasopressin and angiotensin.41 We can not exclude, however, that AVP and DDAVP 
act on slightly different V2 receptors which have been generated by alternative 
splicing of a single gene. An additional conclusion which can be drawn from this 
study is that the V2 receptor mutations of the three NDI patients completely abolis-
hed the vasodilatory effects of AVP and DDAVP. Since the forearm model allows 
the administration of high local doses of the agonist and accurate measurement of 
its in vivo effects, it may be concluded that the three mutations result in a complete 
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loss of function. From some in vitro expression studies42,43, however, it can be 
inferred that patients with mutations which do not completely abolish binding of 
AVP or DDAVP might show some response. 
Whether the absence of a functional extra-renal V2 receptor in the majority of NDI 
patients has any clinical consequences remains speculative. The high levels of AVP 
necessary to induce vasodilation make this unlikely to occur under physiological 
circumstances. Besides, we are not aware of an increased prevalence of hyperten-
sion among patients with a V2 receptor defect. Perhaps, the benefit of the existen-
ce and functionality of these receptors is only brought to light in extreme situations. 
During shock, for instance, when the AVP level is high, V2-receptor mediated 
vasodilation may be involved in the redistribution of the circulatory blood volume. 
This hypothesis might be in agreement with the differences in vascular response to 
AVP and DDAVP between different vascular beds.44 From that viewpoint, the clinical 
consequences of an extra-renal V2 receptor defect could be manifested in vital 
organs like brain and kidney. Thus, it can be hypothesized that circulatory underfil-
ling in patients with a X-linked NDI, for instance caused by extreme dehydration, 
leads to persistent vasoconstriction in certain brain regions which might predispose 
them to the development of intracranial calcifications. 
Knowing the location of the extra-renal V2 receptor would contribute considerably 
to the elucidation of the cellular signaling mechanism which mediates the extra-
renal responses to AVP and DDAVP. The functional studies which indicated that it 
was located on monocytes and not on vascular endothelium45,46 have recently been 
contested by Kanwar et al.47 who addressed the pitfalls of studies in which passa-
ged endothelium is used. They showed that DDAVP elicited an increase of P-
selectin expression in platelets, postcapillary venules and in primary cultures of 
endothelial cells, but not in passaged endothelium or in primary cultures to which 
growth factors had been added. P-selectin is an adhesion molecule which, like von 
Willebrand factor, is a constituent of the Weibel-Palade bodies. Kanwar et al.47 
suggested that the endothelial expression of P-selectin in response to DDAVP was 
mediated by V2 receptors, since they did not observe changes of flow characte-
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ristics during their in vivo experiments on rat venules. The nature of the receptor 
involved in the response of platelets, however, was not addressed. A subsequent 
study by Wun et al.48 suggested that the DDAVP-induced increase of P-selectin 
expression on platelets was mediated by the V1 receptor. This observation is in 
accordance with the location of a V1 receptor on platelets49"52, but the inference that 
DDAVP acts on the V1 receptor seems rather strange and is not in accordance 
with our conclusion that, even in extremely high concentrations, DDAVP is a 
specific agonist for the extrarenal V2 receptor. The only explanation which seems 
to suit all these observations is that platelets express a V1 receptor which is 
capable of binding DDAVP, whereas vascular endothelium expresses the extra-
renal V2 receptor. In this regard, the observation that a change of a single amino 
acid can confer the V1 receptor with affinity for DDAVP is interesting.53 Recently, 
microperfusion studies in afferent renal arterioles have demonstrated a direct 
vasodilatory effect of AVP and DDAVP which was inhibited by V2 receptor antago-
nists.54 This observation not only confirms the involvement of an extra-renal V2 
receptor in both responses, but also indicates that these are located in the vascular 
wall. 
Several problems seem to underly the difficulties encountered in attempts to 
visualize the presence of the extra-renal V2 receptor. An intrinsic problem is the low 
level of expression, which may be overcome by the approach of RT-PCR. Using 
this highly sensitive method, however, Elalouf et al.28 were not able to detect V2 
receptor expression in several extra-renal rat tissues and postulated that, if 
expression occurs, the level is more than 40-fold lower than in kidney. Extremely 
low or even absent expression is also suggested by our RT-PCR analysis of human 
whole blood RNA in which we only detected a signal of the expected size after 65 
reaction cycles (unpublished observations), a result which might be ascribed to 
illegitimate transcription. The problem of raising antibodies against G-protein-
coupled receptors in general and the V2 receptor in particular is another factor 
which hampers localization studies. Using an affinity-purified rabbit antibody against 
a synthetic peptide corresponding to the C-terminal part of the human V2 receptor, 
158 
Summary and general discussion 
we have not been able to obtain a specific signal on Western blots of human 
monocytes (unpublished observations). Hopeful results, however, have recenly 
been reported by Nonoguchi et al.34, who succeeded in developing an antibody 
against the third cytoplasmic loop of the rat V2 receptor which allowed immunohis-
tochemical localization of the V2 receptor along the rat nephron. 
Another methodological problem that warrants caution is the low affinity and lack of 
specificity of radio-active V2 receptor ligands. lodination of AVP on tyrosin in 
position 2, for instance, decreases V2 receptor affinity of this ligand.55,5" This finding 
indicates that it is not justified to draw firm conclusions from studies which used 
this approach to prove the presence of V2 receptors on monocytes and plate-
lets.57·58 
Finally, a more basal question is whether the extra-renal V2 receptor is completely 
identical to the renal V2 receptor. Although our study proves that the extra-renal 
and renal V2 receptor are encoded by the same gene, the possibility remains that 
the extra-renal receptor is the product of alternative splicing, as has been shown to 
occur in kidney59, or is subject to post-translational modifications which might alter 
antibody or ligand binding. 
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Although knowledge of the clinical and molecular aspects of NDI seems nearly 
complete, some questions about this disease and its pathogenesis remain. In the 
search for answers, the identification of more patients will be of central importance. 
The detection of mutations in the AQP2 gene which result in proteins that are not 
impaired in their targetting to the plasma membrane may provide information on 
the structure-function relationship of the AQP2 water channel. Likewise, further 
extension of the number of V2 receptor mutations and performance of in vitro 
expression studies will increase knowledge on the functional domains of this and 
other G-protein coupled receptors. Some of these results might have clinical 
implications. The identification of mutations which result in a reduced hormone 
binding capacity, for instance, might indicate a category of patients who can benefit 
from a novel therapeutic approach. In fact, we observed a slight increase of urine 
osmolality after administration of a double dose of DDAVP in a patient with such a 
mutation. Perhaps, patients with these kinds of mutations can respond to treatment 
with DDAVP, an effect which may not only be studied by measuring urine produc-
tion and osmolality, but also by the assessment of urinary AQP2. 
Assessment of the inactivation ratios of normal versus mutant X-chromosomes in 
female carriers with a complete, partial or absent clinical phenotype will shed light 
on the validity of the X-chromosome-inactivation hypothesis. This can be accom-
plished by restriction fragment length polymorphism analysis to distinguish the two 
chromosomes, followed by digestion using methylation sensitive enzymes, Sou-
thern blotting, hybridization and comparison of the intensities of the polymorphic 
bands.1 Although the patterns of X-inactivation in renal cells and lymphocytes may 
not be identical, detection of skewed distribution in the latter cells will strengthen 
this hypothesis. 
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In one family with two affected male siblings, we have neither been able to demon-
strate a V2 receptor mutation, nor an AQP2 mutation, despite apparent X-linked 
inheritance of the disease and absence of extra-renal responses to DDAVP in the 
proband. A mutation in the promotor region of the V2 receptor gene might explain 
these observations, but the possibility of a third NDI-gene should be kept in mind 
as well. 
The identification of more patients with an AQP2 defect will also allow the assess-
ment of a hypothetical difference in mental outcome between these patients and 
those with a V2 receptor defect. In addition, brain magnetic resonance imaging or 
computer tomography in both patient categories could provide information on the 
causes and consequences of intracranial calcifications. 
A psychological follow-up study of our patients might reveal whether they show an 
initial delay and subsequent catch-up in mental development, a tendency which 
would stress the importance of psychological attention and support in the first 
years of life and which would allow some reassurance of the parents. 
The nature of the L-NMMA-insensitive component of DDAVP-induced vasodilation 
remains to be established. Performance of the experiments during administration of 
a prostaglandin-synthase inhibitor would prove or exclude the involvement of 
prostaglandins. Use of potassium channel blockers like tolbutamide, glybenclamide 
or quinidine may indicate whether hyperpolarizing factors are involved. 
Elucidation of the location of the extra-renal V2 receptor will help to find the 
answers to questions that remain. Therefore, future research needs to focus on the 
development of an antibody against the human V2 receptor and the application of 
V2 receptor-specific radio-ligands. RT-PCR of endothelial cells may be another 
useful approach to confirm the recent indications for the existence of an endothelial 
V2 receptor. Molecular and pharmacological characterization of the platelet 
vasopressin receptor will reveal whether this receptor has the unexpected property 
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of binding DDAVP. 
Increasing knowledge of the extra-renal V2 receptor may be of merit in research 
concerning the clinical application of V2 receptor antagonists2,3 and will provide 
more insight into the therapeutic and adverse effects of DDAVP. Furthermore, it will 
help to assess whether there are circumstances in which the generalized V2 
receptor defect of X-linked NDI has clinical consequences. 
Finally, future research may reveal whether members of the aquaporin family are 
involved in hereditary diseases other than NDI. 
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10. SAMENVATTING 
In dit proefschrift staat de ziekte congenitale nefrogene diabetes insipidus (NDI) 
centraal. Bij mensen met deze erfelijke aandoening zijn de nieren niet in staat op 
het antidiuretisch hormoon arginine Vasopressine te reageren. Het gevolg voor de 
patiënt is dat hij of zij grote hoeveelheden urine produceert en dit vochtverlies moet 
compenseren door veel te drinken. Het doel van het onderzoek was het inzicht in 
de Pathogenese, de erfelijkheid en klinische gevolgen van NDI te vergroten. 
In de inleiding wordt een overzicht gegeven van de reeds bestaande kennis van 
het klinisch beeld, de behandeling, de erfelijkheid en de etiologie van de ziekte. 
Hierna volgt een beschrijving van de aquaporine-waterkanalen, een groep van 
eiwitten die niet alleen cruciaal is gebleken bij het verkrijgen van inzicht in het 
concentrerend mechanisme van de nier, maar ook heeft geleid tot de ontdekking 
van een nieuwe oorzaak van NDI. Het laatste deel van de inleiding is gewijd aan 
het hormoon arginine Vasopressine en diens derivaat 1-desamino-8-D-arginine 
Vasopressine, stoffen waarvan, naast het antidiuretische effect, ook sommige 
vasculaire effecten bij NDI-patiënten ontbreken. 
De moleculaire Pathogenese van NDI (hoofdstuk 2, 3 en 4) 
Kennis van de moleculaire oorzaak van een ziekte vormt de basis voor een goed 
begrip van de ziekte en een gedegen erfelijkheidsadvies. Bij de start van dit onder-
zoek was een van de oorzaken van NDI, een defect in de Vasopressine type 2 
receptor reeds bekend. Dit betrof de geslachtsgebonden recessieve vorm, waarbij 
de ziekte door gezonde vrouwen wordt doorgegeven aan zonen bij wie de ziekte 
tot uiting komt. In de hoofdstukken 2, 3 en 4 wordt de genetische identificatie 
beschreven van patiënten bij wie de overerving niet dit klassieke patroon vertoont. 
In hoofdstuk 2 worden drie families beschreven met een duidelijk autosomaal 
recessieve overerving van NDI. De patiënten uit deze families bleken homozygoot 
te zijn voor mutaties in het aquaporine 2 (AQP2)-gen. Eerder was er één patiënt 
beschreven die samengesteld heterozygoot was voor twee mutaties in het AQP2 
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gen.1 Het vinden van meer patiënten bevestigde de hypothese dat AQP2-mutaties 
de autosomaal recessieve vorm van NDI veroorzaken en dat het AQP2-waterkanaal 
door Vasopressine wordt gereguleerd. In vitro expressie van het mutante RNA in 
Xenopus laevis oöcyten stemde overeen met de gevolgen van deze mutaties bij 
patiënten: de celmembranen van oöcyten waarin het mutante AQP2 tot expressie 
was gebracht vertoonden geen toename van waterpermeabiliteit. Gelijktijdige 
injectie van mutant en normaal AQP2-RNA resulteerde echter in dezelfde waterper-
meabiliteit als injectie van louter normaal AQP2-RNA, een bevinding die in overeen-
stemming is met de autosomaal recessieve overerving van de ziekte. 
De vooruitgang in de zoektocht naar AQP2 mutaties is, zoals was te verwachten op 
basis van de lage prevalentie van niet-geslachtsgebonden vormen van NDI, niet zo 
groot geweest als bij de V2 receptor mutaties. Onze groep Nederlandse NDI 
families, die geacht wordt vrijwel alle Nedrlandse NDI-families te omvatten, bestaat 
slechts uit twee families met een AQP2-defect versus eenentwintig families met een 
V2 receptor defect en één familie waarin het defect nog niet ¡s gevonden. Bij het 
voltooien van dit proefschrift bestond het totaal aantal mutaties dat door onze 
groep was gevonden uit vijfendertig V2 receptor mutaties en acht AQP2 mutaties 
(addendum I en II). 
Op basis van hun klinische Symptomatologie kunnen patiënten met een AQP2-
defect niet onderscheiden worden van patiënten met een V2-receptor-defect. In 
hoofdstuk 3 wordt de betrouwbaarheid van een andere benadering aangetoond. 
Intraveneuze toediening van DDAVP bleek te resulteren in een toename van 
weefsel-type plasminogen activator antigeen en van de polsfrequentie bij drie 
patiënten met een AQP2-defect, een effect dat ontbreekt bij patiënten met een V2-
receptor-defect. Vooral wanneer slechts één manneljke patiënt of een aantal broers 
zijn aangedaan, maakt deze test gerichter DNA-onderzoek mogelijk. Tevens laat de 
test een betrouwbare erfelijkheidsadvisering toe indien faciliteiten voor DNA-
onderzoek ontbreken. In omstandigheden waarin geen mutaties in de exonen en 
intronen en exonen van de bekende NDI-genen gevonden kunnen worden kan 
deze test bovendien richtinggevend zijn voor verder onderzoek. 
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In hoofdstuk 4 worden enkele families beschreven die niet het klassieke geslachts-
gebonden overervingspatroon venionen, maar waarbij ook geen mutaties in het 
AQP2 gen werden aangetroffen. In deze families kwamen vrouwelijke NDI-patiënten 
voor die heterozygoot bleken te zijn voor een mutatie in het V2 receptor gen. Zij 
werden allen in de eerste levensjaren in het ziekenhuis opgenomen om redenen 
die achteraf gezien kunnen worden als de eerste manifestaties van NDI. Naderhand 
troffen we hetzelfde fenomeen aan bij twee patiënten uit andere families. Een 
statistisch scheve verdeling van het X-chromosoom-inactivatie patroon is de meest 
waarschijnlijke verklaring voor het manifest worden van NDI bij sommige draagsters 
van een V2 receptor mutatie. Dit fenomeen, dat ook bij een aantal andere X-
chromosomale ziektes is aangetoond4'10 biedt bovendien een verklaring voor de 
subklinische symptomen van sommige draagsters. Op basis van bovengenoemde 
gegevens kan gesteld worden dat de vuistregel dat draagsters van een V2-
receptor mutatie geen NDI hebben, niet zonder meer van toepassing is. 
Bij twee vrouwelijke patiënten uit onze studie wees de afwezigheid van de extra-
renale respons op DDAVP op een V2-receptor-defect. Een normale respons lijkt 
echter, bij vrouwelijke patiënten, een V2 receptor defect niet uit te sluiten: de 
patiënte die door de groep van Moses2,3 werd beschreven vertoonde een verdub-
beling van factor VIII activiteit. Deze discrepantie tussen extra-renale en renale 
respons op DDAVP kan te wijten zijn aan variabiliteit van het X-chromosoom 
inactivatie patroon tussen verschillende weefsels.11 
Mentale retardatie bij patiënten met NDI 
In de literatuur wordt mentale retardatie vaak genoemd als een van de klinische 
kenmerken van NDI. De algemene veronderstelling dat mentale retardatie onder 
NDI-patiënten een hoge prevalentie heeft, wordt echter tegengesproken door de 
studie die wordt beschreven in hoofdstuk 5. Hierin werden het cognitieve en 
psychosociale functioneren onderzocht van zeventien mannelijke NDI-patiënten, in 
leeftijd variërend van drie tot dertig jaar. Van deze groep hadden veertien patiënten 
een totaal IQ of algemene cognitieve test score binnen (n = 13) of boven (n = 1) 
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de normale spreiding. Twee jonge kinderen vertoonden een algemene cognitieve 
index van meer dan 2 standaarddeviaties (sd) onder het gemiddelde en één 
jongen had een totaal IQ tussen -1 en -2 sd. Ondanks het kleine absolute aantal 
patiënten vormt dit onderzoek de grootste psychometrische studie onder NDI 
patiënten ¡n de literatuur. Bovendien kunnen, gezien de inmiddels opgetreden 
verbetering van de diagnostische en therapeutische mogelijkheden, de twee 
andere publicaties die hierover zijn verschenen niet representatief geacht worden 
voor de huidige situatie.12,13 Hoewel geen duidelijke relatie kon worden aangetoond 
tussen de testresultaten en de klinische gegevens lijkt bovengenoemde medische 
vooruitgang de gunstige uitkomst van de studie te verklaren. Het belang van 
osmotische homeostase in hersencellen is algemeen bekend.14 Klinisch wordt dit 
geïllustreerd door casuTstische beschrijvingen van het optreden van subdurale 
effusies, intracraniële bloedingen, necrose and sinus thombose bij dehydratie.15·16 
De intracraniële calcificaties die, met name frontaal en in de basale ganglia, bij NDI-
patiënten zijn aangetroffen, zouden hier ook een uiting van kunnen zijn (zie tabel 
5.3). Verder zou het genetische defect op zichzelf eveneens een toegenomen risico 
op mentale retardatie kunnen veroorzaken, een hypothese die het bestaan van 
cerebrale V2 receptoren veronderstelt.17 Het laatste is echter nog onderwerp van 
discussie. Bovendien pleit de normale mentale ontwikkeling van het merendeel van 
onze patiënten tegen een belangrijke functie van de V2 receptor in de hersenen. 
Klinische presentatie en beloop van NDI 
In hoofdstuk 6 worden de klinische presentatie en het beloop van de ziekte bij 
dertig mannelijke Nederlandse patiënten beschreven. Bij de meerderheid van de 
patiënten werd de ziekte voor de leeftijd van 2.5 jaar ontdekt. Drie oudere patiënten 
kwamen onder medische aandacht om redenen die niet direct in relatie tot de 
ziekte stonden. De familie-anamnese en/of de daaropvolgende DNA analyse 
onthulde zowel het bestaan van verscheidene volwassenen waarbij de diagnose 
niet eerder was gesteld als zuigelingen die jong overleden waren met verschijnse-
len verdacht voor NDI. De meeste patiënten werden behandeld met hydrochlorothi-
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azide en amiloride zonder bijwerkingen van betekenis. 
Naast mentale retardatie, worden in de literatuur verschillende andere lange-termijn 
effecten van NDI genoemd. In onze groep traden urologische complicaties op bij 
vier patiënten. Twee patiënten vertoonden ernstige hydronefrose ondanks het feit 
dat de diagnose in de eerste achttien levensmaanden was gesteld en ze sindsdien 
medicamenteus behandeld waren. Beiden maakten een kleine ruptuur van het 
gedilateerde systeem door na een gering trauma. Twee anderen vertoonden 
meerdere perioden van acute urineretentie. Van urineweginfecties werd melding 
gemaakt bij drie patiënten. 
Het optreden van groeiachterstand bij NDI-patiënten is, evenals mentale retardatie, 
een veel geciteerd maar weinig bestudeerd fenomeen. In onze populatie was en 
bleef, ondanks een in het algemeen vroege diagnose en instelling van therapie, de 
meerderheid van de patiënten klein voor hun leeftijd. Het gewicht naar lengte was 
laag in het eerste levensjaar maar vertoonde daarna een inhaal-effect. 
De valkuilen op de weg naar de diagnose NDI bestaan dus uit een aspecifieke 
presentatie in de zuigelingenperiode en een aanzienlijk minder dramatische 
Symptomatologie in de jaren die hierop volgen. In zeldzame gevallen wordt de 
diagnose niet gesteld. Desondanks rechtvaardigt het risico op urologische compli-
caties ook na de zuigelingenleeftijd een nauwgezette medische controle. 
Extra-renale effecten van arginine Vasopressine (AVP) en 1-desamino-8-D-
arglnine Vasopressine (DDAVP) 
Zoals reeds eerder werd vermeld, geven de extra-renale effecten van DDAVP 
informatie over de Pathogenese van deze ziekte. Omgekeerd kunnen studies bij 
patiënten met NDI het mechanisme helpen ontrafelen dat aan deze effecten ten 
grondslag ligt. Deze benadering werd gebruikt in hoofdstuk 7 om na te gaan of 
extra-renale V2 receptoren en de endogene vasodilatator stikstofoxide betrokken 
zijn bij door AVP- en DDAVP-geïnduceerde vaatverwijding. De vergelijking van de 
vasculaire effecten van deze stoffen bij gezonde vrijwilligers en bij patiënten met 
een mutatie in het V2-receptor-gen, een benadering die toepassing van receptoran-
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tagonisten overbodig maakt, leverde direct bewijs op voor de betrokkenheid van 
een extra-renale V2 receptor bij het vaatverwijdende effect van zowel DDAVP als 
AVP. Verder toonde deze studie aan dat de hoge specificiteit van DDAVP voor de 
renale V2 receptor ook van toepassing is op de extra-renale V2 receptor. Voort-
bouwende op de conclusie dat de V2 receptor zowel de door AVP- als de door 
DDAVP-geTnduceerde vaatverwijding medieert zou men verwachten dat de gebeur-
tenissen die zich na activering van de receptor voltrekken identiek zijn. De DDAVP-
geïnduceerde vaatverwijding bleek echter, in tegenstelling tot de AVP-geïnduceerde 
vaatverwijding, slechts gedeeltelijk voorkomen te worden door L-NQ-monomethyl-
arginine (L-NMMA), een stof die de synthese van stikstof oxide remt. Aangezien de 
hoge affiniteit van AVP voor de V1 receptor het meest prominente verschil is tussen 
de twee stoffen, zal de verklaring in deze richting gezocht moeten worden. V1-
receptor stimulatie door AVP zou verantwoordelijk kunnen zijn voor de L-NMMA-
ongevoelige component van de V2-receptor gemedieerde vasodilatatie. Een andere 
mogelijkheid is dat, door een lagere beschikbaarheid of door een verschil in 
bindingseigenschappen, AVP slechts één cellulaire route en DDAVP meerdere 
routes activeert. 
Onze studie bewijst dat de V2 receptoren die betrokken zijn bij de AVP- en 
DDAVP-geïnduceerde vasodilatatie gecodeerd worden door hetzelfde gen. Dit is 
belangrijke informatie omdat V2-achtige receptoren ook zouden kunnen bestaan. 
Een additionele conclusie die uit deze studie getrokken kan worden is dat de V2 
receptor-mutaties van de drie NDI-patiënten het vasodilaterende effect van AVP en 
DDAVP volledig verhinderen. Daar het onderarmsmodel de toediening van hoge 
lokale doses van de agonisten en accurate meting van diens effecten toelaat, kan 
men hieruit concluderen dat deze drie mutaties resulteren in een volledig functie-
verlies. 
Of de afwezigheid van een functionele extra-renale V2 receptor enige klinische 
gevolgen heeft is nog onduidelijk. De hoogte van de concentratie AVP noodzakelijk 
om vasodilatatie te induceren maakt het onwaarschijnlijk dat dit onder fysiologische 
omstandigheden gebeurt. Ook zijn er geen aanwijzingen voor een verhoogde 
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prevalentie van hypertensie onder NDI-patiênten. Misschien komt het voordeel van 
het bestaan en de functionaliteit van deze receptoren slechts aan het licht onder 
extreme omstandigeheden, zoals tijdens shock. 
Hoewel uit onze studie blijkt dat in de onderarm V2 receptoren aanwezig zijn, blijft 
onduidelijk wat de exacte lokalisatie is van deze extra-renale receptoren. Tot op 
heden zijn onze pogingen om deze receptor in bloed en monocyten aan te tonen 
vruchteloos gebleven (ongepubliceerde observaties). Recente publicaties vestigen 
echter weer de aandacht op de mogelijke aanwezigheid van V2 receptoren op het 
vaatendotheel.18·1" 
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ADDENDUM I 
Mutation« of the vaaopreaaln V2 receptor gene In congenital nephrogenic diabete· Insipidus 
name 
deletion 5' 
region 
T7S 
98del28 
98ins28 
G12E 
113delCT 
L43P 
L44F 
132insT 
L53R 
A61V 
L62P 
253del35 
255del9 
274insG 
W71X 
L81F 
L83P 
D85N 
V88M 
339del2 
type of 
mutation 
large deletion 
mlssense 
frameshlft 
trameshlft 
missense 
frameshlft 
missense 
missense 
frameshift 
missense 
missense 
missense 
frameshift 
in-frame 
deletion 
frameshift 
nonsense 
missense 
missense 
missense 
missense 
frameshift 
nucleotide 
change' 
large deletion 
prior to nud. 761 
A to Τ at 90 
deletion of 28 bp 
(98-125) 
tandem duplication 
Of 28 bp (98-125) 
G to A at 106 
deletion of CT 
at 113-114 
Τ to С at 128 
С to Τ at 201 
insertion of Τ 
3' to 132 
Τ to G at 229 
С to Τ at 253 
Τ to С at 256 
deletion of 35 bp 
(253-287) 
deletion of 9 bp 
(255-263) 
insertion of G in 
274-277 
G to A at 284 
G to С at 314 
Τ to С at 319 
G to A at 324 
G to A at 333 
deletion of 2 bp 
amino acid 
change 
large deletion 
prior to codon 230 
Thr to Ser at 7 
frameshift 3' to 
codon 10 
frameshift 3' to 
codon 19 
Gly to Glu at 12 
frameshlft 3' to 
codon 16 
Leu to Pro at 43 
Leu to Phe at 44 
frameshift 3' to 
codon 44 
Leu to Arg at 53 
Ala to Val at 61 
Leu to Pro at 62 
frameshift 3' to 
codon 62 
deletion of 
Leu62-Ala63-Arg64 
frameshift 3' to 
codon 70 
Trp to stop at 71 
Leu to Phe at 81 
Leu to Pro at 83 
Asp to Asn at 85 
Val to Met at 88 
frameshift 3' to 
location 
EI-TMV 
El 
El 
El 
El 
El 
TMI 
TMI 
TMI 
TMI 
TMI 
TMI 
TMI 
TMI/CI 
CI 
CI 
TMII 
TMII 
TMII 
TMII 
TMII 
reference 
van Ueburg et al.' 
Bichet et al.2 
Wildin et al.3 
Holtzman et al.4 
Wildin et al.3 
Wenkert et al.' 
unpublished (Nijmegen) 
Bichet et al.2 
unpublished (Nijmegen) 
Knoers et al.' 
unpublished (Nijmegen) 
Wildin et al.3 
Pan et al.7 
Knoers et al.' 
Bichet et al.2 
Bichet et al.2 
Bichet et al.2 
Holtzman et a l . M 
Bichet et al.2 
unpublished (Nijmegen) 
Wildin et al.3 
Knoers et al.' 
Knoers et al.' 
Bichet et al.2 
van Lieburg et al.' 
in region 339-342 codon 90 
P95L missense С to Τ at 355 Pro to Leu at 95 TMII-EII Wildin et al.3 
ADDENDUM I (continued) 
Mutations of the Vasopressin V2 receptor gene In congenital nephrogenic diabetes Insipidus 
name 
W99G 
R106C 
402delCT 
C112R 
C112F 
R113W 
Q119X 
M123R 
Y124X 
S126F 
Y128S 
A132D 
R137G 
R137H 
R143P 
A147V 
528del7 
W164S 
S167L 
R181C 
G1B5C 
W193X 
type of 
mutation 
mlssense 
missense 
frameshift 
missense 
missense 
missense 
nonsense 
missense 
nonsense 
missense 
missense 
missense 
missense 
missense 
missense 
missense 
frameshift 
missense 
missense 
missense 
missense 
nonsense 
nucleotide 
change' 
Τ to G at 366 
С to Τ at 367 
deletion of CT 
at 402-403 
Τ to С at 405 
G to Τ at 406 
С to Τ at 408 
С to Τ at 426 
Τ to G at 439 
Τ to G at 443 
С to Τ at 448 
A to С at 454 
С to A at 466 
С to G at 480 
С to A at 481 
G to С at 499 
С to Τ at 511 
deletion of 7 bp 
(528-534) 
G to С at 562 
С to Τ at 571 
С to Τ at 612 
G to Τ at 624 
G to A at 649 
amino acid 
change 
Trp to Gly at 99 
Arg to Cys at 106 
frameshift 3' to 
codon 111 
Cysto Arg at 112 
Cysto Phe at 112 
Arg to Trp at 113 
Gin to stop at 119 
Metto Arg at 123 
Туг to stop at 124 
Ser to Phe at 126 
Tyr to Ser at 128 
Ala to Asp at 132 
Arg to Gry at 137 
Arg to His at 137 
Arg to Pro at 143 
Ala to Val at 147 
frameshift 3' 
to codon 153 
Trp to Ser at 164 
Ser to Leu at 167 
Arg to Cys at 181 
Gfy to Cys at 185 
Trp to stop at 193 
location 
Ell 
Ell 
Ell 
Ell 
Ell 
Ell 
TMIII 
TMIII 
TMIII 
TMIII 
TMIII 
TMIII 
Cll 
Cll 
Cll 
Cll 
Cll 
ТМГ 
ТМГ 
Elll 
EHI 
Elll 
reference 
unpublished (Nijmegen) 
Bichet et al.2 
Bichet et ai.2 
Bichet et al.2 
unpublished (Nijmegen) 
Holtzman et al.'·10 
Knoers et al.e 
Bichet et al.' 
Wenkert et al.6 
Pan et al.1' 
unpublished (Nijmegen) 
Bichet et al.2 
Bichet et al.2 
Pan et al." 
Bichet et al.2 
Faa et al.12 
Rosenthal et al." 
Bichet et al." 
unpublished (Nijmegen) 
Bichet et al.14 
Tsakaguchi et al.16 
Bichet et al.2 
Knoers et al.' 
Bichet et al.2 
Knoers et al.' 
Bichet et al.2 
WiWin et al.3 
Pan et al.11 
Knoers et al.' 
Bichet et al.2 
van den Ouweland et al.1' 
unpublished (Nijmegen) 
ADDENDUM I (continued) 
Mutations of ttw vasopressin V2 receptor gene In congenital nephrogenic diabetes Insipidus 
name 
R202C 
T204N 
684del2 
Y205C 
V206D 
L219P 
L219R 
Q225X 
753insC 
E231X 
763delA 
786delG 
E242X 
803insG 
804insG 
804delG 
810del12 
834del1 
V277A 
type of 
mutation 
missense 
missense 
frameshift 
missense 
missense 
missense 
missense 
nonsense 
frameshift 
nonsense 
frameshift 
frameshift 
nonsense 
frameshift 
frameshift 
frameshift 
in-frame 
deletion 
frameshift 
missense 
278(279)delV in-frame 
deletion 
Y280C missense 
nucleotide 
change* 
С to Τ at 675 
С to A at 682 
deletion of 2 bp 
(684-685) 
A to G at 685 
Τ to A at 688 
Τ to С at 727 
Τ to G at 727 
С to Τ at 744 
insertion of С 
3' to 753 
G to Τ at 762 
deletion of A 
at 763 
deletion of G in 
region 786-788 
G to Τ at 795 
insertion of G in 
region 803-809 
insertion of G in 
region 804-809 
deletion of G in 
region 804-809 
deletion of 12 bp 
In region 810-821 
deletion of A at 834 
Τ to С at 901 
deletion of 3 bp 
in region 903-908 
A to G at 910 
amino acid 
change 
Arg to Cys at 202 
Thr to Asn at 204 
frameshift 3' to 
codon205 
Туг to Cys at 205 
Val to Asp at 206 
Leu to Pro at 219 
Leu to Arg at 219 
Gin to stop at 225 
frameshift 3' to 
codon228 
Glu to stop at 231 
frameshift 3' to 
codon 231 
frameshift 3' to 
codon 239 
Glu to stop at 242 
frameshift 3' to 
codon 246 
frameshift 3' to 
codon 247 
frameshift 3' to 
codon 247 
deletion of 
Arg247-Arg248-
Arg249-Gly250 
frameshift 3' to 
codon 255 
Val to Ala at 277 
deletion of 
Val 278(279) 
Туг to Cys at 280 
location 
EHI 
EMI 
EHI 
EMI 
EHI 
TMV 
ТМ 
TMV 
TMV 
TMV 
CHI 
CHI 
CHI 
CHI 
CHI 
CHI 
CHI 
CHI 
TMVI 
TMVI 
TMVI 
reference 
van den Ouweland et al.16 
Bichet et al.'4 
Wenkert et al.9 
Knoers et al.' 
Bichet et al.2 
van den Ouweland et al ." 
Wildin et ai.3 
Knoers et al.' 
Cheong et al.17 
van Lieburg et al.' 
Knoers et al.6 
Merendino et a l . " 
Holtzman et al.4 
Pan et al.11 
Tajima et a l ." 
Wildin et al.3 
unpublished (Nijmegen) 
Bichet et al.2 
Rosenthal et al.13 
Bichet al.' 
Pan et al." 
Wildin et al.3 
Wenkert et al." 
Tsukaguchi et a l ." 
Faa et a l . " 
Friedman et al.20 
Wenkert et al." 
ADDENDUM I (continued) 
Mutations of the vasopressin V2 receptor gene In congenital nephrogenic diabetes Insipidus 
name 
910insA 
W284X 
A285P 
P286R 
P286L 
L292P 
W293X 
type of 
mutation 
nonsense 
nonsense 
missense 
missense 
missense 
missense 
nonsense 
977(97B)delG frameshift 
g(intron B)a 
a(intron B)g 
L312X 
1011ins2 
P322S 
P322H 
W323R 
R337X 
del 
aberrant splice 
site 
aberrant splice 
site 
nonsense 
frameshift 
missense 
missense 
missense 
nonsense 
large deletion 
nucleotide 
change* 
insertion of A 
3' to codon 
G to A at 922 
G to С at 924 
С to G at 928 
С to Τ at 928 
Τ to С at 946 
G to A at 949 
deletion of G at 
977(978) 
AAGgt to AAGat 
splice donor 
agGGG to ggGGG 
splice acceptor 
Τ to A at 1006 
insertion of 2 bp 
3'to 1011 
С to Τ at 1035 
С to A at 1036 
Τ to A at 1038 
С to Τ at 1079 
amino add 
change 
Tyr to stop at 280 
Trp to stop at 284 
Ala to Pro at 285 
Pro to Arg at 286 
Pro to Leu at 286 
Leu to Pro at 292 
Trp to stop at 293 
frameshift 3' to 
codon 303 
aberrant splice at 
codon 304 
aberrant splice at 
codon 304 
Leu to stop at 312 
frameshift 3' to 
codon 314 
Pro to Ser at 322 
Pro to His at 322 
Trp to Arg at 323 
Arg to Stop at 337 
deletion of whole 
V2 receptor gene 
location 
TMVI 
TMVI 
TMVI 
TMVI 
TMVI 
TMVI 
TMVI 
EIV 
ЕГ 
EIV 
TMVII 
TMVII 
TMVII 
TMVII 
TMVII 
CIV 
EI-CIV 
reference 
unpublished (Nijmegen) 
Bichet et al.2 
unpublished (Nijmegen) 
Bichet et al.2 
Pan et al." 
Faa et al.12 
Wenkert et al.9 
Bichet et al.2 
unpublished (Nijmegen) 
Knoers et al.' 
unpublished (Nijmegen) 
Wildin et al.' 
Bichet et al.14 
unpublished (Nijmegen) 
Tajima et a l ." 
Tajima et al.1" 
Wildin et al.3 
Knoers et al.' 
Bichet et al.2 
Wenken et al.9 
unpublished (Nijmegen) 
* Nucleotides are numbered according to the sequence numbering of Gen Bank entry 211687. Translation starts 
at nucleotide 72. 
ADDENDUM II 
Mutation· In the aquaporln 2 gene In congenital nephrogenic diabetes Insipidus 
name 
G64R 
N68S 
G100X 
369delC 
T126M 
A147T 
R187C 
S216P 
type of 
mutation 
mlssense 
missense 
nonsense 
frameshlft 
missense 
missense 
missense 
missense 
nucleotide 
change* 
Q to A at 190 
A to G at 203 
G to Τ at 298 
deletion of С at 369 
С to Τ at 377 
G to A at 439 
С to Τ at 559 
Τ to С at 646 
amino acid 
change 
Gly to Arg at 64 
Asn to Ser at 68 
Gly to stop at 100 
frameshift 3' to 
codon 122 
Thre to Moth at 126 
Ala to Thre at 147 
Arg to Cys at 187 
Ser to Pro at 216 
location 
Cll 
Cll 
TMIII 
Ell 
Ell 
TMIV 
EHI 
TMVI 
reference 
van Lieburg et al.21 
unpublished (Nijmegen) 
unpublished (Nijmegen) 
van Lieburg et al.2' 
unpublished (Nijmegen) 
unpublished (Nijmegen) 
Deen et al.22 
van Lieburg et al.21 
Deen et al.22 
' Nucleotides are numbered according to the sequence numbering of Gen Bank entry Z29491. Translation starts 
at nucleotide 1 
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UST OF ABBREVIATIONS 
AQP 
AVP 
CAMP 
bp 
CHIP28 
DDAVP 
FVIIIc 
FBF 
L-NMMA 
MIP 
MR 
NDI 
NO 
Pd 
p. 
RT-PCR 
tPA:Ag 
V1 receptor 
V2 receptor 
WCH-CD 
aquaporin 
arginine vasopressin 
cyclic adenosine monophosphate 
basepairs 
channel-forming integral protein of 28 kD 
1-desamino-8-D-arginine vasopressin 
factor VIII coagulant activity 
forearm blood flow 
L-N°-monomethyl-arginine 
major intrinsic protein 
mental retardation 
nephrogenic diabetes insipidus 
nitric oxide 
diffusional water permeability coefficient 
osmotic water permeability coefficient 
reverse transcriptase polymerase chain reaction 
tissue-type plasminogen activator antigen 
vasopressin type 1 receptor 
vasopressin type 2 receptor 
water channel of collecting duct 
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STELLINGEN 
behorend bij het proefschrift 
CONGENITAL NEPHROGENIC DIABETES INSIPIDUS 
Molecular pathogenesis and clinical aspects 
A.F. van Ueburg 
1 Het wordt steeds waarschijnlijker dat aan de genetische heterogeniteit van de ziekte 
congenitale nelrogene diabetes insipidus slechts twee moleculaire oorzaken ten grondslag 
liggen 
dit proefschrift 
2 Een DDAVP-test met meting van extra-renale parameters is een betrouwbare methode om 
na te gaan of een manneh|ke patiënt met congenitale nefrogene diabetes insipidus een 
defect m het Vasopressine type 2 receptor gen of het aquaponne 2 gen heeft 
dit proefschrift 
3 Een vrouw met congenitale nefrogene diabetes insipidus heeft niet altijd een mutatie in het 
aquaponne 2 gen 
dir proefschrift 
4 Mentale retardatie komt bij patiënten met congenitale nefrogene diabetes insipidus minder 
vaak voor dan in de literatuur wordt gesuggereerd 
dif proefschrift 
5 Na een buiktrauma bij een patiënt met nefrogene diabetes insipidus dient men de mogelijk-
heid van een ruptuur van de urinewegen te overwegen. 
dit proefschrift 
6 Hoewel arginine Vasopressine en 1-desamino-8D-arginine Vasopressine (DDAVP) beiden 
vaatverwijding veroorzaken door stimulatie van een extra-renale V2 receptor is het werkings-
mechanisme van deze stoffen niet identiek 
dit proefschrift 
7 Het feit dat veel patiënten met nefrogene diabetes insipidus deze aandoening eerder als een 
ongemak dan als een ziekte ervaren zou richtinggevend moeten zijn bij discussies over de 
prenatale diagnostiek 
8 Niet zozeer de behandeling als wel de preventie van het hemolytisch uremisch syndroom 
dient te worden verbeterd 
9 Het gebruik van glucose polymeren kan voor de peritoneaaldialyse van jonge kinderen met 
een verminderd ultrafiltraat een belangrijke aanwinst betekenen 
10 In de eerste levensdagen is een bomberend trommelvlies meestal niet pathologisch 
D G Roberts et al, Arch Pediatr Adolesc Med 1995, 149 873-877 
11 Hoewel het netto-effect van een promotie meestal overeenstemt met de voortgang die dit 
woord suggereert, wordt in het algemeen vergeten dat het een resultante van stimulerende 
en remmende factoren is 
12 Wanneer het aantal auteurs boven een wetenschappelijk artikel groot is, is de kans dat 
allen een wezenlijke bijdrage hebben geleverd klem 
13 Doden van tijd doet onrecht aan het leven 
14 Gezien de agressie van veel automobilisten is een extra uitlaatklep geen overbodige luxe 
15 Klapschaatsen verhogen de kans op applaus 
16 In een tijd waann veel vrouwen vóór het huwelijk een eigen identiteit verwerven is het 
praktischer om de mansnaam achter de 'meisjes'naam te plaatsen 
Ni|megen, 29 oktober 1996 



